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INTRODUCTION: There appears to be an accelerated ageing process seen among 
patients with end stage kidney disease. They often exhibit premature aged phenotypes 
which include frailty, sarcopenia and protein energy wasting. These phenotypes are 
associated with increased morbidity and mortality. The exact reason for premature 
ageing in this cohort has been poorly understood. We hypothesised that biomarkers of 
cellular senescence and biological age may be associated with features of ageing 
observed in dialysis patients; in particular the frailty phenotype. 
 
OBJECTIVES: The aim of the study was to investigate the relationship between 
biomarkers of ageing; telomere length (TL) and DNA methylation (DNAm) status 
with frailty phenotype.  
 
METHODS: All patients had their DNA extracted from peripheral leucocytes and 
frailty was measured by using the Fried Frailty Phenotype criteria. Extracted DNA 
was used to measure TL by quantitate polymerase chain reaction and DNAm status 
was measured by sodium bisulphite conversion with targeted sequencing of 48 CpG 
sites. Dialysis patients were followed up after a year for repeat telomere length and 
frailty assessment. 
 
RESULTS: Between the period of December 2015 to July 2018, 339 patients were 
recruited. Of these 335 patients had TL and 253 patients had DNAm status measured 
successfully. Frailty assessment at baseline were completed in 299 patients and 155 




analysis found that baseline TL was longer in the control group of healthy donors in 
comparison to dialysis patients, p=0.006 but this significance was lost after adjusting 
for age and gender. A decrease in mean TL (p=0.001) and increased mean DNAm age 
(p=0.001) was observed in the frail group. TL and DNAm age were significantly 
associated with frailty in a univariate analysis, p=0.010 and p= 0.014 respectively but 
only TL remained significant in a multivariate analysis to predict frailty, p=0.018. A 
receiver operating characteristic curve analysis demonstrated that TL was a significant 
predictor of frailty, p=0.0010 with an area under the curve of 0.64. A decrease of TL 
by 1 standard deviation was associated with a 52.2% increase risk of frailty when 
adjusted for age and gender in the dialysis cohort.  
 
CONCLUSION: The study supports the hypothesis that TL; a biomarker of ageing is 
better associated with frailty, an ageing phenotype in comparison to DNAm age in 
dialysis patients.     
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CHAPTER 1:  GENERAL INTRODUCTION 
 
1.1 The Biology of Ageing 
 
1.1.1 What is ageing? 
 
Ageing is a process of growing old. However, published literature has shown 
that the definition of ageing is much more complex and arguably the least well 
understood aspect of human biology.  Ageing itself is a complicated process 
with multiple hypotheses with more than 300 ‘theories’ of ageing described in 
the past (Medvedev, 1990). Fortunately, recent advances in ageing research 
have simplified some of the theories. Despite this, and due to the intrinsic 
complexity of the ageing process there remains uncertainty about many factors 
and processes involved in its aetiology. 
 
Ageing appears to be a time dependant process characterized by progressive 
decline and gradual deterioration of physiological functioning across multiple 
organ system  necessary for survival and fertility (Kirkwood, 2005). It also 
represents a normal decline in physical, social and cognitive function with age, 
heightened by extrinsic factors. The current challenge in the field of ageing is 







1.1.2 Biological age versus chronological age 
 
All cultures have anecdotes about the relationship between one’s chronological 
age and biological age. “Age is just a number” and “You are as old as you feel” 
are some of the quotes that highlight the difference between biological and 
chronological age. The outcome from The Dunedin Multidisciplinary Health 
and Development Study (Belsky et al., 2015)  have reinforced existing findings 
that support the notion that every human being has a chronological age and 
biological age.  
 
Chronological age is the record of time elapsed since birth which represents 
the period of time an organism exists. Biological age also referred to as 
physiological age or functional age is a concept used to reflect ageing that 
occurs at a cellular level. Biological age occurs at varying rates within 
individual species as it is affected by various factors intrinsic and extrinsic 
factors e.g. lifestyle, genetics, exercise, sleep habits etc. (See Figure 1: 
Biological age vs chronological age). Biological age is a superior index for 
disease related mortality than chronological age. This is because biological age 
takes into account factors that can affect a physical state of an individual’s 
health status which chronological age does not.  
 
Levine and Crimmins showed that biological age could predict 10-year 
mortality more accurately than other measures, such as Allostatic Load and 




Allostatic load is defined as the cost of chronic exposure to fluctuating or 
heightened neural or neuroendocrine response resulting from repeated or 
chronic environmental challenge that an individual reacts to as being stressful 
(McEwen and Stellar, 1993). A study among 557,940 Koreans between 20-93 
years revealed that, the average biological age was almost the same as the 
average chronological age in those that survived during the study duration 
(Yoo et al., 2017). However, in those that died during the 17 year follow up 
period, the biological age was higher than the chronological age with the death 
rate significantly higher as gap between the biological and chronological age 
widened (Yoo et al., 2017). Therefore, biological age may be a better proxy 
















Figure 1: The concept of biological age predictors 
A biological age predictor could be defined as a biomarker correlated with 
chronological age (black line), which brings additional information in the risk 
assessments for age-related conditions on top of chronological age. Hence, adult 
individuals of the same chronological age could possess different risks for age-
associated diseases as judged from their biological ages (x's in figure). Usually, the 
positive predictive value (red line) of a biological age predictor decreases from mid-
life and onwards due to the increased biological heterogeneity at old age (confidence 
interval described by dashed lines increases at old age) (Jylhävä, Pedersen and Hägg, 
2017). Permission not required as for non-commercial use. Refer to Creative 





Biological age has been proposed as a proxy for ageing. There is currently no 
standardised or general consensus on biomarkers accepted for estimating 
biological age. However, the American Federation for Ageing Research have 
proposed a clear set of requirements for a biomarker of ageing as outlined 
below (Johnson, 2006)(Sharman and Zhumadilov, 2011): 
 
1) It must predict the rate of ageing and provide information about the 
functional condition of the body, its metabolic and regulatory systems as 
well as a better predictor of lifespan than chronological age. 
 
2) have quantitative characteristics that underlies the ageing process, hence 
correlates with age and not the effect of disease 
 
3) be reproducible, sensitive, and specific without causing any harm to a 
person 
 
4) be suitable for use in humans as well as in laboratory animals so it can be 
tested in animal models prior to being validated in humans 
 
There are currently 6 potential types of recognised biological age predictors 
and are referred to as 1) epigenetic clock 2) telomere length 3) transcriptomic 
predictors 4) proteomic predictors 5) metabolomics-based predictors 6) 





The biomarkers of interest explored in this thesis are the epigenetic clock better 
known as DNA methylation (DNAm) and telomere length (TL) as both were 
the most plausible candidates out of all the existing predictors of biological 
age. TL and DNAm techniques have been well developed, cost effective and 
practical for the use of large-scale studies in comparison to the other predictors 
of biological age. Both of these biomarkers have been tested in different tissues 
and validated in independent cohorts with more than a 1000 studies on TL and 
more than a 100 studies on DNAm (Jylhävä, Pedersen and Hägg, 2017). TL is 
extensively validated but has a low predictive power of mortality whilst 
DNAm is thought to be a stronger predictor but not validated enough. Other 
biological age predictors are useful but have not been well studied as TL and 
DNAm and still requires further independent validation. TL and DNAm has 
been shown to provide additional evidence of individual ageing independent 
of chronological age as they successfully predict mortality, morbidity and 
physical function which is the basis of this PhD project (Refer to Chapter 2: 
Aims). These are the reasons for favouring TL and DNAm over all the other 










1.1.3 Cellular senescence and replicative senescence 
 
The ageing process at a cellular level is known as cellular senescence which is 
a halt in permanent growth and leads to cellular apoptosis while the lifespan 
of a cell is often defined by replicative senescence which is the decline in the 
fitness of the mother cells for further proliferation (Currais, 2017). Senescence 
was described by Hayflick and Moorhead in 1961 when they discovered that 
primary human cells would only be able to divide a finite number of times 
before dying (Hayflick and Moorhead, 1961). The term given to this 
phenomenon describing cell specific limited capacity of replications, is the 
‘Hayflick Limit’. This is only reported in normal mammalian cells unlike 
immortal, abnormal or cancer cell lines. Once the limited capacity for 
replication has been reached, cells than undergo replicative senescence. 
 
Hayflick and Moorhead suggested that the phenomena of limited replicative 
capacity could represent how old a cell is, based on how many times a cell 
underwent division and this could be linked to ageing (Hayflick and 
Moorhead, 1961)(Hayflick, 1965) (Hayflick, 1979). The mechanism 
underlying the phenomenon of Hayflick limit was subsequently described as 






Figure 2: The leading strand problem of telomere replication also known as the end 
replication problem 
Overextension of parental telomeres by telomerase followed by semi conservative 
deoxyribonucleic acid (DNA) replication does not regenerate a 3’ overhang on the 
leading strand. Sequence added by telomerase is shown by the thick arrow in green. 
Ribonucleic acid (RNA) primers are indicated by wavy line in red. Parental DNA is 
indicated by thin lines in black and replicated by the DNA indicated by the thicker 
lines in orange. Arrows in black indicate the polarity of DNA 5’ to 3’.Reproduced 






1.2 Telomere Biology 
 
1.2.1 A history of Telomeres 
 
Seminal observations by Muller and McClintock revealed that broken 
chromosomes were unstable and prone to rearrangements and fusion (Muller, 
1938) (McClintock, 1939). Protecting chromosome ends from such events 
highlighted the importance of the terminal end of the chromosome as key to 
cell survival and growth (Olovnikov, 1973) (Olovnikov, 1996). However, the 
molecular nature of these structures was yet to be discovered. The discovery 
of the structure of DNA by Watson & Crick in 1953 was a key first step that 
lead to a greater understanding of the molecular nature of terminal section of 
the  chromosome (Watson and Crick, 1969). The end of the chromosome was 
named telomeres from the origin of the Greek word ‘telo’ meaning end and 
‘meros’ meaning part. It was proposed that the finite doubling capacity of 
normal mammalian cells is due to a loss of telomeric DNA and eventual 










1.2.2 The end replication problem 
 
The underlying mechanisms that controls this phenomenon were described by 
Calvin Harley in 1990 (Harley, Futcher and Greider, 1990)  who implicated 
the loss of telomeric DNA as a potential mechanism of senescence. Harley 
demonstrated that the amount and length of telomeric DNA in human 
fibroblasts negatively correlated with serial passages during ageing in vitro and 
possibly in vivo (Harley, Futcher and Greider, 1990). This mechanism was 
described as the end replication problem that was proposed by Olovnikov and 
Watson back in 1970s. (Olovnikov, 1973) (Watson and Crick, 1969). The end 
replication problem refers to a hitch that arises when DNA polymerase, the 
enzyme responsible for DNA replication is unable to fully replicate the 3’ end 
of the parental DNA strand due to the absence of a template strand.  (See Figure 
2). This results in telomere shortening with each round of replication as DNA 
is replicated during each cell division. This mechanism would explain 
replicative senescence (Olovnikov, 1973). Consequently, each replicative 
cycle of the cell results in the erosion of the parental guanine-rich 3’ end and 
telomeric DNA progressively shortens in the absence of any compensating 
mechanism. The shortening by approximately 50-100 bases per round of cell 
division continues until the critical state of replicative senescence is reached, 






1.2.3 The structure and function of telomeres 
 
The telomere is a complex nucleoprotein located at terminal end of each linear 
eukaryotic chromosome (See Figure 3 and Figure 4). 
 
 
Figure 3: Telomeres appear as the bright spots at the ends of each chromosome in the 
picture shown above. Image credit by U.S. Department of Energy Human Genome 






Figure 4: Telomere caps at the end of chromosomes. Image credit by Wikipedia 
 
Due to telomere’s stability, unlike the rest of the chromatin, it is not subjected 
to degradation, recombination or fusion with other chromosomal ends. 
Telomeres are tandem repeats of guanine enriched strands with a repetitive 
sequence of TTAGGG in humans. The guanine rich strand of telomeric DNA 
is always in the direction of 5’-3’ towards the terminal portion of the 
chromosome and contains approximately 200 nucleotides as a consequence of 
end terminal replication. Telomere caps protect the end of mammalian 
chromosomes to prevent the ends from being identified as double strand breaks 
in DNA, thus limiting chromosome shortening and recombination. Telomere 
itself does not carry any genetic information but preserves genetic integrity of 
the chromosome by prevention of degradation and end to end fusion.  
 
In humans, the telomere terminus consists of 4 to 15 kilo base pair (kbp) of the 
hexanucleotides 5′-TTAGGG-3′ (Von Zglinicki, 2002)(Houben et al., 2008). 




20-200 base pairs (bp), hence their length is an indicator of replicative history 
and replicative potential of these cells; serving as a mitotic ‘clock’ (Harley, 
1991) (Houben et al., 2008). As little as 400bp of TTAGGG repeats can lead 
to the formation of a fully functioning telomere (Palm and de Lange, 2008). 
Experiments demonstrate a strong association between telomere shortening 
and a reduction of the replicative life span of human cells invitro, consistent 
with the early genetic evidence obtained in model systems that short telomeres 
induce senescence (Blackburn, Greider and Szostak, 2009). There are a 
number of possible mechanisms for loss of telomeric DNA during ageing, 
including incomplete replication, degradation of termini (specific and non-
specific) and unequal recombination, coupled to selection of cells with shorter 
telomeres (Harley, Futcher and Greider, 1990). 
  
1.2.3.1 Structure of telomeres: Guanine Quadruplexes 
 
The extreme 3’ ends (of the 5’ to 3’ guanine-rich strand) of all telomeres are 
single stranded, with most studies concurring that the average length of human 
telomere is 100-200 bases. (Wright et al., 1997) The 3’ protruding G rich strand 
can form complex structures known as guanine-quadruplexes. The G-
quadruplexes assume different conformation (Spiegel, Adhikari and 
Balasubramanian, 2019). (See Figure 5) The multi-stranded structures are held 
together by square planes of four guanines (G-quartets) interacting by forming 






Figure 5: Structure of guanine-quadruplexes 
(A) Structure of a G-quartet formed by the Hoogsteen hydrogen-bonded guanines and central 
cation (coloured green) coordinated to oxygen atoms. Crystal structure of human telomeric 
guanine quadruplexes G4s (B) top view (C) side view with backbone is represented by grey 
tube and the structure are colour-coded by atoms. Schematic representation of unimolecular 
G4s based on the strand direction: (D) parallel, (E) anti-parallel and (F) hybrid with a bulge. 
(Spiegel, Adhikari and Balasubramanian, 2019) Permission is not required for this non-
commercial use. Creative Commons Attribution-Non-Commercial-No Derivatives License 










1.2.3.2 Structure of telomeres: Telomere (T) loop and Displacement (D) loop  
 
Telomeres are not linear and can form looped fold back structures whose 
stability depends, in a large part, on the involvement of the telomeric repeat 
factor 1 (TRF1) and telomeric repeat factor 2 (TRF2) proteins (Griffith et al., 
1999). Telomeres form large loop structures called telomere loops, or T-loops 
which sequesters the chromosome terminus. Existence of T-loops provide an 
explanation of how single stranded chromosome ends are protected from 
degradation, recombination and fusion (Palm and de Lange, 2008).  At the very 
end of the T-loop the single stranded telomere DNA is held onto a region of 
double stranded DNA by the telomere strand disrupting the double helical 
DNA and base pairing to one of the 2 strands call a displacement loop or D-




Figure 6: The proposed structure of human telomeric end. 
Human telomeres are comprised of a 230kb array of duplex TTAGGG repeats, ending 
in a 100 to 200 nucleotide protrusion of a single stranded TTAGGG repeats. This DNA 
can exist as a t-loop in which the overhang invades the duplex-repeat array forming a 




POT1 binds to the single-stranded TTAGGG- repeat DNA. Two double stranded 
TTAGGG repeat binding factors (TRF’s), TRF1 and TRF2 are associated with the 
duplex repeats. Reproduced with permission (De Lange, 2004).  
 
1.2.4 Telomerase the historical perspective 
 
Telomere length (TL) is regulated by the enzyme telomerase that maintains 
telomere stability and telomere shortening. Blackburn, Szostak and Greider 
were awarded the Nobel Prize in Physiology and Medicine in 2009 for their 
discovery on  how chromosomes are protected by telomeres and the discovery 
of the enzyme telomerase (Blackburn, Greider and Szostak, 2009). Telomerase 
enzyme is essential for genomic stability and is the mechanism by which the 
ends of chromosomes are maintained and spared from erosion or 
rearrangement during repeated cellular divisions.  
 
1.2.4.1 The structure and function of telomerase 
 
Telomerase is a unique cellular reverse transcriptase that contains an integral 
ribonucleic acid subunit (telomerase RNA, also known as TER) and a catalytic 
protein subunit telomerase reverse transcriptase (TERT) as well as several 
species-specific accessory proteins. The function of telomerase is to extend the 
3’ of the linear chromosome by synthesizing multiple copies of the specific 
DNA telomere repeat sequence using a complementary template. The 




2010). The first step is primer recognition followed by binding. Once the 
primer has bound, the telomeric repeats are then synthesized. This is then 
followed by translocation and realignment of the new DNA 3’ to initiate the 
next round of telomere synthesis. 
 
 Data from knockout mice has shown that lack of telomerase activity causes 
telomeres to shorten more rapidly over time leading cell cycle arrest and 
senescence (Lee et al., 1998)(Blasco et al., 1997). Telomerase activity is 
pathologically high in cancer cells, moderate in germ cell and stem cell line 
but mostly undetectable in somatic cells (Armanios and Blackburn, 2012). 
TER subunits contain 2 conserved structural elements; the catalytically 
essential pseudoknot-template core domain and a stem-loop element called 
CR4-CR5 (Sandin and Rhodes, 2014). These 2 conserved TER structural 
elements have been shown to interact directly with TERT (Mitchell and 
Collins, 2000) (Gardano et al., 2012). 
 
1.2.4.2 Shelterin Complex 
 
Telomeres are bound by a six-protein complex called shelterin complex; 
comprised of TRF1 and TRF2 which in turn recruits RAP2, TIN2, TPP1 and 
POT1 (Protection of telomeres 1) that have been implicated in the formation 
and maintenance of telomere structure by preventing DNA damage and 
regulating telomerase activity (Palm and de Lange, 2008). TRF1 and TRF 2 




telomerase activity to inhibit telomere elongation. TRF1 and TRF2 are both 
involved in the ataxia telangiectasia mutated (ATM) and ATM Rad3-related 
(ATR) pathway. These pathways are sensors of DNA damage and induce cell 
cycle arrest upon DNA damage.   
  
 
1.2.5 Mechanisms of telomere shortening and repair/Regulation of 
telomeres 
 
The mechanisms regulating TL by telomerase are poorly studied despite much 
work having been done regarding the complex telomere/telomerase structure.  
 
1.2.6 Telomeres in research and factors affecting it 
 
Telomeres have 3 main features that highlights the reasons for its popularity in 
the field of research; a) telomeres shorten with each cell division b) telomeres 
are shortened by oxidative damage c) telomeres reach a critical length and 
induces a senescent state in cells. These properties of telomeres have formed 
the focus and foundation of research investigating mechanisms of ageing, age-
related diseases and mortality. Both basic science research and clinical studies 
have demonstrated various factors that are associated with TL not limited to 
genetic inheritance, environmental and lifestyle factors. Factors that have been 
consistently shown to affect TL are described below bearing in mind that some 






Both animal and human studies have shown that TL declines with age. A 
systematic review of TL and age among 124 cross-sectional studies and 5 
longitudinal studies revealed a statistically significant inverse correlation 
between mean age and mean TL for both absolute (r = −0.338, p < 0.0001) and 
relative TL (r = −0.295, p < 0.01) (Müezzinler, Zaineddin and Brenner, 2013). 
Weighted linear regression from this meta-analysis yielded an estimated 
telomere loss rate of 24.7 BP/year (p = 0.0071) and 0.010 T/S ratio/year (p = 
0.0071). (Müezzinler, Zaineddin and Brenner, 2013) This rate may not be 
constant throughout life, although it has been a common practice to describe 
TL as a linear function of donor age (Frenck, Blackburn and Shannon, 1998). 
Inverse relationship between age and TL is a consistent observation seen in the 
literature. However current evidence is insufficient to determine or provide an 





There have been inconsistencies in the association between gender and TL in 
the literature as data on variation according to gender remains sparse. The 
hypothesis that women have longer telomeres have risen from strong 
biological evidence supporting the hypothesis that women have longer TL in 




which has been shown to stimulate telomerase activity (Kyo et al., 1999) 
(Barrett and Richardson, 2011) via human TERT (hTERT) gene expression, 
while androgens appear to be a negative regulator of telomerase in normal 
prostate tissue (Bayne and Liu, 2005). Oestrogen also has a protective effect 
against reactive oxygen species (ROS) damage (Aviv, 2002) as oestrogen is 
thought to possess anti-oxidant properties that protects telomeres from 
extensive oxidative stress induced damage  (Von Zglinicki, 2002).  
 
A qualitative meta-analysis exploring the role of TL and gender found that 
males did have shorter telomeres than females (Barrett and Richardson, 2011). 
This was also supported by Muezzinler et.al. showing that females of similar 
ages had longer TL than men, again findings which have not been seen 
consistently throughout all studies (Müezzinler, Zaineddin and Brenner, 2013). 
A systematic review and meta-analysis of 36230 participants showed that 
gender was associated with TL with females having longer TL than males on 
average (Gardener and et al., 2014). However there was significant 
heterogeneity between the studies detected and the authors found that different 
measurement methods affected TL difference in gender. This systematic 
review revealed that the fluorescence in situ hybridisation (FISH) and 
polymerase chain reaction (PCR) based methods showed no difference 
between gender (Gardener and et al., 2014).    
 
It has been suggested that longer TL in females might be due to a slower rate 
of telomere attrition in females (Okuda et al., 2002) as observed in a cross 




2011). However, there have also been studies to dispute these findings with no 
significant gender-related differences in the rate of age-dependent telomere 
attrition (Benetos et al., 2001) (Cawthon et al., 2003). One meta-analysis found 
that the evidence for sex-specific correlation coefficients and yearly telomere 
loss rates showed no statistically significant differences and the effect of 
gender on TL  was not consistently observed in all studies (Müezzinler, 
Zaineddin and Brenner, 2013). 
 
Therefore, this may suggests that perhaps female new-borns may have longer 
telomeres than male at birth which has been observed in one study using flow 
fish (Aubert et al., 2012) but not seen in another study that used terminal 
restriction fragments (TRF) southern blotting (Okuda et al., 2002). There are 
limited studies available in the first 2 decades of an individual which may be 
crucial in answering the dilemma of TL and gender. 
 
1.2.6.3 Oxidative stress and inflammation  
 
Oxidative stress has been reported to accelerate telomere shortening occurring 
during DNA replication, ultimately promoting senescence. Oxidative DNA 
damage constitutes the majority of DNA damage in human cells, causing base 
damage and unrepaired nucleotides. The oxidative damage to nucleotides and 
bases accumulate over the life span of a cell or an organism and contributes to 
senescence (Houben et al., 2008). Senescent cells contain 30% more 




bases; a biomarker of oxidative stress (Chen et al., 1995). A study comparing 
young and senescent cultured human fibroblasts revealed an increase in ROS 
levels, dysfunctional mitochondria, more DNA double stranded breaks and 
shorter telomeres in the senescent cells (Passos et al., 2007). 
 
Telomeres are particularly vulnerable to oxidative damage. Petersen et.al. 
found that repair in telomeres was much slower and incomplete than the rest 
of the genome when human fibroblasts were exposed to oxidative stress 
causing an increase in the frequency of single stranded breaks and telomere 
shortening (Petersen, Saretzki and Von Zglinicki, 1998). In studies by Okaiwa 
et.al., exposure of DNA to 8-oxodG, (a biomarker of oxidative stress) not only 
showed that 8-oxodG accumulated with age but an increased level was found 
in DNA fragments containing telomere sequences (Oikawa and Kawanishi, 
1999)(Oikawa, Tada-Oikawa and Kawanishi, 2001). Further evidence for the 
role of oxidative stress accelerating telomere shortening was observed in 
human fibroblast when the onset of cellular senescence was correlated with 
cellular oxygen exposure (Ahmed and Lingner, 2018). 
 
Oxidative damage at random positions within telomeres interferes with the 
replication fork resulting in stochastic and irregular telomere shortening events 
(Von Zglinicki, 2002) (Von Zglinicki, Pilger and Sitte, 2000). Oxidative 
damage also affects  telomeres by enhancing the end replication problem 
which then interferes with the maintenance of the distal ends of the telomeres 
(Ahmed and Lingner, 2018). Breakage of the DNA backbone can also be 




DNA replication (Aeby et al., 2016). ROS can also trigger premature abortion 
of the replication before reaching the end of the DNA template (Ahmed and 
Lingner, 2018).  
 
The exact mechanism that increases the rate of telomere shortening by 
oxidative stress remains inconclusive. Several reasons have been postulated as 
to why telomeres are particularly vulnerable to oxidative damage. In vitro data 
has shown that oxidative stress can cause specific cleavage at polyguonosine 
sequences in the telomere sequence which may play an important role in 
increasing the rate of telomere shortening (Oikawa and Kawanishi, 1999). 
Telomeres were found to be extremely sensitive to the accumulation of ROS-
induced 8-oxodG DNA-strand breaks (Zglinicki, Martin-ruiz and Saretzki, 
2005). Single strand breaks to telomeric DNA was observed once disruption 
to TL maintenance and function occurs as a result of oxidative damage. 
Telomeres are repaired less efficiently in comparison to the rest of the genome 
and the repair is less proficient when damage is due to oxidative stress  (Von 
Zglinicki, 2002). The high incidence of guanine residues in telomeric DNA 
sequences makes the telomere a more susceptible target for oxidative damage 
(Oikawa and Kawanishi, 1999). Finally, in conditions associated with 
oxidative stress, there is evidence to suggest that oxidative damage/ROS 
promotes telomere shortening and impairing telomerase activity thereby 
accelerating  cellular senescence (Stefanidis et al., 2015)(Aeby et al., 2016). 
 
Most evidence on oxidative stress and TL are from in vitro and animal models. 




markers in clinical studies. A study of 401 men with a mean age of 62.2 years 
revealed that urinary 8-epi-PGF2a was inversely correlated with age adjusted 
TL, therefore increase systemic oxidative stress was associated with shorter 
TL consistent with findings in vitro to suggest oxidative stress accelerates 
telomere erosion (Demissie et al., 2006). A study of 58 healthy premenopausal 
women investigating psychological stress and cellular ageing showed that the 
group with shorter TL had higher F2 Isoprostanes level, a reliable measure of 
oxidative stress (Epel et al., 2004). Most studies investigating biomarkers of 
oxidative stress in chronic disease has been in the field of diabetes. Results of 
increased oxidative stress in the form of 8-oxoguanine level are associated with 
shorter TL in diabetics in comparison to control group (Sampson et al., 2006).  
The reason for lack of studies directly measuring oxidative stress and TL may 
be due to the fact oxidative markers itself are challenging to assess reliably and 
it is difficult to control or account for the change of oxidative stress levels 
which may fluctuate over time with inter individual variation (Boonekamp et 
al., 2017). Therefore, this had led to the wider use of various indirect measures 
of oxidative stress i.e. a surrogate marker which than acts as a proxy for 
biomarkers of oxidative stress to provide a more reliable association. 
 
There are more clinical studies investigating the effect of inflammation on TL. 
Wong et.al showed that  increases in circulating levels of C-reactive protein 
(CRP) and serum amyloid A were associated with proportional decreases in 
peripheral blood mononuclear cells (PBMC) TL in a cohort of middle-aged 
workers exposed to occupational environmental pollution over 2 years of 




population of 1,962 older adults ranging in age between 70 and 79 years 
showed that individuals with elevated circulating levels of either interleukin-6 
(IL-6) or tumour necrosis factor-alpha had significantly higher odds for short 
PBMC telomeres, after adjustment for potential confounders (Donovan et al., 
2011). 
 
1.2.7 Telomeres and mortality 
 
Individuals with shorter telomeres have a mortality rate nearly twice that of 
those with longer telomeres, with the loss in median survival associated with 
shorter telomeres was 4·8 years for women, and 4·0 years for men (Cawthon 
et al., 2003). A study of 143 healthy controls above the age of 60 years revealed 
that those with shorter telomeres in blood DNA had poorer survival, 
attributable, in part to a 3-fold higher mortality rate from heart disease (95% 
CI 1.36–7·45, p=0·008), and an 8·5-fold higher mortality rate from infectious 
disease (1·52–47·9, p=0·015) (Cawthon et al., 2003). This supports the 
hypothesis that telomere shortening in humans contributes to mortality in 
many age-related diseases. TL, when analysed as a continuous variable, was 
inversely associated with the age-adjusted mortality rate (r= -1·87, 95% CI –







1.2.8 Telomere attrition 
 
Humans have a relatively short TLs from 5-15kb and shorten at a rate of ~70bp 
per year (Canela et al., 2007) whilst mice who actually have longer TLs 
starting around 50kb but shorten at a rate of ~7000bp per year (Vera et al., 
2012). Despite the fact humans have shorter TL they have a longer lifespan in 
comparison to mice who have a longer TL. This may be explained by the 
different rates of telomere shortening. Telomere shortening rate but not the 
initial TL alone is a powerful predictor of a species life span (Epel et al., 2009) 
(Vera et al., 2012) (Boonekamp et al., 2014)(Whittemore et al., 2019). These 
studies in animal models support the hypothesis that critical telomere 
shortening and the consequent onset of telomeric DNA damage and cellular 
senescence are a general determinant of life span.  
 
Efforts have been made by several research groups to translate findings from 
animal models to humans. There have been 4 longitudinal studies investigating 
TL changes and lifespan/all-cause mortality as their primary outcome in adults 
(Martin-Ruiz et al., 2005) (Epel et al., 2009) (Bendix et al., 2014) (Yuan et al., 
2018). The follow up duration on average for the study by Martin-Ruiz et.al 
was at least 3.9 years, Epel et.al was 2.5 years, Bendix et.al was 10 years and 
Yuen et.al was 7.4 years. Out of these studies, 3 studies failed to show any 
relationship between telomere attrition and mortality (Martin-Ruiz et al., 2005) 
(Bendix et al., 2014) (Yuan et al., 2018). The 4th study did find a relationship 




The studies by Martin-Ruiz et.al and Bendix et.al had mean ages of 90 and 45 
respectively. Baseline TL and TL attrition in both these mean age groups have 
been shown to be a poor predictor of mortality (Martin-Ruiz et al., 2005) 
(Bendix et al., 2014). The follow up duration in the study by Epel et.al was 
only 2.5 years which may not be long enough to demonstrate a difference in 
mortality. There have also been a few studies that had only investigated 
cardiovascular risk with longitudinal changes in TL. The Heart and Soul study 
had revealed a decrease in mortality in patients who had lengthened their 
telomeres among patients with stable coronary heart disease (Goglin et al., 
2016). This study showed that during an average of 4.2 years of follow up, an 
increase in TL by 325 base pair was associated with a 24% reduction in 
mortality  (HR 0.76, 95% CI 0.61-0.94; p=0.01), adjusted for age, sex, waist 
to hip ratio, exercise capacity, LV ejection fraction serum creatinine and year 
5 TL (Goglin et al., 2016). Mortality was higher in patients with telomere 
shortening with a 32% adjusted increased risk of death versus telomere 
maintenance but this association was not significant (HR 1.32, 95% CI 0.84-
2.08, p= 0.23) (Goglin et al., 2016).  A another study had shown a more 
pronounced TL shortening in those with cardiovascular disease in comparison 








1.3 Telomeres in uraemia (CKD and RRT) 
 
Chronic inflammation and oxidative stress accelerate cellular ageing through 
its effects on telomere biology. Uraemia promotes cellular senescence and 
premature ageing through toxic alterations in the internal milieu. The uraemic 
state in ESKD is considered a pro-inflammatory condition typically 
characterised by enhanced production of ROS (Jofré et al., 2006)(Libetta et al., 
2011). The presence of inflammation and oxidative stress are common findings 
in patients with ESKD which has been widely addressed in the past. Increased 
oxidative stress of DNA is an established feature of uraemia (Tarng et al., 
2000). Oxidative stress has been related to immune system dysregulation in 
patients with uraemia, indicated by increased biomarkers of oxidative stress 
and activation of circulating leucocytes (Sela, 2005). The repeated stimulation 
that cells; in particular PBMC are subjected to during haemodialysis (HD) as 
a result of repeated contact of blood to the extracorporeal circuit and dialyzer 
membranes may lead to the increased production of pro-inflammatory 
cytokines causing chronic inflammation associated with increased risk of 
mortality and morbidity (Pertosa et al., 2000). This may lead to irreversible 
cellular ‘telomere-dependent’ growth arrest called stress induced premature 
senescence (Bernadotte, Mikhelson and Spivak, 2016). 
 
As outlined in the above paragraph chronic inflammation is related to telomere 
attrition and ageing. ‘Inflammageing’ is a condition characterized by elevated 




to chronic morbidity, disability, frailty and premature death (Ferrucci and 
Fabbri, 2018). ‘Inflammageing’ in uraemia is the hallmark of premature ageing 
whereby the phenotypes exhibited are often observed in dialysis patients; 
which include accelerated atherosclerosis, protein energy wasting, sarcopenia, 
osteoporosis, frailty and cognitive dysfunction (Stenvinkel and Larsson, 2013). 
A reduction in lean mass also known as protein energy wasting and increase 
in fat mass known as sarcopenic obesity is associated with inflammation 
(Honda et al., 2007). Protein energy wasting associated inflammation is 
directly associated with increased comorbidity, diminished physiological, 
metabolic and immunological capacity which then leads to reduced survival in 
dialysis patients (Kim, Kalantar-Zadeh and Kopple, 2013). There are currently 
limited studies on the relationship of TL in the context of uraemia despite the 
wide consensus that uraemia is a recognised clinical model of premature 
ageing (Betjes et al., 2011)(Stenvinkel and Larsson, 2013). 
 
Current evidence has revealed that during ageing, TL decreases more rapidly 
in the renal cortex than in the medulla, contributing to the cortical scarring and 
glomerular senescence observed in ageing kidneys (Yang and Fogo, 2010). In 
addition to age-dependent telomere shortening, factors such as oxidative stress 
and dysregulation of the renin-angiotensin system (RAS), commonly seen in 
uraemia can decrease TL and increase the intrinsic biologic age (Vasan et al., 
2008).  
 
Drugs which have revolutionised renal transplant has been shown to affect TL. 




proximal tubular cells in vitro caused cell cycle arrest, inhibited DNA 
synthesis and led to a reduction in TL (Jennings et al., 2007). These findings 
were confirmed by Koppelstaetter et.al. when investigating the effect of 
cyclosporine, tacrolimus and sirolimus on cellular senescence (Koppelstaetter 
et al., 2018). The authors demonstrated reductions in TL and increases in 
hydrogen peroxide production; a marker of oxidative stress after cells were 
treated with cyclosporine but not with tacrolimus and sirolimus 
(Koppelstaetter et al., 2018). The difficulties with in vivo studies revolve 
around the dosage of drugs used in the experiments and extrapolating the 
culture model to in vivo situations. Attempts to study immunosuppression and 
TL in vivo and in clinical studies have shown that TL assessment is useful to 
predict organ transplantation outcome. (Luttropp et al., 2016)(Kłoda, 
Domański and Mierzecki, 2017). However, this has been complicated by 
inconsistencies is immunosuppression protocol, ischaemia reperfusion injury 
and the small size of the clinical studies to allow any conclusions to be drawn. 
 
Several retrospective clinical studies have shown that TL is associated with 
kidney function, but this relationship is inconsistent. Data from a sub study of 
620 patients with heart failure between ages 40 and 80 who participated in the 
metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure 
(MERIT-HF) showed there were significant differences in TL and renal 
function defined by the MDRD equation after adjusting for age, gender and 
other baseline differences (van der Harst et al., 2008). The study revealed that 
TL positively correlated with renal function (van der Harst et al., 2008). In 




marker of renal excretory function in the lowest quartile ratio had reduced TL 
in comparison to their controls which were not only age and gender matched 
but also matched on all the other baseline variables (r= -0.107, 95% CI 0.020 
to 0.194, p = 0.017) (van der Harst et al., 2008). However, the cohort with the 
lowest renal function at baseline had an average eGFR of 42  8.4 and serum 
creatinine (sCr) level of 137 [127-162] mol/L. So, the results of the study 
cannot be applied to those with severe renal disease with or without the 
requirement for renal replacement therapy. This study was also unable to 
confirm if shorter TL is the cause or consequence in this population as this can 
only be determined from longitudinal data.  
 
The Heart and Soul study; a longitudinal study of 954 participants revealed no 
significant correlation between telomere shortening and impaired renal 
function at baseline and over a 5-year period when age was taken into account 
(Bansal et al., 2012). The same study also suggested that accelerated telomere 
shortening is unlikely to contribute to the high burden of morbidity and 
mortality among patients with decreased kidney function independent of other 
risk factors such as advanced age (Bansal et al., 2012). However crucially, this 
study also excluded any participants with severe renal disease or individuals 
requiring renal replacement therapy.  
 
Recent data from a longitudinal study of 80 healthy adults from China 
investigating TL using terminal restriction fragments (TRF) showed that TL 




and eGFR (Zhang et al., 2018). So, TL was negatively associated serum 
cystatin C and positively associated with eGFR (p<0.001). There was 
significant association between changes in TL i.e. telomere attrition over 3 
years with serum cystatin C (p=0.038), but significance was lost after adjusting 
for age (p= 0.0119) (Zhang et al., 2018).  
 
Clinical studies have reported that patients with ESKD/CKD may have shorter 
TL and accelerated telomere shortening compared with the general population 
(Tsirpanlis et al., 2006)(Boxall et al., 2006). The first study looking into the 
role of TL in HD patients were published by Ramirez et al. This study 
consisting of 15 HD patients and 15 healthy controls and revealed that TL 
measured using FISH technique was reduced in dialysis patients and correlated 
with a raised CRP (Ramírez et al., 2005).  Subsequently, a study of 43 HD 
patients and 23 healthy controls revealed no difference in TL between the 2 
cohorts (Stefanidis et al., 2015).  Another study using FISH technique in 
patients (n=137 patient with ESKD) with a mean age of 52.5 showed a 
significantly lower CD4 T cell TL compared with healthy controls (n=144) 
(Betjes et al., 2011). This study concluded that immunological age of ESKD 
patients was increased by 20-30 years compared with chronological age-
matched health controls. A post hoc analysis from the MIMICK study, in HD 
patients showed that those with longer telomeres were younger and less 
inflamed with lower high sensitivity CRP (hs-CRP), IL-6 and 8-OH-dG levels 





A retrospective case control study comparing 62 HD patients and 60 healthy 
age and sex matched adults showed that dialysis patients had shorter TL 
independent of age and sex [mean 8.8 kbp vs 10.5 kbp; p<0.01] when TL was 
measured with Southern Blot (Borras et al., 2012). A multivariate regression 
analysis of the HD subgroup did suggest that patients on active vitamin D 
treatment had greater TL than untreated patients (9.5 kbp vs 8.4 kbp; p=0.003) 
(Borras et al., 2012). In a Japanese observational prospective study, the lengths 
of telomeric G-tails and total telomeres were significantly shorter in 203 HD 
patients than in 203 control subjects that were both age and sex matched 
(Hirashio et al., 2014). Baseline data on TL in a study by Lutropp et.al. 
investigating telomere attrition a year post renal transplant did reveal that 
telomeres were longer in the non-chronic kidney disease (CKD) patients 
(median age of 58 years) in comparison to dialysis patients (median age of 55 
years) supporting the theory that uraemia is a progeric state (Luttropp et al., 
2016). In this study there were 63 patients in the control group and 49 patients 
on dialysis with an inter assay coefficient of variation (CV) of 0.32% for 
telomere and CV of 0.12% for 36B4. However, the data on TL was unadjusted 
for age and gender as the authors did not find any association between TL and 
these variables among healthy controls and dialysis patients. A study on 222 
patients from an outpatient nephrology service in France of varying eGFR 
revealed that CKD was associated with premature senescence of the T cell 
compartment (Crépin et al., 2018). Younger patients with CKD stage 4 and on 
dialysis had shorter TL than those with eGFR>60mls/min [1.116  0.36 versus 




al., 2018). Older patients with CKD Stage 4 and on dialysis had shorter TL 
than those with eGFR>60mls/min (0.986  0.27 versus 0.826  0.23 versus 
0.886  0.22 T/S ratio, p=0.045) (Crépin et al., 2018). Young patients with 
ESKD has the same TL with older patients with eGFR>60mls/min (0.976  
0.21 versus 0.986  0.27 T/S, p=0.810) (Crépin et al., 2018). The authors 
reported a significant difference between TL in younger patients (age<65) and 
older patients (age>65) in 3 different groups; eGFR<60mls/min, CKD stage 4 
and ESKD on dialysis  (Crépin et al., 2018). However, none of the data were 
adjusted for age and gender despite a significant difference between both these 
variables among the 3 group of interest.  
 
A study comparing telomerase activity in 4 different groups of patients (n=20 
in each group) with CKD revealed that the telomerase activity in PBMC were 
similar in CKD stages 2,3 and 4 (p>0.05) while in stage 5 CKD (20 HD and 
10 peritoneal dialysis patients) it was significantly higher compared to other 
stages (p<0.0.5) (Kidir et al., 2017). The study found that telomerase activity 
was significantly lower in the healthy control group (n=20) compared to all 
other groups (p>0.05) independent of age, gender and inflammation (Kidir et 
al., 2017). However a more recent study of 224 patients showed no association 
between age and telomerase activity (Crépin et al., 2018). This study also 
observed no difference between the 3 respective groups of interest; 
eGFR>60mls/min, CKD stage 4 and ESKD on RRT (HD, n=47 and PD, n=37) 
(Crépin et al., 2018). Telomerase activity did not differ significantly in dialysis 





Increased telomerase activity is synonymous with shortened TL. These 
findings suggest that telomerase activity could represent high level of cellular 
stress in dialysis patients and the increased activity is due to the repair and 
regulatory mechanism to maintain and prevent TL shortening. These findings 
support the notion that dialysis patients have an accelerated ageing in 
comparison to healthy controls based on telomerase activity.  
 
Preliminary evidence that telomere shortening in vivo is linked with disease 
states in which oxidative stress plays a significant role comes from recent 
findings (Von Zglinicki, 2002). Increased levels of oxidative stress markers 
are common in the uraemic milieu and predicts poor outcome (Himmelfarb et 
al., 2002). Oxidative stress in association with chronic inflammation has been 
suggested for this increase in mortality (Von Zglinicki, 2002). Carrero et.al. 
was the first to show that shortened TL is associated with higher levels of DNA 
damage in the form of 8-OH-dG and raised mortality in HD patients 
independent of age and gender (Carrero et al., 2008). The study being part of 
participants from Mapping of Inflammatory Markers in CKD (MIMICK) study 
also showed that TL was negatively associated with hs-CRP, IL-6 and white 
blood cell (Carrero et al., 2008).  
 
The cumulative exposure of oxidative stress in dialysis represented by 
telomere attrition has been studied in 70 HD patients which revealed that TL 
was inversely related to time since starting HD, also known as dialysis vintage 




patients also showed that longer dialysis vintage was correlated with telomere 
shortening. (r=-0.332, p= 0.03) (Stefanidis et al., 2015). However, this 
association was largely due to 4 outliers with dialysis vintage between 4-6 
years likely to have affected these findings. The authors did not report if the 
analysis was repeated by excluding the outliers. The largest study till date 
investigating the role of TL in dialysis patients was conducted by the 
Karolinska Institute in 175 HD patients as part of a post hoc analysis. The 
average mean dialysis vintage of patients in the study were 50  60 months 
and there was no correlation between TL and dialysis vintage observed 
(Carrero et al., 2008). Conclusive data on this particular area has yet to be 
established as very limited studies are available on dialysis patients.  
 
Cardiovascular disease is the leading cause of mortality in uremic patients with 
a 5-fold increased risk in comparison to the general population. Traditional 
risk factors commonly associated with cardiovascular mortality in general 
population do not discriminate well in dialysis patients. Telomere shortening 
in the general population is associated with increased risk of premature 
myocardial infarction, coronary heart disease and death (Cawthon et al., 
2003)(Brouilette et al., 2007). Many cardiovascular research groups have 
suggested the use of TL as a novel predictor of cardiovascular outcomes in the 
general population.  
 
Oxidative stress and chronic inflammation are well known risk factors of 




general population (Houben et al., 2008). Increased oxidative stress and 
inflammation have been widely associated in uraemia and these factors have 
been proposed to be a causative or associated factor that contributes to the 
raised cardiovascular mortality in patients with ESKD (Himmelfarb et al., 
2002). A prospective observational study involving 203 Japanese HD patients 
examining the length of telomeric G-tails and total telomeres and subsequent 
cardiovascular events during a median follow-up period of 48 months revealed 
that the length of telomeric G-tail was associated with new onset 
cardiovascular events (Hirashio et al., 2014). These associations persisted 
despite adjustment for age, sex, diabetes mellitus, clinical history of 
cardiovascular disease, inflammation, use of vitamin D, and serum levels of 
phosphate and intact parathyroid hormone. Similar findings were not seen with 
total telomeres in this study. This was the first study to report the findings of 
telomeric G-tail lengths as an independent predictor of new onset 
cardiovascular events in HD patients. Shortening of telomeres have also been 
associated with significant increase in left ventricular mass in HD patients 
(r=0.40, p=0.02) (Murillo-Ortiz et al., 2016). This study also revealed that left 
ventricular mass index was higher in the group of patients with raised ferritin 
and concluded that iron induced oxidative stress could play a fundamental role 
in their findings (Murillo-Ortiz et al., 2016). 
 
Currently, the relationship between ESKD and TL; and mortality has not been 
well explored. Most studies exclude patients on renal replacement therapy 
which makes it impossible to evaluate any association between ESKD and 




data has shown the relevance and importance of investigating telomere biology 
in patients on renal replacement therapy. Telomere biology could be a 
contributing or causal factor in mortality outcomes in the uraemic population 
and could explain the markedly increased risk of cardiovascular mortality in 
patients with ESKD. 
 
1.3.1 Telomere Attrition in uraemia (Chronic Kidney Disease and 
Renal Replacement Therapy) 
 
Longitudinal studies in animal models and non-CKD/RRT patients have 
helped us understand the importance of TL attrition and the role it plays in 
lifespan/mortality. However, the role of telomere attrition in uraemia is not 
well understood as there are only a handful of published work in this area. The 
first and only study thus far investigating telomere attrition in dialysis patients 
(n= 59) did report that dialysis patients with longer TL at baseline had 
increased telomere attrition (Kato et al., 2016) as seen in animal models and 
studies in healthy and non-CKD/RRT adults (Refer to Section 1.2.8 on 
telomere attrition). The study was unable to draw any conclusion on mortality 
due to the small number of study participants and low number of events (Kato 
et al., 2016). Luttropp et.al had investigated the role of telomere attrition post 
renal transplant in 47 patients (median age of 45 years) in comparison to 49 
patients (median age of 55 years) on dialysis and 63 patients with no renal 
disease (Luttropp et al., 2016). Over 12 months, dialysis patients had showed 




who underwent kidney transplant had surprisingly a significantly greater 
telomere attrition (1.02 to 0.84 T/S; p<0.001) (Luttropp et al., 2016). The 
authors had hypothesized that TL attrition would be less after renal transplant 
due to normalization of pro-oxidative, pro-inflammatory and 
hyperhomocysteinaemic uraemic milieu as renal transplant is associated with 
better long-term survival in comparison to dialysis treatment (Luttropp et al., 
2016). One possible reasons for these unexpected findings may be attributed 
to different rates of attrition in different age groups, the effect of 
immunosuppression e.g. mycophenolate mofetil (Luttropp et al., 2016) and 
anti-thymocyte globulin (Crepin et al., 2015), increased BMI post-transplant 
due to steroid use and the probable increase in telomere attrition associated 
with major surgery which may improve with time. However, bearing in mind 
that the authors did not adjust TL findings with age and gender as there was 
no correlation between these three variables in the study cohort. This 
highlights the importance for the need of further studies to investigate these 
findings in different age groups and longer duration of follow up as little is 
known about the dynamic change and regulation of TL over time and 






1.4 DNA methylation and epigenetics 
 
DNA methylation (DNAm) is another promising biomarker that has gained 
recognition as an ageing molecular marker. It is an epigenetic marker of the 
genome linked to gene expression/regulation and is involved in the 
development process of various eukaryotes. Epigenetics is defined as a 
functionally relevant structural and chemical change of DNA and/or associated 
regulatory proteins without any change to the nucleotide sequence (Felsenfeld, 
2014). These changes alter the availability of DNA to bind proteins that can 
either induce or repress gene transcription. 
 
DNAm involves the addition of a methyl (CH3) group to the carbon 5 position 
of the cytosine ring of the DNA resulting in an end product known as 5-
methlycytosine (5-mC). This process subsequently modifies the gene and its 
expression thereafter. DNAm is a heritable and modifiable factor affecting 
gene expression. 5-mC is found in approximately 1.5% of human genomic 
DNA (Lister et al., 2009). The addition of methyl groups is catalysed by DNA 
methyl transferases (DNMT); which consists of a group of enzymes; DNMT1, 
DNMT3a and DNMT3b. DNMT1 is involved in the maintenance of the 
methylation pattern in the genome by replicating the hemimethylated CpG 
sites (Vilkaitis et al., 2005). Whilst DNMT3a and DNMT3b are de novo 
methlytransferases (Okano et al., 1999). Transcription factors and histones are 






Passive DNA demethylation which is thought to occur during replication in 
the absence of a maintenance mechanism. Active DNA demethylation is a 
process whereby the methyl group is removed or modified from the 5-mC 
section of the DNA aided by an enzymatic process. It is only in recent years 
that series of discoveries have led to a better understanding of the mechanism 
involved in active DNA demethylation which involves the ten-eleven 
translocation family of enzymes.  Ten eleven translocation (TET) 
dioxygenases are thought to play an important role in DNA demethylation 
through conversion of 5mC to 5hmC (Kohli and Zhang, 2013).  
 
In the context of gene promoters, hypomethylated CpGs are associated with 
active, constitutively expressed genes. Hypermethylation of gene promoters 
which have high densities of CpG sites (28 millions of CpG sites in the human 
genome), known as CpG islands, leads to chromatin compaction an associated 
with consequent loss of gene expression which is a critical mechanism for 










1.4.1 Factors associated with DNA methylation  
 
The epigenetic profile has shown that DNA methylation is relatively dynamic 
and can be influenced by many factors. Twin studies have discovered that age, 
gender, genetics, habits and environmental factors affect DNA methylation. 
(Fraga et al., 2004)(Tan et al., 2016) . Measures of obesity such as body mass 
index (BMI) and waist circumference are shown to be associated with 
accelerated epigenetic ageing (Horvath et al., 2014). DNA methylation may 
also be influenced by smoking (Park et al., 2018) and stress (Matosin, 
Cruceanu and Binder, 2017).  However, such a correlation was not observed 
in other studies (Sillanpaä et al., 2018).  
 
1.4.1.1 DNA methylation profile and gender 
 
It is generally assumed that the age-related changes in DNA methylation are 
largely similar between males and females. However, a study by Masser et.al. 
showed that methylation does not differ between gender at young age but an 
age related change occurs in one sex termed ‘sex divergence’ (Masser et al., 
2017). A meta-analysis of four cohorts;  the Lothian Birth Cohorts of 1921, 
and 1936, the Framingham Heart Study, and the Normative Ageing Study 
showed that women had significantly lower Δ age (DNAm age minus 
chronological age) estimates than men i.e. men older than women (Marioni, 
Shah, McRae, Chen, et al., 2015). Similar findings were also seen by Hannum 




(Hannum et al., 2013). A recent systematic review investigating the association 
between the epigenetic clock and increased risk of death showed no clear 
difference across gender (Fransquet et al., 2019).  
 
1.4.1.2 DNA methylation in chronic disease states 
 
The pathogenic role of DNAm in diseases is diverse. There is mounting 
evidence to suggest that DNAm has an important regulatory role in the 
development and progression of common diseases, with a systematic review 
showing that an increase in DNAm age predicted the future risk of diseases 
(Fransquet et al., 2019).  
 
A link between DNAm and cancer was first described in 1983 when cancer 
cells were found to be hypomethylated in comparison to healthy cells (Gama-
sosa et al., 1983). However, this hypothesis has evolved with further research 
suggesting that both hypomethylation and hypermethylation are observed in 
virtually all types of cancer. However, the pattern of DNAm differs in different 
types of cancer and different specimens. Recent discoveries in cancer 
epigenetics has led to classification of epigenetics into 3 different 
classifications; epigenetic modifiers that directly modify the cancer 
epigenome and are frequent targets of mutations and epimutations; 
epigenetic mediators that drive the tumour or its progenitor cells towards a 
more stem-like state; and epigenetic modulators that transmit environmental 





Aberrant DNA methylation is not only associated with various cancers but 
it’s may have a role in other chronic conditions including autoimmune 
diseases, neurodegenerative conditions and metabolic disorders (Jin and 
Liu, 2018). Linking DNA methylation status at specific gene regions with 
chronic diseases is an active field of research.  With the hope that this 
knowledge can be used to identify new risk factors and provide more 
sensitive markers for diagnosis, prognosis and potential treatment.  
 
Another area that has gained wide recognition in the field of DNA methylation 
is ageing. There is evidence to suggest that DNA methylation throughout an 
individual’s lifespan exhibits a strong correlation with age and age-related 
outcomes. The first evidence that ageing might have an effect on DNA 
methylation was reported in 1973 whereby total levels of 5-mC in DNA 
isolated from various tissues of albino male rats reduced with age; 1, 12 and 
28 months (Vanyushin et al., 1973). Subsequent studies in animal models and 
cultured human cells confirmed these findings and reported the rate of loss of 
DNA 5-mC residues as an inverse relationship to life span (Wilson et al., 
1987). The relationship between DNA methylation and ageing is extensively 







1.4.2 DNA methylation and ageing 
 
There are 6 types of potential biological age estimators which are epigenetic 
clocks, TL, transcriptomic- based, proteomic- based and metabolomic-based 
estimators and composite biomarkers. DNAm age is often referred to as 
‘epigenetic clock’. A recent review concluded that the epigenetic clock is the 
most promising molecular estimator of biological age (Jylhävä, Pedersen and 
Hägg, 2017).  
 
A small fraction (~2%) of the CpG sites show age related change either 
hypermethylation or hypomethylation. DNAm has an inverse relationship with 
age in humans (Langevin et al., 2011)(Steves, Spector and Jackson, 2012). 
DNAm predicts biological age more efficiently than chronological age (Xiao, 
Wang and Kong, 2019). The difference between the DNAm age and 
chronological age provides the rate of epigenetic age attrition. Accelerated 
epigenetic ageing is when estimated age is higher is than the chronological age. 
Therefore, those with an epigenetic change age that is older than expected 
based on their chronological age are described as exhibiting positive epigenetic 
age acceleration whilst the reverse situation would be described as negative 
age acceleration. DNAm age can predict life expectancy because it has been 
shown to predict all-cause mortality independently of common risk factors 





An ageing phenotype occurs as a result of cellular senescence which refers to 
the process of cell proliferation arrest which is irreversible. One of the 
contributing factors to cellular senescence is stress which leads to DNA 
damage. Cellular senescence shares epigenetic similarities with ageing. 
Studies have shown that the process of replicative senescence is associated 
with loss of DNA methylation as seen in ageing (Wilson and Jones, 1983). In 
fact, senescence can be induced with DNA methylation inhibitors in vitro 
(Vogt and Haggblom, 1998). Recent analyses of primary endothelial cells have 
demonstrated an increased epigenetic age with senescence in an age dependent 
manner (Lowe, Horvath and Raj, 2016). 
 
In general, cellular senescence and epigenetic ageing are distinct phenomena 
though seem to converge under the same circumstances. Even though 
senescent cells exhibit methylation changes of some specific CpGs, these are 
in general have not been similar sites noted in age-related CpGs (Franzen et 
al., 2017). 
 
Many efforts thus far have been spent in identifying dysregulation of the 
epigenetic landscape which has now been recognised as a hallmark of the 
ageing process. Changes to the epigenetic process occurs throughout the entire 
lifetime of an individual. In humans, DNAm changes start early in life as 
demonstrated by longitudinal studies of infant’s blood where increased levels 
of 5mc were shown to have already occurred during the first year of life during 
a 5 year follow up period (Herbstman et al., 2013) (Martino et al., 2013). In 




aged mice exhibited low levels of 5mC (Wilson and Jones, 1983)(Wilson et 
al., 1987).  
 
The first genome wide analysis focusing on 5hmC in ageing was performed on 
human mesenchymal cells that revealed equal amounts of both 5hmC gain and 
loss. The epigenetic theory is currently based on 2 theories as described below: 
 
a) Epigenetic drift  
 
This theory is defined as the general decrease in DNAm or hypomethylation 
whereby the baseline DNA methylation progressively diverges during ageing 
with increases in variability of methylation patterns with age (Fraga et al., 
2004). Epigenetic drift leads to inter individual epigenetic divergence with 
increasing age as a result of lifelong accumulation of epimutations. Evidence 
for this comes from monozygotic twin studies (Fraga et al., 2004) (Jones, 
Goodman and Kobor, 2015) which have shown that twins with similar 
epigenome at birth become more discordant as they age. This may be due to 
influence of environmental factors and intrinsic factors. 
 
b) Epigenetic clock theory  
 
This theory is described as locus specific DNA methylation events in gene-
associated regulatory regions which suggest a programmed epigenetic 
reconfiguration during ageing (Horvath, 2013). Several studies have supported 




which consists of DNA methylation changes at specific CG sites that are 
reproducible across individuals and tissues. These studies led to the 
development of two predictive mathematical models of biological age based 
on ageing associated site-specific DNA methylation changes (Hannum et al., 
2013) (Horvath, 2013). The models were basically age predicting tools that 
were developed after interrogating DNAm states at various CG sites. 
Hannum’s clock had assessed 71 CG sites from whole blood samples of more 
than 650 individuals (Hannum et al., 2013). The model had a 96% correlation 
with a margin of error of 3.9 years. The Horvath’s clock had assessed 353 CG 
sites from more than 7800 samples consisting of 51 different cell and tissue 
types. Horvath confirmed that the hypermethylated sites with ageing were 
compatible with a broad range of tissues with a 96% correlation with a margin 
of error of 3.6 years (Horvath, 2013). Horvath had determined that the ageing 
rate of the methylome follow a logarithmic increase until adulthood following 
by a linear relationship thereafter (Horvath, 2013). Both these models allow 
the calculation of an individual’s epigenetic age despite having only 6 CpG 
sites in common (Chen et al., 2016). The predicative accuracy of the Hannum 
clock, which was developed using blood samples, declines when applied to 
other tissues. In contrast, the Horvath clock performs well with a variety of 
tissues; however, the accuracy of the Horvath clock in predicting age is less 
for skeletal muscle, heart, and breast. Both Horvath and Hannum clocks are 
models based on chronological age which may be account for strong 
correlation between these epigenetic clocks and chronological age. Δ age 
(predicted age or also known as DNAm age minus chronological age) 




epigenetic marker which would be a better predictor of biological age by 
incorporating other clinical measures (e.g. albumin, creatinine, c-reactive 
protein etc) in addition to chronological age. The resulting Pheno-Age clock 
has 41CpG sites it shared with Horvath’s data and 6 similar sites with Hannum 
(Levine et al., 2018). Pheno-Age remains highly correlated (r2=0.92) with 
chronological age and is a better reflection of biological age and mortality 
(Levine et al., 2018).  
  
The revelation of the epigenetic theory has led to increasing efforts to 
determine any association between DNAm and ageing. Research has shown 
that epigenetic changes affect all cells and tissues over the lifespan (Talens et 
al., 2012). Early studies showed that global DNAm decreases with age, 
however subsequent studies have shown that ageing is associated with mainly 
hypermethylation of several genomic loci (Gensous et al., 2017). Studies have 
concluded strong links between DNA methylation, age acceleration, increased 
risk of cardiovascular disease and mortality. There has also been promising 
data from animal studies. Petkovic et.al. reported that the epigenetic clock 
accurately predicted chronological age of mice but none of the CpG sites 
matched the site from either Hannum or Horvath (Petkovich et al., 2017). 
Despite the fact that no CpG sites matched between the mice epigenetic clock 
and the human epigenetic clock there has been promising data on anti-ageing 
therapy in the animal models. Studies have shown that a caloric restriction diet 
lowered the epigenetic age of mice by 20% compared to the chronological age 




rapamycin in animal models had also revealed that mTOR inhibitor had 
increased the lifespan of a variety of mouse models (Wang et al., 2017).  
 
Interest in the role of DNAm and ageing increased following the development 
of the epigenetic clock by Horvath and Hannum following interrogation of 
various CpG sites to predict chronological age. These studies only looked into 
CpG sites. However, despite efforts of these groups, it is still difficult to 
confidently ascertain if methylation changes of CpGs are the driving force of 
ageing or the cause of consequence of the phenotype as the exact mechanism 
by which DNA methylation regulates ageing is still poorly understood. Further 
studies in this area are vital to gain insight into DNA methylation genome 
changes at specific sites with age across different cohorts.  
 
1.4.3 DNA methylation and mortality 
 
The rate of ageing, susceptibility to diseases and death differs from person to 
person. The underlying explanation to explain this variation has been the 
backbone of research in the area of DNAm. A meta-analysis by Marioni et.al. 
reports that the difference between DNAm predicted age and chronological 
age (Δage) using two sets of epigenetic markers (Hannum and Horvath’s 
epigenetic clock) were associated with an increased risk of mortality in four 
independent cohorts of older individuals with a mean age of 72 years (Marioni, 
Shah, McRae, Chen, et al., 2015). This association was independent of life-




APOE, education, childhood IQ, social class, diabetes, high blood pressure, 
and cardiovascular disease (Marioni, Shah, McRae, Chen, et al., 2015). The 
authors also showed that there was no clear association between these factors 
and Δage, supporting the hypothesis that the epigenetic clock and DNA 
methylation Δage is predictive of human mortality, after accounting for known 
risk factors.  
 
A recent systematic review found that a 5 year increase in DNAm age was 
associated with up to a 15% increased risk of all-cause mortality (Fransquet et 
al., 2019) In fact the primary finding of this systematic review of 11 studies 
(278490 participants and 10233 deaths) support an association between 
accelerated DNAm age and an increased risk of all-cause mortality in 
particular when the Hannum epigenetic clock was used (Fransquet et al., 
2019). Ten out of the 11 studies in this systematic review had independently 
found that a higher biological age relative to chronological age is predictive of 
time to death, cancer-related, cardiovascular disease related or all-cause 
mortality (Fransquet et al., 2019). Two meta-analysis; one with 13 studies of 
n=13089 and another with 4 studies of n=4658 reported a significant 
association between an increase in DNA methylation age and mortality risk 
(Marioni, Shah, McRae, Chen, et al., 2015)(Chen et al., 2016). Marioni et.al. 
revealed that a 5-year mortality was higher with the Hannum and Horvath Δ 
age at 21% and 11% when corrected for age and sex (Marioni, Shah, McRae, 
Chen, et al., 2015). Horvath’s calculator is better for development stages e.g. 
puberty and menopause whilst Hannum’s clock may be a better reflection of 





1.5 The importance of DNA methylation and uraemia 
 
DNAm has been associated with different diseases (Laird, 2003)(Feinberg, 
2007). Research into the role of DNAm has been limited in dialysis cohorts. 
There has been some evidence in the role of DNAm in the context of uraemia; 
mainly on cardiovascular risk and inflammation that has shed some light on 
epigenetic DNA modifications in this cohort (Stenvinkel et al., 2008).  
 
Reports from ESKD cohorts have shown that dialysis patients have an 
increased risk of cardiovascular disease; at least 10-30 times higher than the 
general population with a 23% mortality. This increased risk cannot be 
explained by the conventional risk factors alone and has been linked to 
elevated oxidative stress levels, persistent inflammation and 
hyperhomocysteinaemia. Therefore, exploring the role of the epigenetic clock 
in uraemia would seem to be naturally the next step in progressing forward in 
renal research. 
 
A study by Stenvinkel et.al. showed that global DNA methylation was 
associated with both all-cause mortality and cardiovascular mortality even 
when adjusted for age, CVD, diabetes and inflammation in dialysis patients 
(Stenvinkel et al., 2007)(Stenvinkel and Ekström, 2008). The study highlighted 
that global DNA hypermethylation was the strongest independent risk factor 




The study also revealed a strong association between markers of inflammation 
and oxidative stress (IL-6 and 8-OHdG) and global DNA hypermethylation 
(Stenvinkel et al., 2007). There was only a weak significant correlation 
between DNA methylation status and hyperhomocysteinaemia in this study 
though (Stenvinkel et al., 2007). Another smaller study of 20 healthy controls 
and 20 dialysis patients failed to show any difference between global DNA 
methylation between both groups (Hsu et al., 2012). However, the study did 
reveal a reduction in DNMT expression (an enzyme group responsible for the 
transfer of methyl group to the  5-position of cytosine residues in DNA and to 
establish and maintain genomic methylation) in HD patients (Hsu et al., 2012).  
 
Subsequent efforts have taken place to identify probable gene promoter 
regions which could account for these findings. A study of DNA methylation 
status of the MTHFR promoter region showed a significant increase in the 
frequency of the MTHFR methylation status among patients with ESKD in 
comparison to healthy controls (Ghattas et al., 2014). MTHFR gene has been 
associated with hyperhomocyteinaemia which has been associated with 
increased rates of vascular disease. Findings from these studies have given 
researchers a glimpse of potential and importance of the epigenetic clock 









1.6.1 What is frailty- concept and definitions? 
 
Frailty is a biologic syndrome where there is a decreased reserve and resistance 
to stressors, resulting from cumulative declines across multiple physiologic 
systems, which in return causes vulnerability to adverse outcomes (Fried et al., 
2001). Frailty is often recognised as a phenotype that quantifies the functional 
loss that results during the ageing process.  Frailty is also a multidimensional 
construct reflecting the decline in health and function observed in the elderly, 
ultimately resulting in increased risk for adverse health outcomes, falls and 
disability, hospitalization, institutionalization and death (Clegg et al., 2013). 
 
Frailty is not synonymous with either comorbidity or disability, but there is an 
overlap among these 3 phenotypes whereby comorbidity is an aetiologic risk 
factor for, and disability is an outcome of frailty (Fried et al., 2001). Frailty 
was defined by Fried et al based on 5 components; grip strength, walk speed, 
depression scale, weight loss and physical activity. There have been various 
frailty screening tools that has been developed to detect frailty but there is no 






1.6.2 Why is frailty an important? 
 
Old age itself does not define frailty but prevalence of frailty increases with 
age. In the Cardiovascular Health Study, involving 5317 individuals who were 
65 years and older revealed that frailty increased with age (Fried et al., 2001). 
Frailty was also higher in females than male (Fried et al., 2001) (Woo et al., 
2008). Individuals with intermediate frailty (i.e. pre –frail with scores of 1 or 
2) were more than twice the risk of becoming frail over 3 years relative to those 
with no frailty characteristics at baseline (Fried et al., 2001). Presence of frailty 
is also associated with several adverse health outcomes such as functional 
decline [worsening mobility, activities of daily living (ADL) disability, 
recurrent falls, hip and non-spine fractures], hospitalization, and death (Fried 
et al., 2001). Frailty is a strongly associated with impaired physical ability, 
poorer quality of life and increased morbidity and mortality. The International 
Task Force on Nutrition and Ageing concluded that gait speed (one of the 
components of frailty) is strongly associated with adverse outcomes, including 
fall and hospitalization in non-renal patients (Abellan Van Kan et al., 2009).  
 
In men, higher frailty index was positively associated with mortality after 
adjusting for age, while the association was not significant in women (Woo et 
al., 2008). PBMC telomeres were shorter in sarcopenic subjects (T/S= 0.21; 
95% CI: 0.18–0.24) relative to non-sarcopenic individuals (T/S= 0.26; 95% 




comorbidity (Marzetti et al., 2014). A recent overview did suggest that TL may 
provide a better and more accurate assessment and prediction of frailty in 
elderly population (Lorenzi et al., 2018). A recent study has shown that frailty 
can be modified by exercise and nutrition; reversing the frailty state to non-
frail (Michel, Cruz-Jentoft and Cederholm, 2015). Understanding these 
associations can help recognise elderly individuals at risk for adverse 
outcomes and in return improve care for this vulnerable subset of patients as 
well as exploring means of reversing frailty.  
 
1.7 Frailty phenotype in uraemia 
 
The presence of chronic diseases was associated with increased frailty. Frailty 
can be caused by ageing per se, advanced CKD or both. Fried et al. described 
an association between CKD on one hand, and the development of functional 
impairment on the other. This was further reinforced by Roderick et al. 
revealing that measures of morbidity and functional impairment increased as 
renal function worsened (Roderick et al., 2007).  
 
There are various metabolic alterations associated with uraemia which 
inevitably impact and affect frailty in patients with ESKD. Uraemia induced 
alterations such as increased energy expenditure, inflammation, acidosis, 
multiple endocrine perturbations that render a state of hypermetabolism 
leading to excess catabolism of muscle and fat are factors that have significant 




dialysis patient’s frailty level and accelerates ageing. Frailty was found to be 
predictive of poor outcomes among patients with ESKD. The validity of the 
frailty index was supported by its association with mortality (Mitnitski et al., 
2002), and health outcomes such as hospitalization, functional and cognitive 
decline and was also influenced by social determinants (Woo et al., 2008). 
 
Frailty was highly prevalent in patients with ESKD and substantially greater 
in elderly and near-elderly ESKD patients (Johansen et al., 2007). The 
prevalence of frailty in the older adult population is reported to be 11%, 
whereas the prevalence of frailty has been reported to be greater than 60% in 
dialysis-dependent patients (Johansen et al., 2007). Increased mortality and 
higher risk of combined outcome of death or hospitalization was also seen 
independent of age among frail dialysis patients in the dialysis Wave II Study 
(adjusted HR 2.24, 95% CI 1.60-3.15) (Johansen et al., 2007). Frail patients 
were more likely to be hospitalized for any reason and have increased mortality 
rate (HR1.90;95%CI 1.67 to 2.17), a finding that persisted after adjustment for 
multiple potential risk factors for hospitalization (adjusted HR 1.56; 95% CI 
1.36 to 1.79) (Johansen et al., 2007). Even after adjustment for age, gender, 
race or ethnicity, body size, dialysis modality, comorbidities, serum albumin, 
and other factors, frailty remained strongly associated with mortality (adjusted 
HR 2.24; 95% CI 1.60 to 3.15) (Johansen et al., 2007). Multivariable logistic 
regression analysis of the dialysis Wave 11 study also suggested that older age, 
female sex and HD (rather than PD) were independently associated with frailty 
(Johansen et al., 2007). The study also revealed that among HD patients, those 




though these finding are open to confounding of access choice based on 
physician assessment of frailty (hazard ratio HR 0.71; 95% confidence interval 
CI 0.51 to 0.98).  
 
There was a lack of interaction between age and frailty in ESKD cohort 
suggesting frailty is relevant even in the younger patient (Johansen et al., 
2007). In the Dialysis Wave 11 Study a significant proportion of patients in 
the younger age groups were also frail with 44% of these patients being 
younger than 40 years of age and more than half of the frail patients were aged 
between 40 to 50 years.  
 
Shlipak et al. showed that CKD is associated with a greater prevalence of both 
frailty and disability in the elderly population, with the prevalence of frailty 
and disability being 15 and 12%, respectively, in elderly with CKD, versus 
only 6 and 7% in the elderly with normal kidney function, respectively 
(Shlipak et al., 2004).  
 
Frailty also increases over time in the absence of any intervention. There have 
been a few studies evaluating the rate of change in frailty status over a period 
of time but there have been no prospective studies looking into effect of 
intervention on frailty on a longitudinal basis in dialysis patients. The 
investigators of a 2 year follow up study (ACTIVE/ADIPOSE study) on frailty 
among 771 patients showed that components of frailty did not change to the 
same degree or in the same direction over the follow up period (Johansen et 




activity, gait speed and to a lesser extent grip strength declined over time but 
exhaustion was relatively stable and the odds of fulfilling the weight loss 
criteria decreased over the study period (Johansen et al., 2019). All the 5 
components except physical activity were associated with mortality 
independent of all the other components but the use of all 5 components in the 
form of a model provided the most useful information (Johansen et al., 2019).  
 
These findings have led researchers to believe that there is a higher proportion 
of frail patients in the ESKD cohort in comparison to those without kidney 
disease suggesting that ESKD may be a major contributor to the development 
of frailty (or vice versa), such that it can occur in patients who are younger 
than those who are typically expected to be frail. These studies have also paved 
the way into using individual frailty components to help stratify risk of adverse 






1.7.1 Physical Frailty Phenotype/Fried or Hopkins Frailty 
Phenotype 
 
The Physical Frailty Phenotype, also commonly known as the Fried Frailty 
phenotype is the most cited frailty tool in the research literature and validated in 
dialysis cohorts (Buta et al., 2016). The tool defines the frailty phenotype as 
scoring 3 or more of the 5 frailty criteria listed below while pre-frail is defined as 
a score of 1 or 2 of the characteristics and not frail as scoring 0.  
 
a) Weight loss (more than 10 pounds unintentional) 
b) Exhaustion or fatigue 
c) Muscle Weakness (assessed by grip strength) 
d) Slow walking speed (gait speed to walk 15 feet) 
e) Low physical activity 
 
The Fried frailty phenotype is an ideal tool to be used in the dialysis cohorts as 
each of the frailty component represent and reflect changes often seen among 
dialysis patients due to the pathophysiology of the disease condition. The frailty 
components measured affect and regulate each other. Alteration to one component 
may impact another component. Often there is a huge overlap and dependence 





Figure 7: Cycle of frailty. Reproduced with permission. (Xue et al., 2008) 
 
1.7.2 Factors associated with frailty in uraemia 
 
There are various factors that contribute to frailty in the elderly population and 
more so among elderly patients with ESKD as listed below. 
 
a) Increase inflammatory markers  
 
Chronic inflammation is a hallmark finding in dialysis patients and is the main 
feature of uraemic phenotype associated with increased cardiovascular disease and 
protein energy wasting. It is a known predictor of poor outcome in ESKD. C-
reactive protein and interleukin-6 (IL-6) are often raised in ESKD and associated 
with frailty (Cesari et al., 2004)(Cohen, Harris and Pieper, 2003) (Hubbard et al., 




in CKD stage 5 (Sun et al., 2016). All the 5 components measured in the frailty 
component is a direct and indirect measure of inflammation observed in ESKD 




Anaemia is often observed in dialysis patients and is managed with iron and 
erythropoietin The Women’s Health and Ageing Studies I and II (WHAS) 
identified anaemia as a risk factor for frailty (Chaves et al., 2005). Exhaustion is 
associated with anaemia in dialysis patients which subsequently leads to low 
physical activity and this can affect walking speed.  
 
c) Poor nutrition, weight loss and sarcopenia  
 
Anorexia is common among patients on dialysis with a prevalence of up to 
50% (Carrero, 2009). The cause of weight loss in dialysis patients are 
multifactorial. There is true undernutrition due to insufficient food intake 
resulting from poor appetite and various dietary restrictions observed by 
patients on dialysis and pathological nutritional deficiencies due to uraemic 
toxins, chronic inflammation, acidosis, altered hormone function and the 
process of dialysis itself which results in loss of amino acids stimulating 
muscle breakdown. Weight loss is significantly more pronounced among 
dialysis patients and leads to an accelerated loss of muscle mass and strength 
causing sarcopenia. Sarcopenia causes reduced hand grip strength, affects 




Sarcopenia reflected by slow gait speed and low muscle strength from the 
ACTIVE/ADIPOSE study of prevalent HD patients showed that these frailty 
components were associated with mortality even after adjustments for muscle 
size and other confounders (Kittiskulnam et al., 2017). Diminished hand grip 
strength was a significant predictor of death in dialysis patients (Yoda et al., 
2012) and independent risk factor for all-cause mortality (Vogt et al., 2016).  
 
d) Hormonal changes 
 
The kidneys play a major role in endocrine function. ESKD is associated with 
impairment of excretion, synthesis and functionality of many hormones 
including insulin, insulin growth factor (IGF), growth hormone (GH), 
testosterone and thyroid function. These hormones are implicated in 
malnutrition, loss of muscle mass and closely associated with quality of life. 
Giving GH to elderly patients on HD improved muscle performance, 
suggesting a role of GH in preserving muscle function. Studies in CKD 
patients have shown that endogenous testosterone was an independent 
determinant muscle mass and muscle strength measure with hand grip strength 
(S. et al., 2013). Randomized intervention studies with androgen replacement 
in patients with renal dysfunction did show significant improvement in muscle 
mass and nutrition (Johansen, Mulligan and Schambelan, 1999). Therefore, the 
indirect effects of hormonal changes in dialysis patients can be reflected by the 






e) Bone mineral density 
 
Dialysis patients suffer from secondary and tertiary hyperparathyroidism and 
achieving adequate bone mineral density are key goals in managing a dialysis 
cohort. Bone mineral diseases in dialysis patients are associated with 
disturbance of phosphate and calcium homeostasis and changes in key 
regulators such as parathyroid hormone and fibroblast growth factor 23. 
Alterations in these parameters will lead to renal osteodystrophy with loss of 
bone mineral density, increased risk of osteoporosis, fractures, falls and 
premature vascular calcification. Patients on dialysis have been observed to 
have a 2 to 4 fold increase in hip fracture rate (most extensively studied fracture 
type in ESKD patients) in comparison to the general population (Alem et al., 
2000) (Arneson et al., 2013). Poor mineral bone density/osteoporosis is often 
represented by weak hand grip strength, reduced physical activity and may 




Comorbid depression is common in dialysis patients with studies suggesting 
that up to 1/3  of all patients on dialysis have significant depression (Palmer et 
al., 2013). Depression in dialysis patients is associated with fatigue, loss of 
appetite and difficulty in sleeping. Some of the health risk observed in dialysis 
patients with depression include inability to adhere to the prescribed dialysis 
regime, diet, medication and self-harm (DiMatteo, Lepper and Croghan, 




perception of illness to be associated with higher depression scores and lower 
quality of life. Progression of depressive symptoms is associated with the onset 
and progression of frailty in non-dialysis when using the Centre for 
Epidemiological Studies Depression Scale (Ní Mhaoláin et al., 2012). Studies 
have revealed an association between increased markers of inflammation (c-
reactive protein and interleukin 6) in dialysis patients with exhaustion and 
depression (Wang et al., 2012) (Bossola et al., 2015). The exhaustion/fatigue, 
unintentional weight loss and low physical activity component from the Fried 
frailty phenotype can also signify depression. Depression correlates with both 
hospitalization and mortality rates and has been associated with frailty (Lopes 
et al., 2002). 
 
1.8 Telomere biology and DNA methylation 
 
There is emerging evidence to suggests that epigenetics regulates telomere 
dynamics in adults (Buxton et al., 2014; Wong et al., 2014). Studies in animal 
models described the role for mammalian DNA methyltransferases in TL 
control which demonstrated a previously unappreciated role for DNAm in 
telomere maintenance (Gonzalo et al., 2006). Subsequent studies in human 
adults found that there was an increase in global DNAm at the proximal 
subtelomeric regions which was associated with an increased in telomerase 
activity which is involved in telomere maintenance (Ng et al., 2009) Both 
global DNAm and TL are inversely associated and involved with ageing 




epigenetic age acceleration defined by Hannum’s clock and DNAm PhenoAge 
(based on 513 CpG sites and takes into account 42 clinical biomarkers and age) 
and this is probably due to age-related changes in blood cell composition such 
as the decline in naive T cells often affecting TL (Chen et al., 2017) (Levine et 
al., 2018). Both DNAm age and TL are associated with age and mortality 
independent of each other (Marioni et al., 2016). Data from the Lothian Birth 
Cohorts 1921 and 1936 revealed that the variance in age with TL was 6.6% 
and 19.8% with the epigenetic clock (Marioni et al., 2016). The findings from 
this study revealed that both TL and DNA methylation were independent 
predictors of chronological age; but there was only a weak correlation between 
both the biomarkers of ageing. This shows that the mechanism by which DNA 
methylation and TL affect ageing differs and this will require further 











1.9 Biomarkers of ageing and frailty 
 
1.9.1 Telomere Biology and frailty 
 
TL has emerged as a novel biomarker of cellular senescence over the years. 
Research outcomes have suggested that TL/telomere shortening has been 
associated with ageing, mortality and other age-related diseases which does 
constitute a part of the frailty syndrome. There are 8 cross sectional studies, 
with 2 of the studies being longitudinal in nature investigating the role of TL 
and frailty that has been published thus far (Woo et al., 2008) (Yu et al., 2015) 
(Collerton et al., 2012) (Saum et al., 2014) (Breitling et al., 2016) (Marzetti et 
al., 2014) (Brault et al., 2014) (Haapanen et al., 2018). Current evidence 
suggests that shortened telomeres are reportedly associated with low levels of 
physical activity (Cherkas et al., 2008). Studies have hypothesized an 
association between TL and indicators of physical function (e.g. grip strength; 
a component of frailty) in the elderly but failed to prove their hypothesis 
(Bekaert et al., 2005; Harris et al., 2006; Mather et al., 2010). However, these 
studies had relatively small sample sizes and included narrow age ranges. 
Subsequently, Baylis et.al showed that faster telomere attrition represented by 
the percentage change in TL over the 10 years follow period in 253 patients 
was associated with lower grip strength at follow-up (adjusted p= 0.035) 
(Baylis et al., 2014). The association between telomere attrition and lower grip 
strength at 10-year-follow-up is accounted for by greater inflammation burden 




202 patients greater than 60 years of age has shown that there were significant 
difference between frailty groups and TL whereby a 1 kbp increase in TL 
reducing the risk of frailty by 0.55 times (CI 95%[0.448-0.697] p<0.01) (Darío 
et al., 2019).   
 
1.9.2 DNA methylation and frailty 
 
The biological mechanisms that underlie frailty remains poorly understood as 
frailty itself it a complex process part of ageing. The rate of epigenetic age 
acceleration has been associated with symptoms of ageing such as frailty 
(Breitling et al., 2016). There is evidence to suggest that DNA methylation 
patterns at gene promotor regions are altered in frail individuals, but this 
relationship is rather a complex one and the importance of it is still largely 
unclear/unknown.  
 
There have been a few studies that have investigated the relationship between 
DNA methylation patterns and frailty in older populations. One study that 
defined frailty status using cluster analysis reported that global DNA 
methylation was lower in people who were frail compared to non-frail (Bellizzi 
et al., 2012) but another study that utilized the Fried phenotype for frailty 
assessment failed to show a similar association (Collerton et al., 2014). 
Collerton et.al. had examined genome wide DNA methylation levels and 
individual CpGs sites associated with frailty (TUSC3, TWIST2 , HOXD4, 




were associated with a reduced likelihood of being frail (Collerton et al., 2014). 
However, averaging methylation levels across 5 age related methylation 
markers were associated with reduced frailty (Collerton et al., 2014).   
 
One of the largest studies of participants between the age of 50-75years 
(n=1820 people) investigating DNA methylation patterns in frail individuals 
revealed that greater epigenetic age acceleration was associated with greater 
frailty with an increase in frailty index by 0.25% points per year of epigenetic 
age acceleration (Breitling et al., 2016).  Another study that focused on DNA 
methylation in a narrow-age sample of 70-year olds (n=791) found no 
difference in methylation patterns between those who were physically frail and 
not frail as defined by the Fried phenotype (Gale et al., 2018). This study also 
revealed a significant difference in the proportion of methylation at a single 
CPG site (cg18314882 in chromosome 8 in the MAF 1 gene) among the frail 
and non-frail group out of the 485, 512 CpGs measured (Gale et al., 2018).  
Knowledge of the role of this gene is limited (Khanna, Pradhan and Curran, 
2015). Participants who were frail as defined by the Fried Frailty Phenotype 
had a higher mean extrinsic epigenetic age acceleration; older biological age 
independent of potential confounding factors (Gale et al., 2018).  
 
Frailty outcomes such as grip strength (Sillanpaä et al., 2018) were associated 
with epigenetic age acceleration; however, standing balance and chair-rise 
time were not correlated to accelerated epigenetic ageing (Simpkin, Suderman 
and Howe, 2017). A study by Marioni et.al from the Lothian Birth Cohort in 




greater DNA methylation acceleration was correlated with lower cognitive 
score, weaker grip strength and poorer lung function test in humans during 
later life but not walking speed (Marioni, Shah, McRae, Ritchie, et al., 2015). 
The authors also demonstrated that the outcomes were similar using both 
Horvath and Hannum epigenetic clock but the Hannum predictor yielded a 
weaker cross-sectional association.  
 
These studies emphasize that greater epigenetic age acceleration i.e. 
biologically older has been associated with greater risk of being physically 
frail.  It is important to recognize frailty as this clinical syndrome is associated 
with an increased risk of adverse outcomes which include falls, hospitalization, 
prolonged hospital stay and death. It remains difficult to establish if changes 
in DNA methylation are a direct causative role of frailty or merely a driving 






1.10 Is there a relationship between ageing, frailty and 
biomarkers of ageing; TL and DNA methylation in uraemia? 
 
Biological age is much more accurate in reflecting an ageing individuals’ 
overall health wellbeing in comparison to their chronological age. This is 
largely due to the effect of environmental stress and physiological reserve that 
differs in the population which accounts for the variation. Both frailty and 
ageing have some form of commonality. However, growing old in itself is not 
a prerequisite to becoming frail as discussed previously and not all inter-
individual variation can be explained by chronological age alone suggesting 
an alternative mechanism underlying these changes.  
 
Frailty is a well-recognised clinical syndrome in the dialysis cohort whereby 
the prevalence of frailty has been reported to be greater than 60% (Bao et al., 
2012) (Johansen et al., 2007) in comparison to community dwelling adult older 
population with a prevalence of frailty up to 11% (Collard et al., 2012). There 
is growing consensus that frailty does exist as a distinct syndrome which 
occurs principally in a subset of individuals who are most vulnerable and 
independently associated with an increased risk of infection, hospitalization, 
dependency and reduce life expectancy. The concept of frailty is more 
predictive of an outcome than the chronological age per se even in the dialysis 
cohort, suggesting that frailty may be a better criterion to identify older persons 
in need for intervention; a concept that has been echoed throughout various 





This highlights the gravity and the importance of this issue as we are yet to 
know the exact aetiology of frailty in the dialysis cohort and the underlying 
basis for differences between individuals. Factors that contribute to frailty in 
dialysis cohorts includes chronic inflammation, accumulation of uraemic 
toxins, metabolic acidosis, sarcopenia and protein energy wasting. There is an 
overlap between frailty and protein energy wasting. The relationship between 
these 2 components are often dependent and affect each other. (See Figure 8) 
 
 
Figure 8: Causes of frailty and protein energy wasting observed in dialysis patients. 
Reproduced with permission (Kim, Kalantar-Zadeh and Kopple, 2013). 
 
Dialysis patients are affected by the factors outlined in figure 8. These are 
associated with and contribute to premature ageing. TL is also affected by 




Therefore, TL is not only an ideal biochronometer representing biological age 
but could hypothetically be a biomarker to assess frailty and ageing in ESKD.  
 
The area that has yet to be explored in the dialysis cohort is the role of 
epigenetic clock in accelerated ageing and frailty, as epigenetic mechanisms 
have been suggested as a factor/cause of frailty. Epigenetic markers in the form 
of DNA methylation status will be remodelled in response to the lifetime 
exposure to different environment stresses. Epigenetic factors; in particular 
DNA methylation vary significantly across one’s life time and in populations 
of similar age (Rakyan et al., 2010). There is also a genetic basis for frailty as 
shown by Kim et.al revealing that the pattern of ageing differed among 
offspring of long-lived versus short lived parents (Kim and Jazwinski, 2015). 
DNAm status may provide the clue and answer to the phenotypic changes 
observed in the dialysis cohort as both metabolic changes and co-existing 
inflammation has a greater effect on epigenetic mechanisms. Perhaps the most 
exciting feature is that the epigenetic changes are reversible, raising the 
prospect that DNAm status estimates might thus be useful for identifying or 
validating anti-ageing interventions in this cohort. 
 
Identification of these robust associations between DNAm and TL as a marker 
of biological ageing may provide potential diagnostic and therapeutic avenues 
in managing frailty risk in uraemia. These biomarkers may not replace existing 
clinical biomarkers but may aid in patient care especially in cohort of patients 
whereby routine clinical biomarkers may not provide an accurate finding due 




diagnosis of frailty and subsequently help prompt intervention on known, 
recognised and modifiable factors that could reverse frailty. Reversing frailty 
on time could certainly improve quality of life, mortality outcomes and reduce 
hospitalisations.  
 
Research in DNA methylation and TL in the context of uraemia is still in its 
early days as most research outcomes and studies have been conducted in non-
dialysis cohorts. However, studies in the non- dialysis cohorts have paved the 
way and generated the hypothesis for this PhD. One of the aims of the thesis 
was to assess a functional/phenotypic consequence in the form of frailty 
assessment with DNA methylation and TL changes. It is not known if the 
changes in TL and methylation correlate to changes in expression are causative 
and functionally important in ageing phenotype, but further studies are 





CHAPTER 2: AIMS 
 
2.1 An overview of Rationale, Aims and General 
Hypothesis of the research 
 
Chronological age does not reflect the physical state of an organism and does 
not occur at the same rate in individuals. There is a growing body of evidence 
to suggest that patients with end-stage renal disease develop accelerated 
ageing, the mechanisms of which are not fully elucidated. For example, ESKD 
patients develop cardiovascular events at a much earlier age than their normal-
control counterparts when matched for age and gender. ESKD patients also 
appear older than their age as evidenced by sarcopenia, skin thinning, bone 
loss, cognitive dysfunction, frailty etc. It is crucial to recognise that premature 
ageing among ESKD population is reflected by a decline in physical function, 
frailty phenotype and overall well-being which is a major health agenda. The 
frailty phenotype which in recent years has gained increasing awareness 
among health professionals caring for patients on dialysis due to the 
association between frailty with adverse outcome has highlighted the 
importance of this area in dialysis and transplantation. Nephrologists are 
recognising the impact of frailty on the dialysis patients and implications in 
future of decision making e.g. renal transplantation in borderline but younger 
dialysis patients, initiating dialysis in frail patients and escalation of care of 
these vulnerable dialysis patients. However, there is no agreed consensus on 
the best frailty assessment approach and there remains to be insufficient 




There is a lack of research investigating for a reliable objective marker of 
accelerated ageing which could also be a potential biomarker that could reflect 
one’s frailty status in ESKD which forms the initial aim of this research and 
thesis.  
 
Telomeres are a biologically plausible candidate to explore ageing in this 
cohort because of its essential role in genomic stability and normal cellular 
function with both in vivo and in vitro studies suggesting that TL reflects levels 
of oxidative stress and cellular senescence; both factors are hallmarks of 
ageing in dialysis patients. The other aspect of this study is the role of DNAm, 
an epigenetic marker highly correlated with chronological age as another 
potential biomarker of ageing. This PhD project aims to look into TL and 
DNAm status in patients with end stage renal disease with the aim to identify 
if this marker of biological ageing can help identify individuals at greatest risk 
of adverse outcome in the form of frailty status.  
 
This area is an important one as it provides important opportunities for 
targeting prevention and intervention. Investigating how TL and the estimated 
epigenetic age differs across a group of individuals of the same chronological 
age could help determine the impact of endogenous or exogenous stress factors 
on biological ageing.  Based on my current literature review it is evident that 
there a still many gaps in the literature surrounding the use of TL and DNA 
methylation as a biomarker of ageing and frailty in patients with ESKD as well 





The principle aim of this thesis is to further explore and investigate the 
relationship between ESKD, TL, DNAm markers and frailty.  
 
2.1.1 Summary of hypothesis 
 
We postulate that patients with ESKD would have shorter TL suggestive of 
premature ageing in comparison to a healthy cohort. We were also keen to 
analyse TL shortening in patients with ESKD longitudinally to determine TL 
attrition rate and investigate any correlation between TL; a biomarker of 
ageing and oxidative stress with frailty phenotype in the dialysis cohort. We 
hypothesize that dialysis patients will have significant telomere attrition over 
a year. DNAm was chosen to assess if DNAm markers could be surrogate for 
TL. This work will be a hypothesis-generating study which may lead to 
randomised control trials investigating the role of TL and DNAm status as 
ageing parameters in ESKD. 
 
2.2 General Aim of the study 
 
The general aim of the study is to investigate the role of TL, DNA methylation 







2.2.1 Aim of TL analysis in the study cohort 
 
1) To compare TL measurement between a healthy cohort as control with patients 
on dialysis 
2) To explore if there are any difference between TL in HD and PD patients 




2.2.2 Aim of DNA methylation analysis in the study cohort 
 
1) To determine if DNA methylation markers are associated with the 
development of frailty in the dialysis cohort 
2) To investigate the association between TL and DNA methylation markers 
 
2.2.3 Aim of telomere attrition and frailty changes over a year 
 
1) To investigate telomere attrition in the dialysis cohort over a 12-month period 





CHAPTER 3: CLINICAL METHODS 
 
3.1 Introduction to study design 
 
The clinical aspects of the study design and execution are elaborated in the section 
below. 
 
3.1.1 Study design and patient recruitment 
 
This research was based on an observational prospective cohort study that was 
conducted with the current revision from the declaration of Helsinki and carried out 
in accordance with Good Clinical Practice as set down in ICH E6. Ethical approval 
was obtained from Bromley National Research Ethics Service committee. (IRAS 
Project ID 167266, REC reference 15/LO/1073) (Refer to Appendix A for Study 
Protocol Version 4.0 and Appendix B for Full set of project data).  
 
Patients were recruited from Bart’s Health NHS dialysis units and renal outpatient 
clinics from December 2015 until July 2018 as per the inclusion and exclusion criteria 
outlined below. No inpatients were recruited for the study due concerns of the effect 
of an acute illness and inflammation has on telomere length by upregulations of 
oxidative stress. The study also excluded any patients with known malignancy (active 
disease or in remission) due to the associations between gastrointestinal cancer (Zhu 






• Any patient with ESKD established on HD or peritoneal dialysis treatment in 
the outpatient setting 
• Any potential kidney donor 
 
Exclusion criteria 
• Any inclusion criteria not met 
• Lack of capacity 
• Known history of malignancy at point of recruitment 
• Any patient with known history blood borne viruses 
• Felt to have a life expectancy of less than 6 months 
• Less than 18 years of age 
• Acute infection and/or in-patients having treatment 
 
Suitable patients were approached with a patient information leaflet prior to obtaining 
informed written consent to participate in the study (Refer to Appendix C for patient 
information sheet version 2, Appendix D for consent form version 2 and Appendix E 
for GP letter version 1). Consented study patients were followed up for a period of 1 







3.2 Phenotypic investigation and assessment 
 
Basic demographic characteristics at baseline (age, gender, sex, ethnicity, past medical 
history, cause of ESKD, Charlson comorbidity index, dialysis vintage, dialysis access, 
dialysis adequacy,  smoking history, medication history, height and weight, full blood 
count, white cell blood count, c-reactive protein) and 1 year follow up data (weight, 
hospitalisations, mortality and survival outcomes) were extracted from electronic 
health records, through questionnaires developed for the purpose of this study (Refer 
to Appendix F for Frailty Measurement Part 1 and Overall Progress) and direct 
questioning whenever possible.  
 
The Charlson comorbidity index of the study recruits are determined based on 
patients’ age and 16 conditions with its designated score as seen in Table 1. The more 
points accrued by the patient, the more likely the predicted adverse outcome. Patients 
were than grouped into four different categories based on the sum of the final points; 







1 Myocardial infarction (history, not ECG changes only) 
 Congestive heart failure 
 Peripheral vascular disease (including aortic aneurysm 6cm) 
 Cerebrovascular disease: CVA with mild or no residua or TIA 
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Peptic ulcer disease 
 Mild liver disease (without portal hypertension, includes chronic hepatitis) 
 Diabetes without end-organ damage (excludes diet controlled alone) 
2 Hemiplegia 
 Moderate or severe renal disease 
 Diabetes with end organ damage (retinopathy, neuropathy, nephropathy, or 
brittle diabetes)  
 Tumour without metastases (exclude if >5y from diagnosis) 
 Leukaemia (acute or chronic) 
 Lymphoma 
3 Moderate or severe liver disease 
6 Metastatic solid tumour 
 HIV positive with AIDS defining illness 
 
Table 1: Charlson Comorbidity Index (CCI) Scoring System. For each decade of >40 years, 








Dialysis vintage was defined as total time (in weeks) on dialysis up to the point of 
recruitment for the study. Smoking habit were recorded as current smoker, former 
smokers and non-smoker. Development of cardiovascular disease during the follow 
up period was defined as clinical history or signs of ischaemic cardiac disease and/or 
presence of peripheral vascular disease and/or cerebrovascular disease. Whilst 
cardiovascular mortality was defined as death resulting from coronary heart disease, 
sudden death, stroke or complicated peripheral vascular disease. The cause of death 
was registered by a health professional blind to both clinical and biochemical data of 
the patients as well as the objective of the study. Survival was determined from the 
day of sample collection.  
 
3.3 Frailty assessment  
 
The presence of frailty was evaluated in accordance to the definition by Fried et.al. 
The assessment is based on 5 domains (see Table 2); weakness, poor 








Description of assessment 
Weakness Meets criteria for frailty if grip strength on 3 average trials 
measured with an analogue hand grip dynamometer (Takei, UK) 
of the dominant or non-fistula arm as below:  
 
Men                                                                Women 
29kg for BMI 24                                    17kg for BMI 23 
30kg for BMI 24.1-26                              17.3kg for BMI 23.1-
26 
30kg for BMI 26.1-28                              18kg for BMI 26.1-29 





Exhaustion based on 2 questions from the CES-D Depression 
scale: 
1) I felt that everything I did was an effort 
2) I could not get going 
How often in the past week did you feel this way? 
Patients who felt either way for 3 days in the past week were 
considered frail. 
Slowness Walking time of 15 feet (4.57m) adjusting to gender and height 
Considered frail if normal walking pace is: 
 
Men                                                          Women 
7 seconds for height 173cm          7 seconds for height  159cm 
6 seconds for height >173cm          6 seconds for height >159cm 
Low physical 
activity 
Based on short version of Minnesota Leisure-Time Physical 
Activity Questionnaire. (See Appendix G for Frailty Measurement 
Part 2: Minnesota Leisure Time Physical Activity Questionnaire). 




Shrinking Considered frail if 10 pounds (4.5kg) of unintentionally weight 
loss (i.e. not due to dieting or exercise) in prior year. At follow up, 
weight loss was calculated as: (Weight in the previous year-current 
weight)/ (Weight in the previous year) = K. If K0.05 with 
unintentional weight loss of at least 5% of previous year’s body 
weight, then considered frail for weight loss. 
 
Table 2: Fried Frailty Phenotype Scoring Criteria. (Refer to Appendix F: Frailty 
Measurement Part 1 and Overall Progress and Appendix G: Frailty Measurement Part 2: 
Minnesota Leisure-Time Physical Activity Questionnaire) 
 
Frailty assessment was completed at the time of or within 4 weeks of blood sample 
collection at recruitment (time point 0) and at 1 year follow up (time point 1). Patients 
on HD had frailty assessments completed prior to dialysis treatment during a midweek 
session. We chose to assess all patients pre dialysis for 2 reasons: firstly, patients were 
more available before dialysis while waiting to start and not wanting to wait around 
after dialysis particularly those on transport. Secondly to reduce any effects of the 
acute dialysis treatment on the frailty assessments, for example many patients may 
intermittently feel ‘washed out’ immediately post dialysis. Studies have demonstrated 
that hand grip strength and walking speed is affected by dialysis treatment due to post 
dialysis associated fatigue (Jhamb et al., 2008) (Pinto et al., 2015). 
 
All remaining patients were assessed at outpatient clinics. All the frailty components 
were recorded using the convention that ‘0’ indicates the absence of a deficit, and ‘1’ 
indicates the (full) presence of a deficit. On the basis of the assessment, study recruits 
were given a final score and classified into one of the three frailty stages; non-frail 




3.4 Patient recruitment for the study 
 
 
Figure 9: Flow chart on patient recruitment during study period of 1 year 
 
 
Patients were recruited from Barts Health NHS Trust between the period of December 
2015 to May 2018 from the dialysis units and outpatient clinics. A total of 371 patients 
were approached with patient information leaflets and 357 had provided written 
consent for the study. Unfortunately, 18 patients did not proceed with the study and 
the remaining 339 patients who consented had their blood samples taken as per 
protocol. Only 299 patients had Frailty Assessments completed in full and 40 patients 
who had already provided blood samples subsequently did not complete the 





Reasons for patients not proceeding with the study or not completing Frailty 
Assessments are as below: 
  
a) having changed their mind subsequently 
b) moved to another trust 
c) absent on the day of their scheduled blood test and frailty assessment 
d) unexpected hospitalisation 
 
Only study participants from the dialysis arm were followed up for a 12-month period. 
Frailty assessments were completed by 155 patients out of the 299 patients who had 
also completed baseline assessments for frailty. Blood sampling at 12-month follow 
up period was taken from 228 patients.    
 
Reasons for patients not having their blood sampling or completing their frailty 
assessments at 12-month follow up are similar to reasons as to why patients had not 










3.5 Statistical Analysis 
 
Each continuous variable was tested for normality using the Shapiro Wilks test. The 
data for continuous variables with normal distribution were expressed in the form of 
mean  standard deviation (SD). Any other continuous variables that were not 
normally distributed was reported in the form of median  interquartile range (IQR). 
All categorical variables were presented in percentages or ratios.  
 
Categorical variables were compared using Chi-Square, Fishers exact and McNemars 
test. Numerical variables were compared with various T test, ANOVA, Kruskal 
Wallis, Mann Whitney U-test and Wilcoxon test. Univariate and multivariate analysis 
was used to evaluate differences between variables and simultaneously adjusting for 
confounding variables.  The association of variables were tested using Pearson’s or 
Spearman’s correlation based on the data distribution.  
 
All the statistical analysis was performed using the IBM Statistics Package for Social 
Sciences (SPSS) version 25 for MAC and R version 3.0.1. P values < 0.05 (two sided) 






CHAPTER 4: LABORATORY METHODS ON 
TELOMERE LENGTH 
 
4.1 Blood sample collection and buffy coat isolation 
 
Blood samples were collected in a 6ml EDTA vacutainer tube for all study recruits. 
For patients undergoing HD, blood sampling was done before the start of dialysis 
treatment and during a midweek session via their existing access whilst all the other 
study recruits including peritoneal dialysis patients were bled from their peripheral 
vein when attending clinic. All samples were centrifuged for 10 mins at 2500G at 
room temperature to isolate the buffy coat layer within 30minutes of sample 
collection. Buffy coat layer was cautiously transferred into polypropylene tubes of 2ml 
volume for storage. DNA extraction was performed immediately and remaining buffy 
coat were stored at -80c for future use.  
 
4.2 DNA Extraction Materials and Protocol 
 
Genomic DNA was extracted from isolated buffy coat using an automated DNA 
extraction machine (Qiagen Bio Robot EZ1) with the aid of a prefilled reagent 
cartridge (EZ1 DNA Blood 350l kit from Qiagen, Cat No./ID: 951054) according to 
manufacturer’s protocol. The kit contained all the required reagents and lab ware for 




magnetic particle technology. The final elution volume of purified genomic DNA was 
200l.  
 
4.3 DNA Quantification and Quality Control 
 
Extracted genomic DNA was assessed for purity and quantified with a Thermo 
Scientific NanodropTM 2000/2000c spectrophotometer. Calibration of 
spectrophotometer was performed first using DEPC- Treated Water (nuclease free) 
prior to measuring 1l genomic DNA in duplicates. The spectrophotometer provides 
the quantity of the measured DNA in ng/l and quality in the form of the 260/280 
ratio. 
 
Nucleic acid has a peak absorbance in the ultraviolet range rate at 260nm. Whilst 
protein has a peak absorbance at 280nm. A ratio of absorbance at 260nm and 280nm 
of ~1.8 is generally accepted as ‘pure’ for DNA. Any samples with a 260/280 ratio of 
less than 1.8 was excluded from further analysis due to probable protein contamination 
and repeat DNA extraction is done for these samples. The repeat DNA is re-assessed 
for quality and quantity with a spectrophotometer and the sample was excluded for 











4.4  DNA integrity using gel electrophoresis 
 
All genomic DNA integrity was assessed by gel electrophoresis. Approximately 10l 
of genomic DNA was used for this purpose. The samples were run on a 0.7% Agarose 
gel. The gel is made by dissolving 1.4g of Agarose MP powder (Sigma-Aldrich, Cat. 
No 11388983001) in 200mls of Tris-acetate-EDTA (TAE) buffer 1x (Premix TAE 
Buffer 10x, Sigma-Aldrich, Cat. No. 11666690001) by heating in a microwave until 
boiling. The solution is poured into gel casts with a comb in-situ and any bubbles were 
removed with a pipette tip. The gel was subsequently transferred to a gel tank once it 
had set and the comb removed. 
 
Each sample was mixed with 5l of tracking dye (Sigma, Cat No: G2526) to make up 




adds density to the final mixture to facilitate sample loading and allows visualisation 
of the sample migration. A 10l DNA marker mixed with 5l of tracking dye was 
loaded at extreme ends of the gel which is than run at 90V. Once the marker has 
migrated ¾ of the gel from the loading position, the gel runner is switched off and the 
gel is transferred into a container filled with approximately 200mls of distilled water 
and 50l of Gel Red Nucleic Acid Gel Stain (Cambridge Bioscience, Cat No. 
BT41003). The gel is left on a slow shaker for 60 minutes. Following this period, the 
coloured solution was discarded, and the gel was visualised under an ultraviolet (UV) 
trans illuminator to establish DNA integrity. Intact DNA will appear as a band under 
UV light with no smear below the band. If there is a smear after the band then this 










4.5  Standardisation of DNA 
 
Stock samples of genomic DNA of 100l was stored in -20 for long term use. The 
remaining 100 l of stock DNA was than standardised to a concentration of 10ng/L 
and aliquoted into a 96 well deep ABgene PCR plate and stored at 4c for short term 
used. 
 
4.6 Rationale for chosen methodology for TL analysis 
 
TL is measured from peripheral blood leucocytes and is often used as a proxy for TL 
in other tissues (Daniali et al., 2013) There is generally a good correlation in TL 
between different tissue compartments of an individual and blood is an easily 
accessible tissue. Different methods have been utilised to measure TL which include 
terminal restriction fragment length analysis using Southern Blotting, polymerase 
chain reaction-based techniques and fluorescent in-situ hybridisation (FISH) 
technique. The current gold standard for TL measurement is Southern Blotting. 
Unfortunately, this technique is rather laborious. It takes up to 3-5 days and a large 
amount of DNA (3.0ug per sample) is required (Kimura et al., 2010). The chosen 
approach to answer the research question is to use RT-PCR to determine the relative 
TL. This method is quick, inexpensive and will allow analysis of larger samples 





4.7  Polymerase chain reaction and its principles 
 
Polymerase chain reaction or better known as PCR is based on the ability and nature 
of the DNA to self-replicate. The method also relies on the use of short primers to 
initiate synthesis of a target sequence by a DNA polymerase.  
 
4.7.1 The basic steps involved in PCR 
 
a) Hot start step 
 
Both telomere and single copy gene run is set at 95 degrees for 10 minutes 
initially. This step is required to activate the Hot Start Taqman DNA 
polymerase, which prevents amplifications of primer dimers and other non-
specific products in the reaction. The fluctuating temperature does not denature 
the DNA polymerase used in this assay during the PCR.  
 
b) Denaturation step 
 
The double stranded DNA is first heated up to a high temperature for a brief 
period of time in order to denature the double strand of the DNA into single 
strand templates required for the next step. 
 





During this step, the primer anneals to the complementary bases of the single 
strand templates of the DNA. 
 
d) Extension step 
 
New complimentary strands of DNA are synthesised at the 5’ end of each 
primer as initiated by the polymerase. 
 
The process outlined above accounts for 1 cycle of the PCR and this process is 
repeated multiple times. Each time the cycle repeats itself, this will result in the 
synthesis of a new piece of double stranded DNA. Therefore, only a small initial 
amount of DNA is required to subsequently produce a large amount of a specific 
sequence of interest. Theoretically, each cycle of a PCR would lead to the doubling of 
a target sequence resulting in an exponential increase of the PCR product. However, 
in practice the increase in PCR product will depend on the amount of the reaction 
component remaining in excess for further PCR cycles. After a number of cycles, the 
rate of amplification will finally reach a plateau phase due to a) saturation of the 
amplified target sequence b) eventual failure of the DNA polymerase and c) the 
consumption of dNTPs (triphosphate deoxyribonucleotides). Once a plateau phase has 
been achieved, subsequent cycles will eventually lead to the formation of primer-
dimers and non-specific products.    
 
There are 2 types of PCR widely used. An end point PCR is used to detect a specific 
sequence and the PCR product is determined by gel electrophoresis or high-resolution 




study the target sequence of interest was TL. In real time quantitative PCR, the 
amplification of the PCR product is measured by the fluorescence emitted from the 
chosen probe in each cycle. 
 
4.8 Real time quantitative PCR protocol to measure TL  
 
The protocol to measure TL for this study was based on the methodology developed 
by Richard Cawthon with an improvised set of primers using real time PCR (Cawthon, 
2002). Longer telomeres will have more potential primer annealing sites and hence an 
increase in the fluorescence and reduction in the number of cycles needed to reach a 
given threshold in comparison to a shorter telomere. This concept allowed the ability 
for researchers to measure TL due to the simplicity of the technique and amenability 
to enable rapid high throughput processing of samples at a large scale. All PCRs were 
performed on the Rotor Gene 6000 (Corbett Research), a thermal cycler.  
 
4.8.1 Primer design 
 
The primer sets for telomere were Tel 1b and Tel 2b and 36B4 for single copy gene 
(SCG). The telomere primers were HPLC purified to avoid primer-dimer formation 
from primers that are not full length which are found in lower purification synthesis. 
Primers for telomere run; Tel 1b and Tel2b are both diluted to a final concentration of 
300nM. Whilst primers for SCG run; 36B4F and 36B4R were diluted to a final 





Telomere PCR Primers and Thermal Profile 
            








Thermal Profile Number of cycles Temperature Duration 
Activation 1 95c 10 min 
Amplification  20 95c 15 sec 
Cooling 1 58c 1 min 
 
Table 3: The primer sequences and thermal profiles for telomere PCR amplifications 
36B4 PCR Primers and Thermal Profile 
 
36B4 Forward Primer: 5’-3’: CAGCAAGTGGGAAGGTGTAATCC 
 




Number of cycles Temperature Duration 
Activation 1 95c 10 min 
Amplification  30 95c 15 sec 
Cooling 1 58c 1 min 
     




4.8.2 Preparation of reaction mix 
 
The reaction mix composition is made up of SensiMix TM SYBR No-ROX Kit reagent 
(Bioline, Cat.No. QT650-05), primers at the concentration described in Section 4.8.1 
and genomic DNA at 10ng/l. Master mixes for both runs are made up at the same 
time to ensure the same enzyme mix is used. Each run had a negative template as 
control (NT) and a calibrator sample (K562 Genomic DNA, Promega). The final 
reaction volume was 25l. Each sample was plated in duplicates.  
 
 
4.9 PCR run and results from real time quantitative PCR 
 
Both telomere (T) and 36B4 (S) runs were performed separately as per the cycling 
conditions described in Table 3 and 4. The T run is performed for the samples first 
followed immediately by the S run to keep all conditions uniformed. The section 
below outlines the results of the RT-qPCR of TL analysis performed in this study and 
outlines the overall quality of the RT-qPCR runs performed for TL assay.  
 
4.9.1 Standard Curve 
 
The aim of a standard curve in RT-qPCR is to provide relative concentration of 
samples, demonstrate efficiency and accuracy of the assay. A standard curve was not 




inaccuracies from dilution error when preparing standard curve samples. However, a 
standard curve was performed prior to preparing TL RT-qPCR assay to demonstrate 
primer and master mix efficiencies.  
 
In this protocol, the standard curve was used solely for the purpose of ensuring primer 
and overall PCR run efficiency. The standard curve generated for TL assay protocol 
consisted of 8 different concentrations of DNA from a pooled sample at 2-fold 
dilutions from 100ng/l to 0.78ng/l. 
 
Figure 12 and 13 demonstrate a one cycle difference for each standard curve which 
represents a dilution factor of 0.5 revealing accuracy of the dilution process performed 
subsequently demonstrated in Figure 14 and 15. These results highlight the linear 
correlation between the serial dilution performed and the amount of target sequence 
copies measured, which indicates the accuracy of the quantification process in RT-
qPCR. Demonstrating this step is an important quality control measure prior to 







Figure 12: Standard curve appearance for SCG RT-qPCR 
 
 






Efficiency (E) is calculated by the slope (M) of the curve with the formula E=10 -1/M. 
Slope (M) of a reaction is used to determine the exponential amplification and 
efficiency of the standard curve reaction. Optimal values for M, amplification and 
reaction efficiencies are -3.322, 2 or 1 respectively.  
 
Under ideal conditions the amount of template is doubled in each PCR cycle which 
gives an efficiency of 100%. Lower efficiencies suggest problems from the primer 
design and master mix performance. Efficiencies above 100% would indicate the 
probability of primer-dimer formations. Generally, efficiencies between 90% and 
110% are acceptable as seen in the standard curve generated for the TL assay in this 
study. 
 
Efficiencies were calculated using the Rotor-Gene Q Series Software. For both the 
assays, the linearity observed over the chosen range of DNA concentration was > R2= 




















4.9.2 TL RT-qPCR assay 
 
 
The figures below show an example of the RT-qPCR assay performed to measure TL 
which consists of 48 samples, the calibrator and NT. Each sample was measured in 
duplicate. The average amplification of each sample and run should be > 1.6. Samples 
and runs that failed to achieve these amplifications were repeated. The overall average 
amplification of Tel run was 1.83  0.01. The overall average amplification of SCG 
run was 1.74  0.01. Figure 16 and 17 shows that there was no amplification seen in 







Figure 16: RT-qPCR of Tel run with study samples 
 
 






4.9.3 Melt Curve 
 
The melting profile was interrogated once the PCR run is complete. Determining the 
melting point is an important step to validate the amplicon signals. It also helps 
identify if any non -specific products have been detected during amplification.  
 
The fluorescence in the melt curve analysis is initially high because the sample starts 
as a dsDNA. The peak point in the melt curve represents the melting temperature (Tm) 
of telomere DNA fragment. The fluorescence will continue to decrease as the 
temperature continues to rise as the dsDNA dissociate into single strands. As shown 
in Figure 18 and 19, the melting curve has only one single peak at ~ 82.50c which is 
the telomere PCR product. The NTCs appear to have generated a non-significant 





















4.9.4 TL Analysis from RT qPCR 
 
There are several ways to analyse the raw data obtained when determining relative TL 
from real time qPCR. These analysis methods include the standard curve concept, 
CT analysis, Pfaffl method and comparative quantification (Lin et al., 2019) 
 
The chosen method of analysis for the purpose of this research project was based on 
the comparative quantification method. This method is well established, widely used 
and published (McCurdy, McGrath and Mackay-Sim, 2008). The principle of this type 
of analysis is based on measuring the relative expression/concentration of the sample 
of interest to a control sample/calibrator without the need to rely on a standard curve. 
The analysis is performed with the aid of the Qiagen Rotorgene Comparative 
quantification software. 
 
This method calculates the efficiency for each sample of interest based on the change 
of fluorescence and mean efficiency across the run rather than taking values from a 
set based on standard curves. This increases the accuracy of the analysis compared to 
the other methods. 
 
The software plots the second derivative of the amplification plot whereby the peak 
of this curve would be the maximum exponential growth of the product. The point 
80% back from the peak is defined as the take-off point and the reaction efficiency is 
calculated from the slope between take-off and the point where maximum 




less subjective as it avoids the investigator having to set the threshold value/line or 
depending on the auto threshold mode for each run to give the CT results in other 
analysis methods. The threshold value/line is best placed in the exponential 
amplification across all of the amplification plots for each run which can be variable 
and contribute to inconsistent results.  
 
The software calculates the mean amplification efficiency (MAE) of all samples in the 
run. The concentration of each sample relative to the calibrator (reference) sample is 
calculated using the equation: 
 
Sample concentration = MAE (Calibrator take-off – sample take-off) 
 
This is done for both the T run and S run for each sample duplicate and TL is expressed 
as T relative conc. / S relative conc. (T/S). This method takes both the differences in 
amplification efficiency between samples and between runs into account. All data is 







4.9.5 Quality control and reproducibility of the method 
 
Each sample was analysed in duplicates to assess for intra-assay variability. Any 
sample whereby the duplicate value in the RT-qPCR run had a cycle difference for the 
take-off value of >0.2 was excluded from the run and repeated later. Any sample or 
run with an average amplification of <1.6 was excluded and repeated again. 
 
The TL assay for this study used genomic DNA from K-562 cell line which is known 
to have short telomeres. Cawthon had measured TL for K562 which consists of 5290 
base pairs in 2009 using Southern Blotting (Cawthon, 2009). K-562 acted as an 
internal control and calibrator sample in each run when samples are analysed with RT-
qPCR. The average take-off value for K562 DNA for telomere run for the study was 
10.38  0.27 with a CV of 2.12%. The average take-off value for K562 DNA for single 
copy gene run for the study was 18.85  0.25 with a CV of 1.33%. These values 
indicate consistency of the calibrator sample efficiency through out all the runs 
performed for the samples in this study.  
 
Reproducibility of the TL assay was tested randomly by repeating any run on a 
separate occasion. The inter-assay coefficient variation (CV) was determined by using 
the formulae: (standard deviation/mean) x 100%. The inter- assay CV for TL assay in 
this study was 4.86%. Cawthon had observed an inter-assay CV of 5.8% (Cawthon, 
2002). The CV result in our study indicates that the assay variation is low, in keeping 
with other published data (Refer to Section 1.2 and 1.3) and the result from the assay 





A linear regression model between the data obtained from Tel run (see Figure 20) and 
SCG run (see Figure 21) measurements repeated on 2 separate occasions showed a 
strong correlation. The same data was used to calculate TL (T/S ratio) that showed 















































Figure 22: T/S ratio for 48 samples calculated based on repeat Tel and SCG paired runs from 
















CHAPTER 5: LABORATORY METHODS ON DNA 
METHYLATION 
 
5.1 DNA methylation methodology 
 
There are 3 different recognised methods of measuring DNA methylation status. The 
choice of method selection is based on the aim of either the discovery of unknown 
epigenetic change or assessment of DNA methylation status within a particular 
region/gene of interest.   
 
The methods described in measuring DNA methylation are: 
 
A) Sodium bisulphite conversion and sequencing which is used in gene 
specific/GWAS studies. It is also the current gold standard in measuring 
DNAm status. Target BS sequencing is based on prior selection of predefined 
genomic regions of interest which have been identified by PCR amplification 
whereby the region of interest was identified from Whole Bisulphite 
Sequencing Data (See Figure 23).  
 
B) Differential enzymatic cleavage of DNA which is used in locus specific 
analysis 
 





Figure 23: DNA sodium bisulphite conversion 
Step 1: Denaturation of the template, Step 2: Sodium bisulfite deaminates cytosine residues, 
Step 3: Desulphonation removes the sulfite moiety to generate uracil, Step 4: Subsequent 
PCRs convert the Uracil to Thymines 
 
 
The technique chosen for this PhD project was the sodium bisulphite conversion and 
sequencing as the candidate gene of interest were known, the number of samples to be 
analysed were large, speed, single nucleotide resolution, the amount of DNA/input 
material required is small, low cost of simultaneously assaying multiple CpG loci in 
multiple DNA samples with high reproducibility and the technique provided the 
highest level of coverage and resolution. Whole genome bisulphite sequencing is the 





5.2 DNA methylation methodology based on targeted 
bisulfite (BS) amplification sequencing using the Fluidigm 
Access Array (IFC) 
 
5.2.1 Assay Design 
 
The assay for measuring DNA methylation was performed with the assistance of Barts 
and The London Genome Centre; part of Queen Mary University of London. 
Methylation assays for this project was designed manually using the Pyromark assay 
design software or by running a script which uses ‘R package’, Bismark and Python 
Primer design software to output the primer sequences. A list of desired CpG sites for 
the study were sent to the Genome Centre for primer design. The gene names and 
chromosome position coordinates were identified from Hannum’s database to design 
the assay. Unfortunately, only 44 out of 77 CpG sites had passed the initial design 
tests. The algorithm used in the primer design were unable to identify a pair of primers 
that would amplify the desired portion of the remaining 33 CpG sites of the genome 
within a pre-specified range of stringency. Therefore, we had to reduce the design 
stringency which subsequently enabled us to design primers for all the CpG sites but 
had to accept that in doing so, we will be increasing the likelihood that a proportion 
of the PCR reactions might fail. Primer pairs usually amplify portions of DNA 
containing multiple CpG sites. Therefore, by overlapping the PCR product of the 





5.2.2 Sample quality control 
 
All extracted DNA samples are assessed for DNA integrity using gel electrophoresis 
(Refer to Section 4.4; DNA integrity using Gel Electrophoresis). Then the DNA 
samples are quantified using the Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, 
Ca, USA) with the dsDNA BR reagent kit. DNA is then diluted in 45uL of Tris-EDTA 
to give a final concentration of 500ng. Any samples below the minimum 500ng input 
was excluded. 
 
5.2.3 DNA Bisulfite Conversion 
 
Bisulphite conversion method involves treating DNA with bisulfite which converts 
unmethylated cytosine into uracil whilst methylated cytosine remains unchanged 
during the treatment (See Figure 23). 
 
Bisulphite conversion of DNA was performed with the 96-well plate using the Zymo 
EZ DNA MethylationTM Kit (Catolog Nos. D5001 & D5002, Cambridge Biosciences). 
The following protocol and kit converted non-methylated ‘C’s to ‘T’s through a 3-step 
process. An alternative incubation conditions recommended in the manufacturers 
guide was chosen for the bisulphite conversion for this project, which was 95oC for 
30 secs, 50oC for 60 mins for 16 cycles with a 4oC hold.  
 
The bisulphite converted DNA was measured by the NanoDrop 8000 




Following the sodium bisulphite treatment of the DNA samples, the methylation 
profile is then determined by PCR amplification followed by DNA sequencing. 
 
5.2.4 Library Generation Using Fluidigm Access Arrays and 
sequencing 
 
Targeted methylation amplicon libraries for each sample were prepared using the 
Fluidigm 48: 48 Access Array integrated fluid circuit (IFC) (Fluidigm, Amsterdam, 
Netherlands). The Fluidigm platform enables up to 192 methylation targets (2-4 assay 
pools per well) to be amplified on a single access array across 48 DNA samples.  
 
The 48:48 Access Array Integrated Fluidic Circuits (IFC) enables target enrichment 
of 48 samples at one time. 68 primer pairs targeting 68 CpG sites were generated with 
commons sequence tags (CS1- and CS2-). A 20x assay mix was prepared as per the 
manufacturers’ protocol with assays at a final concentration of 1uM. Sample mix was 
prepared using 3uL of bisulphite converted DNA per sample. Bisulfite converted 
DNA is added to the Access array with the 48 primer assays and PCR mastermix. The 
primer inlets of the access array were loaded with pooled primer pairs (forward and 
reverse) diluted to a final concentration of 1uM per primer; on to the Pre-PCR IFC 
controller AX which loads the PCR components into the array chamber. PCR 
amplification is performed using the FC1 cycler with a custom programme as follows: 
70oC for 20min, 95oC for 10min, [95oC for 15secs, 60oC for 30secs, 72oC for 1 min] 
x 10 cycles, -1oC touchdown, [95oC for 15secs, 51oC for 30secs, 72oC for 1 min] x 29 




to the 5’ end of each primer (CS1 is added to the forward and CS2 is added to the 
reverse), allowing for the later addition of unique barcodes to each sample allowing 
for PCRs from the same DNA sample to be pooled together. Each of the 48 sample 
inlets were loaded with 4uL of bisulphite converted DNA and mastermix solution. 
Once prepared the Access array was place in the primed pre-pcr IFC controlled AX 
for the samples and primers to be automatically combined over a 1.5-hour period. The 
array was then transferred to the Fluidigm FC1TM Cycler for target amplification by 
PCR.  
 
Following amplification, 1ul of the harvested enriched PCR product is run on an 
Agilent 2200 Tapestation and D1000 screentape (Agilant Technologies, Waldbronn, 
Germany) to assess the product size after which they are recovered and transferred to 
a 96-well PCR plate. This was only done for a random subset of samples as a quality 
control measure to determine the quantity and integrity of the PCR product. All the 
samples exhibited a product at the expected size.  
 
All harvested samples/PCR products were than barcoded (with a unique Fluidigm 
barcode) using a second PCR amplification reaction and were taken forward for 
sample-specific barcoding using the Access Array Barcode Library for Illumina 
Sequencers (Fluidigm, Amsterdam, Netherlands). The function of this step was to 
label all amplicons form a given sample with a common sequence to allow subsequent 
identification once all of the PCR products had been pooled for sequencing. In 
addition, the barcode contains an Illumina sequencing adaptor (p5 and p7) that allows 
the final library of PCR products to bind to the oligo lawn of the Illumina Flow Cell 




from harvest quality control were re-run on an Agilent Tapestation D1000 tape post 
barcoding to ensure a shift in size indicating successful ligation of index sequences 
and that the barcode has been incorporated. A successful reaction will generate a 
















An equal volume of each uniquely barcoded sample was combined to create one 
pooled library which was purified using Ampure XP beads at 1x ratio. The final 
cleaned library was quantified using the Qubit 2.0 Fluorometer (Life technologies, 
Carlsbad, CA, USA) and the Agilent 2200 Tapestation with D1000 screentape 
(Agilent Technologies, Waldbronn, Germany). Once the PCR products had been 
successfully barcoded, they were pooled for sequencing using the Illumina MiSeq 
v2 300 cycle kit to generate 150bp paired end reads.  
 
The sequencing process generates millions of reads in total representing all of the 
DNA fragments. Sequences within the pooled DNA library are separated into 
individual samples based on the unique sample specific barcodes attached to each 
fragment during preparation of the library. Within fragments from the sample, reads 
with similar base sequences are clustered and grouped by forward and reverse reads. 
Any discrepancies are resolved by comparison within the grouped reads. Finally, the 
percentage of methylated cytosine residues is calculated for each CpG site for all 











5.3 DNA methylation analysis  
 
The proportion of methylation at a particular CpG site is referred to as a beta value 
which can change over a course of one’s lifespan. To understand the nature of DNA 
methylation based (DNAm) age estimators, it is necessary to appreciate what is being 
measured. Each CpG clock takes a value between 0 and 1, whereby 1 indicates 
methylated and 0 indicates unmethylated. Importantly, the values of the clock CpGs 
(and the vast majority of all CpGs) are almost never 0 or 1 but a value in between. For 
example, a value of 0.66 indicates that 66% of the thousands of copies of that 
particular CpG, which were derived from thousands of cells, are methylated.  
To define an ageing methylation signature, a similar approach to that of both Hannum 
et al. (Hannum et al., 2013) and Horvath (Horvath, 2013) was used. All the analysis 
was restricted to those CpGs which were covered by > 100 reads to reduce the effect 
of highly noisy methylation values, leaving a total of 316 CpGs. A model was initially 
built from the data provided by using 27 “healthy” control samples with known ages. 
Three samples were removed due to low amount of sequencing leaving 24 samples to 
build a model on. Ages in years were transformed using the following function as 
suggested by Horvath (Horvath, 2013). 
 
𝑓(𝐴) = {
log(𝐴 + 1) − log⁡(𝐴 + 1), 𝐴 ≤ 20
𝐴 − 20
𝐴 + 1







Where 𝐴 is the age of a sample in years. The rationale for this transformation is that it 
is  
a) Continuous 
b) Logarithmic up till 20 years old and then linear from that point onwards 
c) Is defined for prenatal samples e.g. A can be -1.  
 
Following this conversion, an elastic net regression model was used to regress the 316 
CpGs and then a prediction based on the methylation levels of each of these 316 CpGs 
can be made. As part of the elastic net regression a single hyper-parameter is fitted 
using a 5-fold cross validation. To test the model, we used a leave one out cross 
validation. Specifically, we removed a single sample and trained the model as above 
and then predicted the age of the missing sample. We did this for each sample and 
calculated the RMSE of the prediction resulting in a RMSE of 11.59 years.  
 
To see if we could improve this prediction we used existing Illumina 450K data 
provided by Hannum et al. (n=656)(Hannum et al., 2013) . First, we overlapped the 
316 CpGs with probes contained on the array leaving a total of 49 CpGs in common 
between the two experiments. The CpG ID of these is provided in the file 
probes_used.csv (Refer to Appendix H: CpG ID’s of Probes Used in Measuring DNA 
Methylation Status). Following the same approach as above an elastic net regression 
model was used to regress the 49 CpGs. The hyper-parameter was fitted using a 10-
fold cross validation (due to larger number of samples available) and the model was 
trained on the Hannum et al data tested on the 24 “healthy” control samples. This 
resulted in a reduced RMSE of 6.60 years and a spearman correlation of 0.76 (See 





The model was than run on the remaining samples to predict the ages of each sample. 
A 95% prediction interval based on the sample distribution of the 24 samples was 
calculated.  
 
A measure of disproportionate ageing; in the form of age acceleration and apparent 
methylomic ageing rate are calculated for each study participant and subsequently 
used as variables for data analysis. DNAm delta age is the difference between DNA 
methylation age (derived from the model) and chronological age (derived from 
patients’ DOB at the time blood samples were taken). Whilst apparent methylomic 
ageing rate (AMAR) is calculated by dividing DNA methylation age by chronological 
age. AMAR greater than 1 is interpreted as fast ageing whereas AMAR less than 1 







Figure 25: Predicted age in years against actual age in years for the 24 healthy controls. Grey 
dashed line is y=x, or a perfect prediction. Double dashed lines are +/- 5 years. 
 
It is not surprising that the DNAm age is an excellent correlation of chronological age 







CHAPTER 6: RESULTS ON TELOMERE 
LENGTH, DNA METHYLATION AND FRAILTY 
IN STUDY COHORT 
 
6.1 Summary of background demographics of study 
recruits at baseline 
 
A total of 339 patients were recruited for the study during the period of December 
2015 to July 2018 from Barts Health NHS Trust dialysis units and outpatient clinics. 
Table 5 outlines the details of the three different cohorts of patients recruited for the 
study and distribution of their various characteristics (where data was available). 
Patients on dialysis were grouped into haemodialysis (HD) and peritoneal dialysis 
(PD) according to their respective modality at the time of recruitment. Potential live 















Age (mean  SD) 53.2  13.6 55.7  14.2 44.5  13 <0.001 
Female (n, %) 44 (35.2) 43 (37.7) 56 (56) 0.004 
Ethnicity (n, %) 
 White/Caucasian 
  Asian 
  Black/Afro-Caribbean 























Pyelonephritis/interstitial    
nephritis  



















disease (n, %) 
31(24.8) 31(27.2) 0 (0) 0.784 
Diabetes (n, %) 35 (28) 55 (48.2) 0 (0) 0.002 
Previous Cerebrovascular 
even (n, %) 
11 (8.8) 8 (7) 0 (0) 0.788 
Charlson’s Comorbidity 
Index (n, %) 
    Score ≤ 2 
    Score 3 
    Score 4 
    Score 5 
























BMI (mean  SD) 26.9  5.4 27.6  5.1 26.6  4 0.274 
















Dialysis access (n, %) 
      Arteriovenous fistula 
      Catheter 

















Haemoglobin (mean  SD) 11.17  1.30 10.79  
1.72 
NA 0.056 
White cell count (mean  
SD) 
6.99 2 7.77  2.26 NA 0.005 
Albumin (median, IQR) 42 (40,45) 39 (37,42) NA <0.001 
C-reactive protein (n, %) 
    <5 









Table 5: Basic demographics of all patients recruited for the study. 
Data presented in the form of n=number, %= percentage, mean  standard deviation (SD) for 
normally distributed data and median with interquartile range (IQR) for skewed data. All 
significant results in bold. Significance testing was not conducted in the group with unknown 
smoking.  
 
Table 5 summarises the basic demographic data and variables of interest from the 
study recruits. The score derived from the Charlson’s comorbidity index (CCI) was 
grouped into 5 categories based on their scores as depicted in the table above. C-




categorical variables which include; gender, ethnicity, cause of ESKD, pre-existing 
cardiovascular disease, diabetes, pre-existing cerebrovascular disease, Charlson’s 
comorbidity index, smoking and CRP were tested for significance between groups by 
using the Chi Square test. Age and BMI where analysed with ANOVA whilst 
haemoglobin (Hb) and white cell count (WCC) were analysed using 2 sample T-test. 
Both dialysis vintage and albumin results were skewed and were analysed with Mann 
Whitney U-test. All significant difference in variables between groups are in bold.  
 
 
6.1.1 Age distribution among study cohorts 
 
There was a total of 239 patients on renal replacement therapy (RRT) with an age 
range of 23 to 83 years of age. There were 100 patients consisting of healthy potential 
live donors in the control group with an age range between 20 to 75 years of age. The 
mean age and standard deviation (SD) of the case cohort was 54.4  13.93. There was 
no difference in age between the haemodialysis and peritoneal dialysis groups, 
(p=0.18) using a 2 sample T-test. There was a total of 125 patients on chronic 
haemodialysis with an age range of 23 to 80 years among the study recruits. There 
was a total of 114 patients on peritoneal dialysis recruited for the study with an age 
range of 23 to 83 years. There was significant difference in ages between the two-
dialysis groups and healthy control, p<0.01. This is due to the fact that the healthy 
control group which consists of potential donors are more likely to be younger with a 
mean age of 44.5  13 in comparison to the case group which had a mean age of 54.4 





6.1.2 Gender distribution among study cohort 
 
Table 5 shows that the gender distribution among the three groups of patients in this 
study were significant, p<0.01 but there was no significant difference between gender 
in the case group consisting of HD and PD patient, p=0.787.  
 
6.1.3 Dialysis vintage distribution in case groups 
 
Dialysis vintage was defined as the duration of time spent on dialysis treatment in 
weeks. Data on dialysis vintage distribution was only available in 226 patients with a 
range of 2.1 to 1367.3 weeks. The dialysis vintage in the HD group ranged from 2.1 
to 1367.3 weeks with a median of 162 weeks (Interquartile range: 221.8). The PD 
group had a dialysis vintage range of 7 to 546.7 weeks with a median of 79.8 weeks 
(Interquartile range: 107). Patients on HD had a significantly longer dialysis vintage 
than patients on PD, p<0.01. This difference is likely due to the nature of the two 
modalities whereby prolonged exposure to PD is associated with failure of this 
treatment in the long run. In fact, most patients on PD are electively switched to HD 
after five years due to risk of encapsulating peritoneal sclerosis in the current 
recruitment renal unit, if deemed appropriate. Younger patients also usually opt for 






6.2 Frailty at baseline and one year follow up 
 
Completed frailty assessments at baseline were available for 299 patients in total; 213 
(71.2%) dialysis patients and 86 (28.8%) healthy controls. Frailty scores were 
calculated as outlined in ‘Chapter 3: Clinical Methods’ for each domain and a final 
score out of five determines ones frailty status. Those with a total score of 3 were 
considered frail and scores <3 were not frail. Dialysis patients were followed up for 
12 months and had repeat frailty assessments done. 
 
6.2.1 Frailty in healthy control and dialysis 
 
There were no frail patients in the healthy control group which was expected as these 
patients consisted of potential live donors. Table 6 outlines the distribution of frailty 
between control and dialysis cohort. 
 
Frailty level Control (n=86) Dialysis (n=213) P value 
Not frail (n, %) 86, 100 143, 67.1 < 0.001 
Frail (n, %) 0, 0 70, 32.9 
 
Table 6: Difference in Frailty status in control and dialysis group 
 







6.2.2 Frailty and gender 
 
Table 7 shows the gender distribution of frailty status among the dialysis cohort. A 
total of 78 females completed the frailty assessment at baseline and 21 females 
(26.9%) were considered frail. The relative risk of frailty was 1.078 which shows that 
females were 7.8% more likely to be frail than men whose odds of frailty was 
increased by 6.3%.  
 
 Frail (score 3) Non-frail (score <3) Total 
Male (n, %)  49 (36.3) 86 (63.7) 135 
Female (n, %) 21 (26.9) 57 (73) 78 
Total (n, %) 70 (32.7) 143 (67.3) 213 
 
Table 7: Frailty distribution and gender 
 
A Pearson’s Chi-square test was used to compare the frequency of frailty in men and 
women. There was no significant interaction found for gender and frailty using a Chi 
square test with a p=0.860.  
 
6.2.3 Frailty and age 
 
Frailty data were available from patients aged 23 to 83 years. The image below shows 
the age distribution in each category of frailty based on their total scores from five 





Figure 26: Age distribution among frailty score of 0 to 5 in the dialysis cohort 
 
 
Frailty and age were strongly correlated in this study, this association was significant 













6.2.4 Frailty among haemodialysis and peritoneal dialysis 
 
Table 8 outlines frailty scores between the two dialysis cohorts. The relative risk of 
being frail was 1.69 times higher in the haemodialysis cohort in comparison to 
peritoneal dialysis, p=0.012. The differences in frailty status between the two groups 
was significant, p=0.015. There may be an effect of longer dialysis vintage in the HD 
group contributing to this significance.  
 
Modality Frail (score 3) Non-frail (score <3) Total 
Haemodialysis (n, %) 45 (40.9) 65 (59.1) 110 
Peritoneal dialysis (n, %) 25 (24.3) 78 (75.7) 103 
Total 70 143 213 
 











6.2.5 Frailty component data 
 
Figure 27 shows the distribution of frailty components among the 110 HD patients 




Figure 27: Frailty components in dialysis study cohorts at baseline 
 
A univariate logistics regression was conducted to assess each of the frailty 
components and modality with HD as a reference (See Table 9). Exhaustion was less 
in the PD cohort in comparison to the HD with an OR of 0.497, p=0.012. This may be 
related to the fact many HD patients reported exhaustion associated with dialysis 
treatment in hospital on average thrice weekly leading to fatigue which affected the 




































Odds ratio Standard 
Error 





Shrinking 0.598 0.321 0.318 1.121 0.109 
Exhaustion 0.497 0.278 0.288 0.858 0.012 
Weakness 1.117 0.276 0.650 1.920 0.688 
Slowness 0.551 0.358 0.273 1.112 0.096 
Physical 
activity 
0.655 0.279 0.38 1.132 0.129 
 






6.2.6 Difference in frailty scores at baseline and at 1 year follow up 
 
Dialysis patients were followed up at 12 months and had repeat frailty assessments. 
Only 155 patients (58.7% from HD group) had repeat frailty assessments completed.  
Out of the 155, 86 patients (53.5% from HD group) remained on dialysis as modality 
for renal replacement therapy and 69 patients had a kidney transplant during the first 
year of follow up which will be discussed separately in Section 6.2.7.  
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Figure 28: Changes in frailty component from baseline to year 1 in patients remaining on 







Changes in frailty components were calculated as percentage change from baseline 
therefore, percentage of a frailty component at baseline minus percentage of frailty 
component at 1 year follow up. A positive result indicates improvement in the frailty 
component and vice-versa.  
 
Figure 28 shows that slowness and exhaustion improved in the PD group but physical 
activity and shrinking worsened at the 1 year follow up. There was no change observed 
in weakness. For the HD group, only shrinking had improved but weakness, slowness 
and exhaustion had worsened. No change was seen in physical activity at the 1 year 
follow up in the HD group. Shrinking as reflected by weight may have improved due 
to improvement in appetite or better diet. However, there is always a difficulty in 
establishing shrinking over a year as assessment of weight in dialysis patients are 
affected by fluid weight and changes in fat to muscle composition. There is a drive to 
using alternate measures of weight in dialysis patients e.g. body composition monitor. 
There are also increasing attempts and efforts to develop and validate other frailty 
tools such as comprehensive geriatric assessments, Clinical frailty scale, FRAIL and 
frailty assessment for care planning tool (Clark et al., 2017) (Nitta, Hanafusa and 
Tsuchiya, 2017). (Refer to Section 8.1: Challenges and limitations with laboratory and 
clinical methodology).  
 
Physical activity in the PD patients had deteriorated and the reason for this may be 
due to changes in the dialysis regime limiting one’s activity level. The study did not 
take into account episodes of PD peritonitis which may have contributed to change in 
dialysis regime and dialysis adequacy which could affect physical activity directly and 





There was no significant difference in change over a year between the five frailty 
components. Grip strength at baseline and at 1 year was also not different, p=0.612. 
There was no significant change in overall frailty scores at baseline and at 1 year 
follow up in either of the HD or PD group, p=0.357. 
 




Figure 29: Distribution of frailty components in patients who had renal transplant during study 




































Frailty was measured at baseline and 1 year in 69 dialysis (45 HD, 24 PD) patients 
who subsequently had a renal transplant during the study period. The study was unable 
to account for the exact time of the renal transplant but all patients with 1-year frailty 
assessments had their renal transplant for at least three months minimum. The frailty 
components that have improved in this cohort are shrinking, exhaustion and weakness 
(See Figure 29). Physical activity level remained fairly similar at both time points (See 
Figure 29). However, exhaustion was the only component that was significantly 
different from baseline to 1 year, p=0.007 which may represent a better quality of life 
and energy levels with renal transplantation.  
 
6.3 Baseline Telomere length analysis in the study cohort 
 
TL was measured in the form of T/S ratio. Therefore, results on TL are presented in 
this form i.e. T/S ratio in this section. T/S ratio was measured in 239 dialysis patients 
and 100 healthy controls recruited for the study. However, three samples were 
excluded from the dialysis group and one from the control group for further analysis, 
as the take-off value difference between the duplicate repeats in the run was >0.2 or 
two cycle difference. Therefore, T/S ratio results were available for 335 patients (124 









6.3.1 Telomere length and age 
 
It is widely known that TL declines with age. This association was observed in the 
current study cohort of 339 patients demonstrating a negative correlation between T/S 
ratio and age, r= -0.416, p<0.001 (See Figure 30). The correlation between T/S ratio 
and age in the dialysis population only (See Figure 31) remained significant, r= -0.403, 
p<0.001. (See Figure 31) Both these results remained significant at p<0.001 even with 
gender as a co-variate in a multi variate regression analysis.  
 







Figure 31: Correlation between T/S ratio and age between HD and PD group 
 
6.3.2 Telomere length and gender among study cohort 
 
The mean T/S ratio among male and females in the control group was 2.24  0.39 and 
2.22  0.28 respectively (See Figure 32). There was no significant difference in mean 
T/S ratio between gender in the healthy cohort in our study p=0.778. However, mean 
T/S ratio was higher in females than in males among dialysis patients (See Figure 33). 
Females had a mean TL of 2.21  0.38 in comparison to males who had a mean TL of 
2.07  0.31 from the dialysis cohort (See Figure 33). These differences were found to 
be significant, p=0.007. This significance diminished following a multivariate analysis 







Figure 32: Whisker box plot showing T/S ratio (y-axis) distribution in male and female in 
the healthy control group. Horizontal line represents median value, box represents 
interquartile range and vertical line indicates range.  
 
Figure 33: Whisker box plot showing T/S ratio (y-axis) between gender in the dialysis 





6.3.3 Difference in telomere length between dialysis (case group) and 
control group 
 
Mean T/S ratio in the healthy control group was 2.23  0.33 in comparison to mean 
T/S ratio in the dialysis group which was 2.11  0.34 (See Figure 34). This difference 
was significant when analysed with a univariate linear regression model, p= 0.006. A 
multivariate linear regression model adjusting for age and sex revealed no further 
significance between the case group and control group, p=0.886.  
 
Subsequent analysis was done to investigate if there was a difference between T/S 
ratio in the three different study groups. The mean T/S ratio in the control, HD and PD 
group were 2.23  0.33, 2.11  0.34 and 2.12 ± 0.34 respectively. A univariate linear 
regression model showed that T/S ratio between the three groups were significant, 
p=0.022 (See Figure 35). Table 10 shows that HD patients had a mean T/S ratio of 
less than 0.114 and PD patients had a mean T/S ratio of less than 0.113 in comparison 








Figure 34: Whisker Box plots for T/S ratio in control and Dialysis groups.  
 
 
T/S ratio Estimate Standard 
error 





HD -0.0114 0.046 -0.204 -0.024 0.014 
PD -0.0113 0.047 -0.205 -0.021 0.017 
 
Table 10: Univariate linear regression model to evaluate the relationship between T/S ratio 





Figure 35: Whisker Box plots for T/S ratio in HD, PD and control group, P=0.022 
















However, this significance was lost following adjustment for age and gender in a 
multivariate linear regression model between the three groups (See Table 11). Table 
11 shows that being on dialysis is not associated with T/S ratio after the data was 
adjusted for age and sex, p= 0.876 in PD and p= 0.708 in HD. The change in T/S ratio 
is reflected by the estimate, this was due to the dialysis group being older than the 
controls.  
 
T/S ratio Estimate Standard 
Error 





Age -0.010 0.001 -0.012 -0.007 0.000 
Female 0.062 0.035 -0.007 0.132 0.077 
HD -0.017 0.044 -0.103 0.070 0.708 
PD 0.007 0.046 -0.082 0.097 0.876 
 
Table 11: Results from multivariate linear regression model comparing dialysis and control 












A multivariate linear regression analysis was then conducted to investigate any 
difference between the two dialysis groups. The analysis showed that T/S ratio in PD 
was not significantly different to HD, although the T/S ratios were on average 0.0225 
longer in PD patients in comparison to HD patients following adjustment for age and 
sex (See Table 12). 
 
  
T/S ratio Estimate Standard 
error 





Female .0890 .04273 .0048 .1731 0.038 
Age -.0096 .00149 -.0125 -.0067 0.000 
PD .0225 .04104 -.0584 .1034 0.584 
 
 
Table 12: Multivariate Linear regression analysis between the 2 dialysis groups adjusted for 








6.3.4 Telomere length and mortality in dialysis group  
 
 
There was a total of 10 deaths during the follow up period (365 days). There was no 
loss of data in the follow-up dialysis groups. The T/S ratio were standardised and 
converted to Z scores to evaluate the probability of death for analysis. There was no 
significant association with ZT/S (standardised T/S ratio) and mortality observed 







Z P>[z] 95% confidence 
interval 
Age 1.0764 .0343 2.31 0.021 1.0112 1.1458 
Female .9090 .6594 -0.13 0.895 .2193 3.767 
ZTS .6899 .2680 -0.96 0.339 .3222 1.477 
 
Table 13: Logistic regression model using Standardised T/S ratio (ZT/S) as a predictor for 
death. 
 
However, the risk of death was 31% lower (1-0.689) per SD increase in TL. Therefore, 
the direction of effect is consistent with expectations, i.e. longer = less risk of death 
but the small number of events meant that this test was underpowered to detect a 
difference. A longer duration of follow up or a larger number of patients is required to 
evaluate the effect of T/S ratio and mortality outcome which may provide a higher 










A total of 228 patients had repeat blood samples taken at 12 months but only 142 
sample pairs were selected to investigate telomere attrition. There were 86 samples 
excluded for further analysis due to reasons as listed below: 
 
1) There were no 12 months follow up frailty scores available 
2) Patients who transitioned to a different dialysis modality 
3) Any blood samples that were taken during period of illness requiring 
hospitalisations 
4) Any repeat sample with evidence of compromised DNA quantity and quality 
assessed by spectrophotometry 
 
These blood samples from baseline and year-1 (12 months from initial blood 
sampling) were analysed simultaneously i.e. the original samples were re-run side by 
side along with the year-1 sample to minimise the effect of potential technical 
variation associated with the assay for analysis. This would mean that the DNA of the 
baseline sample would have been stored for at least a year longer than the samples 





 Out of 142 paired samples, only 136 paired samples were successfully measured. 
Failure of either sample from a pair meant that the sample had to be excluded from 
further analysis. Therefore, data on telomere attrition changes (T/S) was reported for 
136 patients with results in paired samples (79 HD, 57 PD). T/S was calculated by 
deducting year 1 T/S ratio from baseline T/S ratio. There were 66 patients with a 
positive T/S, 63 patients with a negative T/S and 7 patients had no change in T/S 
ratio at baseline and year 1. Positive T/S represented telomere shortening and 
negative T/S would indicate telomere elongation. Mean T/S was 0.0002  0.23. A 
univariate analysis was conducted to investigate if T/S differed in either of the 
dialysis modalities and no significance was found, p=0.129 (See Figure 36). A 
multivariate analysis adjusting for age and gender revealed a borderline significant, 
p=0.05 between modalities with PD group having mean difference in T/S of -0.075 
(See Figure 37 and Table 14). This would imply that the PD group have a slower rate 
of telomere attrition or underwent telomere elongation in comparison to the HD group.  
 
The change in T/S ratio at baseline and year 1 was estimated with a mixed model 
approach (See Table 15) using patient ID as a random effect to estimate the change in 
standardised T/S ratio over time (not the T/S) which showed no significant observed 
changes in standardised T/S ratio within 12 months, p= 0.992, age and gender 






Figure 36: Delta T/S ratio between HD and PD group (all case group included).  




Figure 37: Correlation between delta TS and age in HD and PD group.  









Delta T/S Estimate Standard 
Error 





Female 0.0614 0.03880 -0.015 0.137 0.116 
Age 0.0050 0.0014 0.002 0.008 0.001 
PD  -0.0753 0.03801 -0.150 -0.001 0.050 
 










Age -0.0108 0.0020 -0.0146 -0.0070 0.000 
Female 0.1840 0.0545 0.0772 0.2907 0.001 
Time -0.0002 0.1395 -0.0384 0.0380 0.992 
 








6.3.6 The role of telomere length and frailty status among the dialysis 
cohort? 
 
Data was available for 213 dialysis patients who had completed a frailty assessment 
at baseline as well as had their TL measured.  
 










A score of ≥ 3 from the frailty tool would indicate that the patient was frail whilst a 
score of ≤ 2 was considered non frail. Figure 38 shows the corresponding mean T/S 
ratio and distribution according to frailty status. The difference in mean T/S ratio was 
significant between frail and non-frail group p=0.001 (See Table 16).  
 
Ageing parameters Non frail (n=143) Frail (n=70) P value 
T/S ratio (mean, SD) 2.17 (0.34) 2.00 (0.31) 0.001 
 












T/S ratio Beta 95 % Confidence Interval P Value 
Upper bound Lower bound 
Age -0.00879 -0.01179 -0.00578 <0.001 
Female 0.09376 0.00776 0.179759 0.0328 
Frail -0.1016 -0.1871 -0.0161 0.0170 
 
Table 17: Linear regression model to compare frail vs non frail adjusting for age and sex 
 
 
Frailty Odds ratio Standard 
Error 





Age 1.0303 0.0139 1.0047 1.0564 0.020 
Female 0.7109 0.2326 0.37433 1.3500 0.079 
ZTS 0.6567 0.1160 0.4646 0.9283 0.017 
 
Table 18: Logistic regression model using standardised T/S ratio (ZT/S) with frailty as the 







A logistic regression model was used to analyse the role of TL and frailty status in the 
dialysis cohort. The study showed a significant trend in frailty when patients were 
grouped into frail (those who score >=3) and non-frail group (those scoring <3) when 
regressed against TS ratio correcting for age and sex as potential confounders p= 0.017 
(See Figure 39 and Table 17).  
 
TL was standardised for this analysis to have a mean of 0 and SD of 1. Therefore, a 
unit increase in ZT/S will reflect a change in 1 SD. The risk of frailty is 48.8% higher 
for each SD decrease in T/S ratio after adjusting for age and sex in all patients and 
52.2% higher for each SD decrease in the T/S ratio in the dialysis patients. However, 
this does not show that the rate of change in T/S ratio is different in dialysis patients 
and control group with regards to the risk of frailty. The data was modelled using all 
patients but adjusted for case to show how the risk of frailty due to TL was independent 
of dialysis. However, there are no frail controls found in this study. Therefore, the 
frailty status of all controls was discounted for the current analysis and further 
analysis. This does not reduce the impact of T/S ratio or cause any bias with the 
analysis because T/S ratio was not significant in both dialysis and control group 










6.3.7 Is there an association between Frailty, Telomere Length and 
Dialysis Vintage 
 
Frailty scores were available from patients with dialysis vintage of 2.14-1367.29 
weeks. There was a significant correlation between frailty and dialysis vintage, R= 
0.174, p<0.01. There was no correlation between dialysis vintage and T/S ratio in this 
study, R=0.093, p =0.470. The data was then analysed with a linear regression model 
by grouping dialysis vintage into quartiles (See Table 19).  
 
Quartile N Minimum (weeks) Maximum 
(weeks) 
1 59 0 36.4 
2 60 36.6 100.1 
3 59 101.7 195.6 
4 61 198 1367.3 
 
Table 19: Quartile ranges of dialysis vintage in weeks of case groups 
 
A multivariate analysis was conducted to assess the relationship between dialysis 
vintage in quartiles and T/S ratio following adjustment for age and gender (See Table 









Z T/S Coef. Standard 
Error 





Age -0.0281 0.0044 -0.0367 -0.0194 0.000 
Female 0.0380 0.1277 0.0503 0.5534 0.019 
Quartile 2 0.1978 0.1702 -0.1376 0.5333 0.246 
Quartile 3 0.2384 0.1733 -0.1030 0.5798 0.170 
Quartile 4 0.0805 0.1706 -0.0256 1.7189 0.637 
Table 20: Multivariate analysis on effect of dialysis vintage and T/S ratio 
 
 
Frailty Odds Ratio Standard 
error 
95% confidence interval P values 
Age 1.025794 .0136932 .9993037 1.052986 0.056 
Female .6710864 .2337797 .3390422 1.328321 0.252 
ZTS .6494982 .1196786 .4526191 .9320153 0.019 
TOD 2 2.646621 1.232402 1.062499 6.59257 0.037 
TOD 3 1.047526 .5172768 .3979559 2.75737 0.925 
TOD 4 3.04102 1.395366 1.23722 7.474661 0.015 
 
Table 21: Logistic regression model to analyse the influence of dialysis vintage (time on 








The data was then adjusted to interrogate the Z T/S relationship with frailty but taking 
into account dialysis vintage as a probable confounder/risk factor for frailty. This was 
conducted to check that T/S ratio remained an independent predictor of frailty 
irrespective of time on dialysis. The odds of being frail were associated with longer 
dialysis vintage. The association between T/S ratio and frailty are independent of each 
other though there may be some confounding effect of dialysis vintage on this model. 
The effect of ZT/S and frailty (See Table 20 and Table 21) remained largely 












6.4 DNA methylation analysis in dialysis patients  
 
 
Data on DNA methylation was available in 228 dialysis patients. Missing data was 
observed in 11 patients (7 HD and 4 PD) due to loss of DNA integrity that led to a 
failure in the sequencing process. Even though all the samples were tested for DNA 
integrity, it may be that the subsequent repeated thawing process may have led to some 
degradation of the sample. Sequencing of DNA methylation status requires DNA with 
high structural integrity as outlined in the methodology section. As described in the 
methodology section, DNA methylation age is the predicted aged derived from the 
model built using information from 48 CpG sites. Apparent methylomic aging rate 
also better known as AMAR is the ratio of methylome derived predicted age to the 
true chronological age. Therefore, a higher value of AMAR means a higher predicted 
age which also means accelerated ageing. An AMAR >1 is synonymous with fast 
ageing and an AMAR <1 is synonymous with slow ageing (Kim and Jazwinski, 2015). 
DNA methylation delta age is the difference between the predicted age and 
chronological age. So, the higher the DNA methylation delta age, the higher the 
predicted or DNA methylation age is. Therefore, raised DNA methylation age 
represents accelerated ageing. The range of the methylation age observed in the cohort 





Figure 40: Correlation between DNA methylation age (predicted age) and age. R=0.79, 
p<0.001 
 
Figure 40 shows a positive correlation between DNAm age and chronological age, 





















6.4.1 Relationship between DNA methylation and telomere length in 




Figure 41: Correlation between DNA methylation age against T/S ratio. R= - 0.29, p<0.001 
 
Figure 41 shows that a significant negative correlation between DNA methylation age 
and T/S ratio. This implies that the higher the predicted age the lower the T/S ratio 


















Figure 42: Correlation between DNA Methylation Delta Age against T/S ratio. R= 0.12, 






























Figure 42 shows no significant correlation between DNA methylation delta age and 
T/S ratio. Figure 43 shows a significant correlation between AMAR and T/S ratio with 
an R =0.18. DNA methylation age had the best correlation with T/S ratio as seen in 
Figure 40. Table 22 shows the mean distribution for each DNAm ageing parameters 




Ageing parameters HD PD P values 
Age (mean, SD) 53.24 (13.53) 55.65 (14.26) 0.181 
DNA Methylation age (mean, SD) 55.35 (15.24) 57.06 (14.07) 0.381 
DNA methylation delta age (mean, SD) 1.60 (8.96) 1.60 (9.60) 0.999 
AMAR (mean, SD) 1.04 (0.19) 1.05 (0.21) 0.634 
 










6.4.2 Role of DNA methylation markers in frailty among the dialysis 
cohort? 
The study was aimed at investigating if biomarkers of ageing can predict frailty in the 
dialysis cohort. Results on frailty have been extensively discussed in Section 6.2.  
 
Ageing parameters Non frail (n=143) Frail (n=70) P 
Methylome age (mean, SD) 54.28 (14.60) 61.41 (13.66) 0.001 
DNA m delta age (mean, SD) 1.75 (9.57) 2.22 (8.96) 0.736 
AMAR (mean, SD) 1.05 (0.21) 1.05 (0.17) 0.947 
 
Table 23: Baseline comparison of ageing parameters between frail and non-frail group 
 
 
Figure 44: Box plot showing the distribution and spread of methylome age against frailty. 0 





Figure 45: Box plot showing the distribution and spread of DNA m delta age (methylome 
age minus chronological age) against frailty. 0 is not frail and 1 is frail 
 
 
Figure 46: Box plot showing the distribution and spread of AMAR (methylome 





Figure 44, 45 and 46 are box plots looking at the spread of methylation markers in 
both frailty groups. Increased methylation age was observed in the frail group in 
comparison to the non-frail group, this was significant, p<0.001. However, a 
multivariate analysis performed with frailty as the outcome and methylation age as the 
predictor adjusted for age and gender revealed no significance, p=0.245. An increase 
in mean methylation age by 0.02 years is associated with being frail after adjusting for 
age and sex.  
 
Frailty Odds ratio Standard 
Error 







1.020 0.017 0.986 1.055 0.245 
Age 1.022 0.019 0.985 1.061 0.246 
Female 0.678 0.332 0.353 1.300 0.242 
 
Table 24: Multivariate analysis of methylation age as predictor and frailty as outcomes. 
 







1.020 0.017 0.986 1.055 0.245 
Age 1.043 0.013 1.018 1.069 0.001 
Female 0.678 0.332 0.353 1.300 0.242 
 





Frailty Odds ratio Standard Error 95% confidence 
interval 
P value 
AMAR 2.777 0.887 0.488 15.787 0.249 
Age 1.044 0.013 1.018 1.071 0.001 
Female 0.669 0.334 0.348 1.288 0.229 
 
Table 26: Multivariate analysis of AMAR and frailty outcome 
 
Table 25 and 26 show that chronological age is significantly associated with DNA 
methylation age, DNAm delta age and AMAR. This is because DNAm delta age and 
AMAR are calculated based on chronological age. DNA methylation age-based model 
is built from chronological age of healthy adults which will account for the high 






6.5 Predictors of frailty in the dialysis cohort 
Variables Odds ratio Standard 
Error 





Age 1.0391 0.0117 1.0155 1.0632 0.0011 
Female 0.6466 0.3118 0.3510 1.1913 0.1620 
Asians 1.2755 0.3315 0.6660 2.4426 0.4630 
Blacks 0.7623 0.3991 0.3487 1.6667 0.4966 
CCI score 3 11.958 0.4812 4.6564 30.7094 0.000 
CCI score 4 4.5455 0.4536 1.8686 11.0573 0.000 
CCI score 5 14.546 0.5250 5.1981 40.7013 0.000 
CCI score >5 18.409 0.6805 4.8502 69.872 0.000 
BMI 0.9940 0.0282 0.9407 1.0504 0.8313 
Smoking 
current 
1.35 0.4517 0.5570 3.2719 0.5064 
Ex-smokers 0.8617 0.3296 0.4517 1.6440 0.6515 
Haemoglobin 1.2141 0.0984 1.0012 1.4722 0.0486 
WCC 1.1909 0.0700 1.0382 1.3661 0.0126 
Albumin 0.8725 0.0392 0.8080 0.9421 0.0005 
CRP ≥ 5 2.5578 0.2990 1.4236 4.5957 0.0017 
Modality PD 0.4630 0.3007 0.2568 0.8347 0.0104 
 




Table 27 above shows that age, Charlson Comorbidity index of ≥ 4, Haemoglobin, 
White cell count, Albumin and C-reactive protein, modality have significant 
associations with frailty as an outcome.  
 
 









Age 1.0391 0.0117 1.0155 1.0632 0.0011 
T/S ratio 0.2082 0.4780 0.0816 0.5313 0.0010 
Methylome 
Age 
1.0355 0.0109 1.0135 1.0579 0.0014 
DNAm delta 
age 
1.0054 0.0160 0.9744 1.0375 0.7347 
AMAR 0.9506 0.7568 0.2157 4.1896 0.9467 
 
Table 28: Univariate logistic regression on biomarkers of ageing to predict frailty including 
age 
 
Table 28 highlights that both T/S ratio and methylome age have significant association 
with frailty as an outcome in a univariate logistic regression despite the fact that both 





All the significant variables from the univariate logistic model as seen in Table 27 and 
28 in predicting frailty as an outcome were selected to fit a multivariable logistic 
regression model.  
 
Variable Odds ratios Standard 
error 





T/S ratio 0.211 0.693 0.054 0.820 0.025 
Age 0.980 0.027 0.930 1.033 0.449 
Modality PD 0.167 0.481 0.065 0.429 0.000 
CCI score 3 16.364 0.620 4.851 55.20 0.000 
CCI score 4 7.538 0.594 2.352 24.16 0.001 
CCI score 5 19.457 0.723 4.720 80.20 0.000 
CCI score >5 22.814 0.806 4.699 110.75 0.000 
Hb 1.418 0.147 1.062 1.892 0.018 
WCC 1.179 0.096 0.977 1.423 0.086 
Albumin 0.861 0.067 0.756 0.981 0.025 
CRP ≥ 5 2.636 0.419 1.158 5.997 0.021 
Methylome 
age 
1.007 0.022 0.964 1.052 0.759 
 
Table 29: Multivariable logistic regression model to predict frailty as an outcome for T/S 





A multivariate analysis was repeated for methylome age instead of T/S ratio to assess 
if there was a change in significance (See Table 30). 
 
Variable Odds ratio Standard 
Error 







1.006 0.015 0.977 1.035 0.694 
PD  0.214 0.445 0.089 0.511 0.001 
CCI 3 15.464 0.587 4.893 48.870 0.000 
CCI 4 6.606 0.567 2.176 20.058 0.001 
CCI 5 22.432 0.685 5.864 85.810 0.000 
CCI >5 25.416 0.784 5.468 118.143 0.000 
Hb 1.383 0.138 1.055 1.813 0.019 
Alb 0.891 0.062 0.789 1.007 0.065 
CRP 5 2.795 0.409 1.254 6.230 0.012 
 
Table 30: Multivariate logistic regression for methylome age to predict frailty as outcome. 
The table only reports significant variables. 
 
Table 28 highlights that there was no change in significance of methylome age in 
predicting frailty as an outcome in a multivariate logistic regression which was 





6.5.1 Receiver Operating Characteristic curve analysis 
 
Receiver operating characteristic (ROC) curve analysis was performed for T/S ratio 
and DNA methylome age against the development of frailty. The graphical plot 
determines the diagnostic ability of a variable to predict a binary outcome (e.g. frail 
Vs non-frail). Using every value of the variable as a cut-off point, the sensitivity (true 
positive rate) of a variable is plotted against the corresponding 1-specificity (false 
positive rate). The greater the area under the resulting curve, the more useful the test 
is at predicting the outcome. An area under the curve (AUC) of 1 represents a test that 
predicts the correct outcome by a 100% whilst an AUC of 0.5 implies that the 
measurement of interest was unable to distinguish the outcome. Generally, a positive 
test outcome requires an AUC of >0.5.   
 
 
Figure 47: A ROC curve analysis showing the predictive ability of the significant variables 





The Receiver operator characteristics (ROC) curve was built taking into account all 
the significant variables from the multivariate logistic regression analysis from Table 
29 to measure the predictive ability of these factors. A combination of these variables 
produced an AUC of 0.88. Table 29 shows that both methylome age and age becomes 
insignificant with frailty as outcome, therefore were not included in the ROC curve 
analysis.  
 
There were 9 significant variables from the multivariate logistic regression analysis 
which produced an AUC of 0.88 to predict frailty. However, these results may be 
affected by ‘overfitting of the model’. This is because there were only 70 events in the 
form of frail patients and by applying the ‘rule of 10’ would mean that each variable 
tested will have an average outcome/contribute to 10 events. So, this would imply that 
the model had to be adjusted to include only 7 variables. This was achieved by further 
categorising Charlson’s Comorbidity Index to two different levels. A multivariate 
logistic regression analysis was repeated with the new group of variables to generate 











Variables Odds ratios Standard 
Error 





T/S ratio 0.194 0.673 0.052 0.725 0.015 
Age 0.982 0.026 0.932 1.034 0.481 
PD 0.171 0.472 0.068 0.432 0.000 
CCI >2 13.103 0.508 4.843 35.45 0.000 
Hb 1.463 0.142 1.107 1.934 0.007 
WCC 1.194 0.094 0.993 1.434 0.059 
Alb 0.857 0.065 0.754 0.974 0.018 
CRP  5 2.630 0.408 1.182 5.849 0.018 
Methylome 
age 
1.010 0.022 0.967 1.055 0.648 
 






Figure 48: ROC curve analysis to predict frailty with significant variables from multivariate 
logistic regression analysis 
 
Figure 49: A ROC plot adding the adjusted covariates one by one, but not including the 
insignificant variables. The legend outlines the order in which the variables were added to 





The ROC curve above is a step wise ROC curve analysis which was done to 
investigate the effect of each variable and changes to the AUC. Adjusted covariates 
that were significant from the multivariate analysis were added one by one to see the 
progressive change in the AUC. From the ROC plot, it appears that the addition of 
Charlson’s Comorbidity Index significantly changes the AUC from 0.668 to 0.827, 
meaning that CCI has a significant role in predicting frailty.   
 
6.5.2 Biomarkers of ageing as predictors of frailty status in dialysis 
patients (Univariate Logistic Regression Analysis) 
 
A ROC curve was also built using the three different measures of ageing which are 
shown in Figure 50 with corresponding AUC values. Chronological age, methylome 
age and T/S ratio were statistically significant predictors of frailty in the dialysis 
cohort. Of the three, T/S ratio was most significantly associated with predicting frailty 
with AUC of 0.637, p<0.001. DNA methylation delta age and AMAR were not 
included in the ROC curve analysis due its dependence on age and these variables 
were not significant from the univariate logistic regression with frailty as outcome 











Figure 50: ROC curve demonstrating the diagnostic ability for the three measured ageing 














Age 0.6492 0.0117 0.5709 0.7275 0.0011 
T/S ratio 0.6375 0.4780 0.5596 0.7154 0.0010 
DNAm Age 0.6404 0.0109 0.5608 0.7200 0.0014 
DNAm delta 
age 
0.5291 0.0160 0.4451 0.6130 0.7347 
AMAR 0.5192 0.7568 0.4373 0.6011 0.9467 
 
Table 32: Diagnostic ability of chronological age, T/S ratio, DNA methylome age, DNA 
methylation delta age and AMAR for predicting frailty. P values for statistically significant 




CHAPTER 7: DISCUSSION  
 
7.1: General Discussion 
 
The process of ageing remains to be a complex phenomenon that is heightened in 
uraemia and remains a challenge; not only when it comes to understanding the factors 
involved but also when identifying methods to measure ageing in uraemia. As 
described in Chapter 1, the aim of the PhD was to gain a better insight in assessing 
and quantifying premature ageing in uraemic patients through parameters that have 
shown promise in healthy control and non-CKD patients.  
 
As elaborated in Chapter 1, TL is a well-established novel biomarker of ageing that 
declines with increasing age and has been associated with survival outcomes in healthy 
donors. Since the discovery of this biomarker of ageing that represents biological age, 
there has been a surge in research and publications in the field of cardiovascular and 
cancer and ageing. However, only a handful of researchers have investigated the role 
of telomere biology as an objective ageing marker in uraemia. Another biomarker of 
ageing that has gained recognition is frailty; a phenotypic measure that represents 
overall health and functional status which has a great impact on survival. Frailty has 
been studied among patients with uraemia through various screening tools, but no 
consensus has been established on the criteria used to define frailty in these patients. 
There is also limited data on the use of frailty phenotype as a subjective ageing 





The parameters that were studied to fulfil the aim of this Ph.D. was the role of TL and 
frailty phenotype as markers representing ageing in uraemia. This was the first study 
to investigate if there was any association between TL, DNA methylation and frailty 
phenotype as biomarkers of ageing in patients with end stage kidney disease. Results 
of these outcomes of interest will be discussed below. 
 
7.2 Discussion on frailty outcomes in study cohort 
    
7.2.1 Age and gender effect on frailty status in dialysis patients 
 
There was no significance between frailty status and gender found among 212 patients 
in this study. In an older population, the prevalence of frailty was higher in women 
than men. (Collard et al., 2012). Similar findings were also seen in patients on dialysis 
from the Dialysis Morbidity and mortality study (DMMS) Wave 2 consisting of 3931 
patients from HD and PD whereby women were more likely than men to be frail in all 
categories of age. However, ACTIVE/ADIPOSE (A Cohort Study to Investigate the 
Value of Exercise in ESKD/ Analyses Designed to Investigate the Paradox of Obesity 
and Survival in EKRD); a multicentre study of 745 patients on HD who had their 
frailty status measured revealed no association between female sex and frailty (Kutner, 
2014). Similar findings were also noted by a recent study conducted by McAdams-
DeMarco et.al (McAdams-Demarco et al., 2013). These 2 studies had used 
performance-based measures for muscle strength and gait speed. The DMMS Wave 2 
study by Johansen et.al and Bao et.al both showed than women were frailer than men 




grip strength and walk assessment. A patient reported health status measure 
representing physical function is clearly a different metric from a performance based 
assessment of muscle strength and gait speed which could account for the different 
outcomes seen with regards to gender and frailty (Painter and Kuskowski, 
2013)(Kutner, 2013). The baseline data from the ACTIVE/ADIPOSE study revealed 
that 61% of patients scored less than 75 based on the SF-36 PF scale but only 5% were 
found to be frail in both measured grip strength and walk speed (Kutner, 2013). These 
findings underscore the potential for misclassifying patients as frail when using a self-
reported physical function questionnaire instead of a performance-based assessment 
of weakness and slowness domain.  
 
The sample size of this study was limited but consisted of 212 patients from 2 different 
types of dialysis modality having completed their frailty assessments at baseline. Even 
though no association was seen between gender and frailty as observed by other larger 
studies it is important to note that the gender distribution in this study cohort was 
unequal and females were younger than men. The statistics in this study was corrected 
for age and gender whenever possible.  
 
The prevalence of frailty increases with age in the general population (Hanlon et al., 
2018). Frailty has generally thought to be a phenotype predominant in the elderly 
however among uraemic patients on dialysis, frailty occurs at an early age and 
frequently below the age of 65. Our work demonstrated a significant correlation 
between age and frailty scores. Frailty was seen in 12% of patients under the age of 
40 year and 26% between the ages of 40-50 years from a total of 212 patients. This is 




age of 40 and more than 50% of patients between the ages of 40-50 were frail out of 
a total of 2393 patients. In non-dialysis patients, older age was clearly associated with 
frailty but data from DMMS Wave 2 study also showed that there was lack of 
interaction between age and frailty suggesting that a significant proportion of younger 
dialysis patients were also frail (Johansen et al., 2007). Frailty in patients under the 
age of 40 years from the Comprehensive Dialysis Study consisting of 1576 patients 
revealed that 63% were frail (Bao et al., 2012). Taken together it is clear that ESKD 
is a strong risk factor for frailty particularly in the young. While our current study 
demonstrates significant rates of fragility in young dialysis population, the other larger 
studies found an even higher prevalence of frailty. Possible explanations for this may 
be due to a difference in different scoring systems in comparison to the one used in 
the current study that could explain the differences observed. A modified version of 
the Fried criteria for frailty were applied in these large studies to provide a final score 
on frailty that did not utilise hand grip strength to assess weakness but instead used 
the Rand 36 PF and SF 12 PF questionnaire to provide a score for this component 
which may have led to a relative overestimation of frailty in the larger cohort studies. 
 
7.2.2 Frailty phenotype among haemodialysis and peritoneal dialysis 
patients 
 
The prevalence of frailty is 6.9% in community dwelling older adults (Fried et al., 
2001) and thought to be much higher in patients with ESKD. The current data suggests 
that the prevalence of frailty among dialysis cohort ranges from 3 to 10 fold higher 




Frailty Phenotype is commonly applied among dialysis patients however the 
prevalence was found to be lower  when measured by this method but remained to be 
significantly much higher by 4 to 6 times in comparison to healthy elderly adults 
(Nitta, Hanafusa and Tsuchiya, 2017). There has been variability between frailty status 
between ESKD cohorts probably a result of different methods used to assess frailty. 
 
This study demonstrates that among 70 frail patients in total, 64.3% were on 
haemodialysis at the time of recruitment. Among the whole study cohort consisting of 
213 patients, frailty was observed in 21% of haemodialysis and 11.8% peritoneal 
dialysis patients despite the mean age of PD cohort and female distribution being 
similar in HD cohort. This study showed that the overall prevalence of frailty 
phenotype in patients on HD was substantially higher (21%) in comparison to 
community-dwelling older adults (6.9% in the Cardiovascular Health Study and 
16.3% in the Women’s Health Initiative Observational Study) (Fried et al., 
2001)(Woods et al., 2005). The DMMW 2 study showed that HD rather than PD 
modality was independently associated with frailty with an odds ratio of 0.80 (95% CI 
0.65-0.97)  (Johansen et al., 2007). However, a large study consisting of 1616 Korean 
patients comparing 1250 patients on HD and 366 patients on PD revealed the opposite 
finding (Kang et al., 2017)(Lee et al., 2017). There was no significant difference in 
frailty between patients treated with the 2-different dialysis modality in the Korean 
studies. The dialysis vintage in the Korean studies aforementioned were similar in HD 
and PD. The DMMW 2 study had no information on dialysis vintage. The studies by 
Johansen et.al., Kang et.al and Lee et.al. had utilised the questions from KDQOL and 
RAND 36 and SF 36 which both consist of identical items. The possibility for a 




HD cohort could be explained by a shorter dialysis vintage in our study. Another 
important factor is that patients are not randomly assigned to PD vs HD:  in our pre 
dialysis clinic the patient’s functional status is considered when counselled for 
treatment modality. A shared decision is made with the patient, with PD recommended 
for those patients who are more self-caring, ambulant and have less cognitive 
impairment. This may also account for HD patients having a higher frailty score in 
comparison to PD patients. There are also a small number of patients on assisted PD 
due to impaired functional status, but this study did not have a record of patients on 
assisted PD. 
 
7.2.3 Dialysis vintage and frailty status in dialysis cohort 
 
There was strong correlation seen between dialysis vintage and frailty status among 
our cohort. Exposure to prolonged periods of dialysis is associated with various 
adverse outcomes which subsequently affect ones’ frailty status directly and 
indirectly. Increased dialysis vintage is associated with accumulated losses of nutrients 
during dialysis/protein energy wasting (PEW), inflammation as a result of oxidative 
and carbonyl stress, superimposed catabolic illness and stress from the dialysis 
procedure, prolonged exposure to uraemic toxins and altered hormone profiles; factors 
that contribute to frailty status measured by the 5 domains of Fried Frailty Phenotype.  
 
Duration of dialysis is a relative contributor towards frailty and ageing in patients with 
ESKD (Kim, Kalantar-Zadeh and Kopple, 2013). A retrospective cohort study of 216 




dialysis vintage was associated with lower level of body mass index (BMI) which 
reflects loss of muscle mass (Sumida et al., 2016). An cross-sectional study showed 
that 31.5% of patients have sarcopenia as defined by the European Working Group on 
Sarcopenia in Older People (EWGSOP) which was associated with a  longer dialysis 
vintage (Bataille et al., 2017). Loss of muscle mass or sarcopenia is associated with 
physical inactivity and reduced hand grip strength which would affect the frailty 
domains of exhaustion, weakness, slowness, physical activity and weight loss. In fact, 
the frailty scores of the dialysis cohort in this study are more likely to be higher as 
weight loss was reported by patients based on their reflection of recorded weight 
measured a year ago. Patients may not be aware of age-related changes in body 
composition causing sarcopenic obesity which refers to a reduction in muscle mass 
but matched by the gain in body fat (Gallagher et al., 2000).  
 
A study of 97 elderly patients with a mean age of 84.5 years revealed that 78% were 
independent in their activities of daily living (ADL) at the time of dialysis initiation, 
but >30% of patients had functional loss after 6 months of dialysis treatment and their 
frailty level, defined by loss of independence continued to decline during a 2.5 year 
follow up period (Jassal, Chiu and Hladunewich, 2009). US registry data from  nursing 
home residents  with a mean age of 73.4  10.9 revealed a downward trajectory in 
their functional status assessed from 7 ADL from 3 months prior to dialysis initiation 
to 12 months of dialysis treatment (Kurella Tamura et al., 2009). Even though these 
studies did not formally measure frailty using the Fried criteria, the clinical outcomes 
do support a decline in functional status over a period of time on dialysis. However, 




registry in US were in nursing home patients who are likely to have a high prevalence 
of disability at baseline to start off with.  
 
There have been few studies which have reported outcomes on frailty scores and 
dialysis vintage. The ACTIVE-ADIPOSE study failed to show any association 
between length of time on HD and frailty status with a median dialysis vintage of 3.3 
years (Kutner, 2014). A single prospective study of haemodialysis cohort of 146 
patients did not reveal any association between frailty status and time on HD 
(McAdams-Demarco et al., 2013). In a prospective study of 1658 patients (1255 on 
HD and 403 on PD) showed that frailty was not related to the dialysis duration of 5.2 
 4.5 years (p= 0.744), however this study used the Korean version of Kidney Disease 
Quality of Life SF36 questionnaire to measure frailty; a modified version of the 
Physical Frailty Phenotype whereby all the frailty components were assessed  from 
questionnaires with no objective measures (Lee et al., 2017). The studies had no 
information on frailty status prior to HD initiation or longitudinal data which may have 
affected the outcome of frailty status and dialysis vintage.  
 
7.2.4 Changes in frailty status over time 
 
This study was a 1-year longitudinal study aiming to ascertain if there was any 
significant change in frailty status from baseline. There was no significant difference 
seen between overall frailty score at baseline and after 12 months in the dialysis group 
and there was no difference between HD or PD group. This is because the change in 




a year and perhaps the change in frailty occurs over a longer period of time. The study 
also excluded any patient with a life expectancy of 6 months or less which reflects the 
frailest group on dialysis which would have inevitably affected the overall frailty 
scores and 1 year follow up scores if these patients survived.  It is difficult to know if 
the largest difference in frailty is seen before initiation of dialysis and a specific time 
frame post dialysis as there are no studies that have looked into this aspect. There were 
69 patients who had transitioned over to transplantation. A subgroup analysis of this 
cohort revealed that there was a significant difference in exhaustion at baseline and 1-
year post transplant. The significance of this finding may be affected as the protocol 
for the study did not censor or exclude patients who had transitioned into 
transplantation. Therefore, the duration of these patients having a renal transplant 
varied from 2 months to 12 months. Studies evaluating frailty post transplantation has 
been well published in the literature but there are no longitudinal studies to assess 
frailty pre and post transplantation. These findings are certainly worth investigating 
further especially since recent data revealing that telomere attrition is more 
pronounced post renal transplantation than on dialysis (Luttropp et al., 2016).   
 
Frailty is bidirectional and potentially reversible. There has been consistent evidence 
on the positive effects of aerobic exercise on physical fitness, muscular strength and 
quality of life in ESKD patients (Jhamb et al., 2008). So, there needs to be greater 
emphasis in applying these measures or interventions to address modifiable aspects of 
frailty components in the dialysis population at all health institutions. This can include 
working together with primary care to providing aerobic and anaerobic exercise 
regimes which can be administered in the dialysis unit or in the community. There are 




access to this by incorporating an exercise regime to treatment will be step forward in 
the correct direction to address physical inactivity in dialysis patients. There needs to 
be greater emphasis on nutrition and education not only to patients but especially for 
those caring for ESKD individuals. Perhaps a cooking video providing nutrition ideas 
and recipes for dialysis patients to incorporate cultural values which can be easily 
accessible from the trust website. Clearly this will need to be tailored according to 
units due to variation in patient population and ethnicity.  
 
There is also need for longitudinal studies to assess frailty status over a longer period 
of time to investigate practical and cost effective intervention strategies which may 
lead to promising findings as frailty is reversible as a duration of 1 year may not be 
sufficient enough to see a significant difference in frailty status. This could also 
include strategies on optimal type of exercise and dose, when best to intervene for 
optimal outcomes and ways to reduce interruption to training taking into financial 







7.3 Telomere length outcomes in the study cohort  
 
7.3.1 Age and gender effect on telomere length in dialysis cohort 
 
Published data in healthy controls and non-CKD patients have consistently revealed 
that TL shortens with age. This inverse relationship was also observed in our study 
cohort with a statistically significant TL decline with age in our dialysis cohort. This 
observation was also seen in other published data of similar sample size in patients 
with ESKD. These findings reinforce the validity and reliability of RT-qPCR 
technique.  
 
The present study has also shown that women who are on dialysis have a significantly 
longer TL in comparison to men who are on dialysis even after adjusting for age. 
However, this effect of gender was not seen in the control group with p=0.07. Despite 
the evidence that females have longer TL than males for a given chronological age, 
there have been 2 systematic reviews revealing that findings of TL in gender has not 
been consistent and not universally observed in studies that did not use Southern blot 
methods (Müezzinler, Zaineddin and Brenner, 2013) (Gardener and et al., 2014).  
 
Longer TL in women has been attributed to the slower rate of TL attrition in women 
which is thought to be due to the high oestrogen exposure during the premenopausal 
period. There was an argument that similar findings many not been seen in women on 
dialysis due to alterations to their hormone panel leading to premature menopause. 




a woman’s menopausal status, TL remains longer in women than men.  Controversies 
on gender and TL remain; on the one hand, emerging evidence to suggests that female 
new-born babies may have longer telomeres than new-born males using flow fish 
(Aubert et al., 2012) but not seen in another study that used TRF southern blotting 
(Okuda et al., 2002).  
 
7.3.2 Telomere length between dialysis patients and healthy controls 
 
This study revealed that there was a difference between TL in the control group and 
ESKD group. However following adjustment for age and sex this significant 
association was lost. This was because the control group were younger than the 
dialysis group. This study failed to show any difference between TL; a marker of 
biological ageing to demonstrate that patients on dialysis age faster than healthy 
controls. The exact reason for this in unclear. The age group of the dialysis patients 
studied at our unit were younger than the average age of dialysis patients in the UK 
which is approximately 65 years. So perhaps this would account for the insignificant 
difference especially when measured with PCR technique between TL in healthy 
control and dialysis cohort. Studies which have revealed a difference between TL in 
healthy group and ESKD cohort had used FISH technique, Southern Blotting and G-
tail telomeric length. The difference in TL measured with PCR technique is reported 
as a ratio and does not reflect the absolute length of telomeres and could underestimate 
the actual difference observed between the cohort (Refer to Chapter 8.2: Challenges 
and Limitations with Laboratory and Clinical Methodology on RT-qPCR technique 




converting TL reported as T/S ratio to absolute kbp. The numbers have also been 
smaller than this study. Medications that dialysis patients are often on which include 
a statin, angiotensin converting enzyme and erythropoietin has been associated with 
longer TL (Tran, Meeker and Platz, 2018) (De Vries et al., 2018)(Zhang, 2014). 
Therefore, it is possible that patients on dialysis had preservation of TL due to 
interventions in the form of medications and no difference was found between TL in 
healthy control and dialysis cohort.   
 
This does not preclude current evidence suggesting that dialysis patients do have an 
accelerated ageing in comparison to healthy cohort but merely that TL may not be the 
ideal biomarker of ageing to demonstrate this difference or that the difference in TL 




7.3.3 Telomere length in haemodialysis and peritoneal dialysis  
 
An area of interest in this study was to investigate if there were any differences 
between TL in HD and PD patients. The hypothesis was that a difference in TL may 
be observed in the different dialysis modality due to the different nature of the RRT 
process especially since TL is known to reflect oxidative stress. There has only been 
one study published to date that has attempted to compare TL in HD and PD cohorts. 
The study measured TL in CD4+ and CD8+ cells using flow fluorescence in situ 




TL in HD patients only. There has been no published literature to date investigating 
TL in peritoneal dialysis patients with qPCR technique, therefore this work is unique 
in attempting to do so.  
 
The results from this study failed to support the hypothesis that T/S ratio would be an 
ideal senescence marker representing premature senescence in ESKD cohort: as the 
mean T/S ratio between the HD and PD group showed no significant difference 
compared to the healthy controls. This outcome may also imply that T/S ratio; a form 
of a biomarker that reflects oxidative stress (Houben et al., 2008) was similar in both 
groups. However, the study did not investigate and measure specific markers of 
oxidative stress that is associated with TL in uraemia (Tarng et al., 2000)(Carrero et 
al., 2008)(Murillo-Ortiz et al., 2016). Meijers et.al; the only study comparing TL in 
HD and PD patients similarly found no statistically significant difference. These 
results may be due to HD and PD cohorts sharing many characteristics known to affect 
TL including age, gender, cardiovascular disease and uraemia. Data on 1-year 
mortality was similar between groups however the low number of events may mean 
that a small difference in mortality can’t be excluded from this study due to a type 2 
error. Besides, the increased survival data on PD was only seen in the early phases of 
starting PD and was influenced by multiple factors which include residual renal 
function which a large proportion of our patients had lost. However, the one interesting 
finding in this study is that the PD patients had T/S ratios on average of 0.0225 longer 
in comparison to HD patients following adjustment for age and sex at baseline 
suggesting there may be some influence of the modality itself affecting TL and may 





7.3.4 Dialysis vintage and telomere length 
 
Prolonged dialysis exposure represented by dialysis vintage is a strong predictor of 
mortality as a result of multiple uraemic factors including increased oxidative stress 
and inflammation. Both oxidative stress and inflammation accelerate TL shortening 
leading to premature cellular senescence and reduced longevity as a result of 
accelerated biological ageing. These factors led us to believe that TL would be affected 
by dialysis vintage which was one of our hypotheses in this study.  
 
However, our results have shown that there was no association between dialysis 
vintage and TL in our cohort irrespective of dialysis modality. There has been no data 
published previously on TL measured with qPCR and dialysis vintage in peritoneal 
dialysis cohort thus far. In fact, there has only been one study which had measured TL 
in 41 peritoneal dialysis patients using flow fluorescent in-site hybridisation (FISH) 
technique (Meijers et al., 2012). Most published data investigating TL and dialysis 
vintage of HD patients have utilised other techniques mainly Southern blotting and 
FISH except one study that measured TL using qPCR which was published by Carrero 
et.al.  
 
The results of dialysis vintage and TL from this study was comparable to results 
published by Carrero et.al that was similar in sample size and technique. Results from 
a study measuring TL in T-cells of ESKD patients showed that dialysis vintage was 
not significantly associated with TL (Meijers et al., 2012). The duration of dialysis in 




revealed that the younger dialysis patients with mean age of 35.7  8.5 years had 
decreased TL in CD8+ T-cells which may be accounted by the longer dialysis vintage 
with a mean of 4.3 years. However, these findings were not statistically significant. 
There have been several other published data supporting our initial hypothesis but the 
sample sizes in these studies were smaller and the techniques used to measure TL 
differed.  
 
A study investigating the role of TL measured with Southern Blotting in 43 HD 
patients showed an inverse relationship between TL and dialysis vintage (Stefanidis 
et al., 2015). The dialysis vintage in this study was 19.9  15.6 months and the 
associations were only found between the 2 variables due to 4 outliers who have been 
on HD for 4-6 years. Another study using Southern Blotting from 38 HD patients 
revealed that TL was inversely proportional to time on dialysis but the mean/median 
dialysis vintage was not stated in the paper (Boxall et al., 2006). The authors revealed 
that TL shortening was at 189bp per year of treatment on dialysis with the slope of the 
regression line for this relationship. Telomere shortening rate in healthy individuals 
are usually 20-40 bp/year (Lindsey et al., 1991)(Vaziri et al., 1994)(Boxall et al., 
2006).  
 
Failure to confirm our hypothesis may be due to several factors; Probable 
measurement error in the assay when measuring TL in a small group of study cohort 
maybe a contributing factor as to the lack of consistent results among published data 
when addressing this hypothesis. With variable CV values reported in these studies 




The total sample size of dialysis patients who had TL measured successfully was 223. 
This study was a pilot study hence a power calculation was not done risking a type 2 
error.  
 
7.3.5 Telomere length and mortality 
 
This study saw no association between TL and 1-year mortality as there was only 10 
deaths within the 1 year of follow up risking a type 2 error. It may be interesting to 
evaluate TL and 5-year mortality data in this cohort as this is the median life 
expectancy for patients starting dialysis and as such, we would expect approaching 
50% of patients who have remained on dialysis to have died in 5 years.    
 
7.3.6 Telomere attrition in the case group 
 
There are 3 longitudinal studies on TL changes in CKD and dialysis patients (Bansal 
et al., 2012)(Luttropp et al., 2016)(Kato et al., 2016) . However, findings from these 
studies will need to be interpreted cautiously. The study by Bansal et.al found that 
kidney function was not independently associated with telomere shortening over 5 
years, but the study participants had a mean eGFR (CKD-EPI) of 72.6  21.5 
ml/min/1.73m2 and eGFR (cys) was 71.0  23.2 ml/min/1.73m2. The patients in this 
cohort were also relatively older with a mean age of 66.7 and stable coronary heart 
disease. A relevant study for comparison with this thesis findings reported that 
telomere attrition over 12 months in the dialysis group (n=49, HD=19 and PD=30) 




0.88 to 0.85 in this cohort. The authors also showed that a greater decrease in mean 
TL was observed after 12 months following renal transplantation. However, the study 
failed to show any association between age of the patients with TL at baseline.  
 
The current study failed to show any significant difference in telomere attrition over a 
year using a mixed model approach. This is because the differences observed, even 
over several years, are very small and cannot truly be distinguished from measurement 
error or background noise.  The general estimation for TL attrition is 30bp per year 
with the lengths of human telomeres estimated at 5-15kbp (so per year decline would 
be ~0.3%, current CVs (measurement error) are 4-5%).  
 
Another major factor worth considering is the difference in the DNA sample storage 
times as the baseline DNA sample would have been stored for at least a year longer 
than DNA sample extracted at year 1. DNA storage conditions are known to impact 
quantitative PCR reaction. Dagnall et.al showed that samples that were stored at a 
higher concentration; 25ng/uL maintained strong correlation to the original results 
after 6 months but samples stored at 1ng/uL weekly correlated to the original samples 
(Dagnall et al., 2017). There are no studies to show if these findings are largely 
unchanged in DNA stored longer than a year. There may be changes in DNA integrity 
that may not be detectable by using a spectrophotometer and the use of Qubit dsDNA 
Br Assay Kit or Quanti iT Picogreen dsDNA assay to measure double stranded DNA 
content of the sample may offer a solution (Lin et al., 2019). The same DNA extraction 
facility and kit were used for DNA extraction from samples at baseline and 1 year as 





Measurement of TS ratio from an unpublished data of ~1000 individuals 10 years apart 
saw very little difference in TL for the majority of the cohort, which is what one would 
expect. This may explain the reason as to no significant change observed TL over 12 
months in the study. The delta TS ratio of patients on PD was longer than HD patients 
but this likely be due to the fact the PD patients already had a baseline TL which was 
longer than HD. 
 
7.3.7 Telomere length as a predictor of frailty in the case group 
 
This is the first study to show a significant association between TL and frailty status 
in the dialysis patients. Increasing frailty was observed in dialysis patients with shorter 
TL which remained significant following multivariate logistic regression analysis. A 
ROC curve analysis showed that TL was a predictor of frailty with an AUC of 0.64.  
 
There have been various studies in non-dialysis cohort demonstrating that TL is 
associated with frailty as reported in a recent systematic review of 10, 079 older adults 
(60 years and older) (Araújo Carvalho et al., 2019). The review reported that frail 
older adults (n=355) had shorter telomeres than the non-frail (n = 1894) (Araújo 
Carvalho et al., 2019).  
The results of our work have demonstrated that TL may be a potential adjunct in 
identifying frail dialysis patients and may play a larger role in risk stratifying these 
patients with regards to mortality. In fact, results from this study support the use of TL 
analysis as an adjuvant biomarker which explains the intrinsic and multi system nature 




A recent study demonstrated that a frailty measure constructed from standard 
laboratory tests and physiological parameters exhibits a significant association with 
TL among a cohort of the USA general population aged ≥60 years (Bello, Chiu and 
Dumancas, 2019). A combination of biomarkers of ageing and frailty reflecting this 
process across a range of physiological system may provide a better specificity and 
sensitivity than a single biomarker in predicting adverse health outcomes in a much 
more accurate manner especially in a complex group of patients e.g. dialysis patients.  
The findings from this study is important in future research on frailty in uraemia as 
further investigations on the exact process and mechanism of TL shortening that 
eventually leads to frailty at a basic molecular level can be explored further.  
7.4 Discussion of significant findings in ageing model of 
DNA methylation 
7.4.1 DNA methylation and age 
The findings of this study reveal that DNA methylation age had a strong correlation 
with age, r= 0.79 in the dialysis cohort (See Figure 40). Similar findings were shown 
by Hannum and Horvath with high age correlations (r=0.91 and r=0.96) and small, 
mean deviations from calendar age (4.9 and 3.6 years) (Hannum et al., 2013)(Horvath, 
2013). The mean deviation from calendar age in this study cohort was 11.3 years. 
Mean DNA methylation age was 1.78 years higher in the dialysis patients than their 




7.4.2 DNA methylation and frailty 
The non- frail group had a mean DNA methylation age of 54.28   14.6 in comparison 
to the frail group who had mean DNA methylation age of 61.41  13.66. This 
difference was significant and supports our original hypothesis that frail dialysis 
patients’ exhibit features consistent with accelerated ageing and that biological age 
may be a better predictor of frailty outcomes in dialysis patients than their 
chronological age. In this study we have used previously validated group of 71 CpG 
sites that have been shown to be highly predictive of age and built a model of 
methylation age based on a population of healthy controls. In applying this model to 
predict the ages of the study population, predicted methylation age referred to as DNA 
methylation age in this thesis as a surrogate marker of biological age.  
Previous studies into methylation signatures of ageing have used AMAR or DNA 
methylation delta age as surrogate marker of biological age. However, in this study 
there was poor correlation with AMAR and DNA methylation delta age with 
chronological age as well as no association with frailty status. Both AMAR and DNA 
methylation delta age area derived from an individual’s chronological age and may 
not be the best surrogate for chronological age. Therefore, to use either of the measures 
seems rather counter intuitive as the incorporation of chronological age might mask 
clinically significant associations that exist when the predicted methylation age is 
considered in isolation.  
DNA methylation age was no longer significant with the development frailty 
following a multivariate analysis. As chronological age appeared to be a major 




the development of frailty in the dialysis cohort though not superior to age based on 
the ROC curve analysis. Therefore, the current epigenetic signature for predicting 
methylation age is unlikely to be useful in terms of risk stratification as it was not 
possible to determine if these findings were causal or consequential or both. However, 
these findings provide a preliminary proof of concept validation that targeted 
methylation signatures are associated with frailty and may provide the basis of future 
research.  
7.5 Comparison of results with previous studies 
This is the first study looking into TL and DNAm as biomarkers of ageing to predict 
frailty as an outcome in the dialysis cohort. There are studies that have investigated 
TL in dialysis and DNAm in dialysis separately in other areas of nephrology but not 
specifically in frailty despite wide consensus on the major role frailty plays in dialysis. 
With regards to TL and ageing in dialysis, this would be the largest study in the dialysis 






CHAPTER 8: CHALLENGES AND LIMITATIONS 
WITH LABORATORY AND CLINICAL 
METHODOLOGY  
 
8.1 Fried frailty phenotype 
 
There have been inconsistent outcomes in frailty measured in dialysis cohorts as a 
result of varying patient characteristics, different definitions of frailty and several 
ways of assessing frailty status. There is no consensus on the criteria, nor the scoring 
used when measuring frailty in uraemia. The chosen method to assess frailty for the 
purpose of this study was based on the Fried frailty phenotype which has been 
validated in the multi-ethnic dialysis population. Large scale population-based studies 
investigating frailty in dialysis patients were conducted in United States of America 
and often classify their patients into Caucasians, African American, Asian and others. 
The data available on the role and use of Fried frailty phenotype among Asians on 
dialysis is poorly described. Patient numbers in the Asian cohort are small in 
comparison to other ethnic groups which may account for lack of association or 
predictor of frailty.  
 
One of the first studies investigating the association of frailty and ethnicity in non-




those aged 45 to 54 years with Caucasian participants being more likely to be frail 
than their African American counterparts (Griffin et al., 2018). However this was not 
observed in other studies which reported an increase in frailty in African Americans 
aged between 65 and 79 years (Fried et al., 2001) (Szanton et al., 2010). A study from 
the UK investigating frailty by ethnic groups of patients >65 years of age based on 
demographic data revealed that the greatest prevalence of frailty was in the South 
Asian community (Pradhananga et al., 2019). Prevalence of frailty was highest in the 
Bangladeshi population followed by Pakistanis and Indians (Pradhananga et al., 
2019).  
 
Studies investigating frailty in the dialysis cohort showed black patients were less 
likely to be classified as frail in comparison to White Caucasians but the black 
participants were younger with mean age of 55 (Kutner, 2014). A study of 2275 
dialysis patients showed that the 2.3% of Asian patients with mean ages of 58 were 
less likely to be frail in comparison to whites (Johansen et al., 2007).   
 
Black ethnicities have an increased proportion of muscle mass so one would expect a 
higher hand grip strength and reduced sarcopenia that would improve frailty.   
However, this was not the case in this study. There was no difference observed 
between hand grip strength and overall frailty scores between ethnic groups due to the 
small group numbers and unaccountable factors such as socioeconomic status.  
 
As with all subjective assessments, the Fried frailty phenotype had several 
disadvantages which were encountered during this study, even though the 




questionnaire depends on the patients being able to remember answers to the list of 
activities specified in the questionnaire. The activity questionnaire used in this study 
was based on the Minnesota Leisure Time Activity Questionnaire (MLTPAQ) which 
was utilised by Fried et.al. to calculate estimated energy expenditure. The 
questionnaire is elaborate and time consuming not to mention is subject to recall bias 
as patients are expected to report on frequencies and duration of each physical activity 
listed over a 12-month period. The MLTPAQ does not include more recent type of 
activities which patients engage with e.g. Zumba classes or fitness yoga. Many 
patients also keep track of their physical activity using their smart phones and apps 
mainly in the form of step counts. This meant that patients found it difficult to 
subsequently translate their step count to the required information on the physical 
activity questionnaire to enable energy expenditure calculation. Other studies have 
used various forms of questionnaires and assessments to assess the physical activity 
component. These include the use of LoPAQ (low physical activity questionnaire), 
PASE (physical activity scale for the Elderly), self-reported physical function using 
the physical function (PF) scale of the SF-36, self-reported questions on frequency of 
activity performed as well as the use of pedometers to measure physical activity  in 
CKD cohort (Johansen et al., 2015)(Johansen, 2015). 
 
Patients also found it difficult to report on weight loss, as often the reported weight 
loss was related to fluid removal rather than actual flesh weight. The Fried frailty 
phenotype methodology used for the purpose of this study measured weakness 
objectively through grip strength which requires the body mass index to assess the cut 
off for grip strength when determining ones’ frailty score. Often an overhydrated 




affecting end scores for frailty domains. A similar issue was encountered when 
assessing weight of PD patients as due to the nature of their dialysis, these patients 
often have dialysis fluid in their peritoneum at all times. This was addressed by 
establishing their weight at clinic when there is no fluid in the peritoneum or by 
assessing their dry weight based on the known amount of fluid infused into the 
peritoneum. 
 
8.2 RT-qPCR technique for TL measurement and quality 
control measures 
 
The technique utilised for the purpose of this PhD has many advantages and is the 
preferred choice for large population-based studies due to its high throughput. 
However, despite the fact that this technique is well established, there are some 
limitations which could potentially affect the outcome of this study which this PhD 
has tried to address to its best.   
 
One of the main challenges has been the reproducibility of the technique which is 
affected by several factors including pipetting errors and DNA quality. The RT-qPCR 
assay to measure TL needs to have high quality DNA that is not compromised by 
degradation. This is addressed by evaluating each sample by gel electrophoresis. The 
assay precision is also affected by small changes in efficiency in earlier cycles which 
may result in larger changes due to amplification in subsequent cycles. These changes 
in efficiency is caused by primers mis-priming, changes in thermal cycling 




positive control. A negative control is included on each run to assess for any 
unexpected amplification or contamination in the assay. 
 
Cawthon, who first described this technique to measure TL had observed an inter-
assay coefficient variation of 5.8% and an intra-assay coefficient variation of 13.8% 
for triplicates and 3.4% for duplicates. The inter-assay CV in this study was 4.86% 
whilst the intra-assay CV for the Tel run was 1.57% and 1.51% for SCG run. Samples 
in this study were performed in duplicates. The intra-assay CV of both Tel and SCG 
run in this study was lower than the intra-assay CV observed by Cawthon as this study 
excluded any samples where the duplicate values were more than 0.2 of a cycle 
differences for the take-off value.  
 
Other disadvantages of RT-qPCR are that the results do not provide an absolute kilo 
base length estimate of TL, but a relative TL or better known as T/S ratio. This proxy 
measurement however has been shown to be an accurate representation of absolute 
TL. Another disadvantage of this technique is the difficulty in directly comparing 
different samples between studies due to probable differences in the DNA quality and 









8.3 DNA methylation and limitations 
 
There are several strength and limitations to the current study. A significant strength 
of the study is that DNA methylation status is gaining wider interest and has been 
postulated as a better biological marker. In fact, the role of individual CpG sites from 
DNA methylation analysis may be able to offer more information in clinical studies 
which can set the platform for investigating the effect of intervention based on the 
changes of these CpG sites. There are currently 850,000 CpG sites mapped in the EPIC 
methylation array and 450,000 sites mapped in the Illumina Human Methylation 450 
bead chip. This study mapped 71 CpG sites instead of the mapping the CpG sites 
described as a targeted approach which has been well established. There is increasing 
literature on targeted identification of CpG sites to help reduce cost when using an 
epigenetic marker for a study. Firstly, not all of the 71 of the ageing signature CpG 
sites of interest or the 6 CpG sites described by Koch et.al as correlating with cellular 
senescence was successfully mapped in this study. This was due to a failure to design 
primers specific enough to amplify the CpG of interest. This is one of the limitations 
of CpG target specific approach. Due to this only 48 of the 71 CpG sites were used to 
generate the model used to calculate the methylation age in this study cohort. 
However, despite this limitation the model correlated well with the chronological age 
of healthy donors with an RMSE of 6.89, R= 0.75. The loss of the original CpG sites 
described by Hannum was not a limitation for this study but it is important to note that 
the final model used in the analysis for this study was based on the Hannum epigenetic 
clock but not the exact same signature as described in his paper (Hannum et al., 2013). 




a mathematical model to estimate DNA methylation age in the group of interest. The 
model is built based on the CpG sites from healthy donors. Therefore, it is not 
surprising that DNA methylation has a strong correlation with chronological age. 
There is increasing interest in investigating specific target CpG sites for ageing which 
may provide a targeted approach in investigating ageing in a cohort of interest as the 





CHAPTER 9: CONCLUSION AND FUTURE 
WORK 
 
9.1 Summary of key findings 
From the results of this study the following conclusions can be drawn: 
 
1) Frailty was higher among HD patients in comparison to PD patients and this 
difference was significant, p= 0.015. The relative risk of frailty was 1.69 times 
higher in HD than in PD and this was significant, p=0.0122.  
 
2) A univariate analysis revealed that mean TL was shorter in ESKD patients in 
comparison to healthy controls, but the significance was lost following a 
multivariate analysis adjusting for age and sex as potential confounders.   
 
 
3) Telomere attrition was borderline significant, p=0.05 with patients in the PD 
group having a mean estimate of T/S by -0.060 i.e. less telomere attrition or 
accelerated ageing.   
 
4) No significant association between mortality outcomes and TL was observed, 
though the direction of effect is consistent with expectations, i.e. longer TL is 




5) TL is associated with frailty status. The risk of frailty on dialysis is increased 
by 52.2% for each reduction of telomere length by one SD. TL remained to be 
an independent predictor of frailty status when adjusted for 12 variables.  
 
6) DNA methylation age was significantly higher in the frail group in comparison 
to the non-frail group with a univariate analysis, but this association was lost 
in a multivariate analysis.  
 
9.2 Clinical impact of these findings 
 
These results from this single-centre prospective pilot study suggest that TL; a novel 
biomarker of ageing and senescence may be able to better predict frailty status in 
ESKD cohort. The study also showed that telomere attrition difference in both the 
dialysis modalities reached near significance with p=0.05 with reduced degree of 
telomere attrition in the PD group. Both these findings are crucial and relevant in 
ageing among dialysis population. More importantly these outcomes will pave the way 
for a larger study to be conducted in this area/subject matter. More longitudinal studies 
are required to investigate the role of TL and telomere attrition as the current study 
was not be able to comment if the findings on TL and frailty were causal or 
consequential.  
 
It is interesting that despite TL was correlated with methylome age, only TL had 




into. There may be a different pathophysiology on the way these genetic and 
epigenetic ageing biomarkers function.  
 
Findings as revealed in this study can obviously have potential clinical impact as many 
decisions in the field of nephrology is determined by chronological age e.g. 
consideration for dialysis initiation, advanced care planning, listing for renal 
transplantation and escalation of care. The self-reported age of a dialysis patient may 
not be a true reflection of their chronological age as a large proportion of these patients 
were not born in the UK; with the possibility of having an incorrect birth date due to 
missing identification during settlement process (Anderson, Herr and McCowan, 
2013). Incorrect chronological age will certainly have an impact on adjusted data 
analysis and correlation analysis for TL, DNAm and frailty scores. Both TL and 
DNAm parameters are correlated with age and all data presented in this study were 
adjusted for chronological age as a confounder. Therefore, the extent of incorrect 
chronological age and the impact on analysis will be difficult to ascertain. Performing 
all analysis by excluding patients who were born outside UK will not be possible due 
to the small numbers.  
 
Often many of the well-established risk scoring systems used in the general population 
are not validated in dialysis patients. This also includes the limited options for 
measuring frailty in the dialysis patients and the accuracy of these measurements 
having observed the limitations and difficulties faced by my study recruits when 
completing the assessments. It is possible that a personalised measure of genetic or 
epigenetic age might offer a better predictive power in models taking into account 




9.3 Potential future analysis 
Results from this study raise the possibility of investigating the role of TL and DNAm 
further not only to the limit of predicting frailty outcomes but also the individual 
components of interest.  Ageing and frailty are important factors in the field of dialysis 
and transplantation and investigating the role of genetic and epigenetic ageing markers 
in this field is clinically relevant.  
 
There may be relationships and associations between the variables collected during 
the study which may become more apparent and significant with further follow up of 
this cohort. Whilst no statistical significance was seen in TL at baseline and death, but 
the direction of effect was consistent with an increased risk of death with shorter TL 
in the dialysis cohort. A longer follow up duration might also result in us detecting a 
difference in morbidity and mortality outcomes based on frailty status, TL, telomere 
attrition rate and DNA methylation-based parameters. As such, significant difference 
might become apparent on longer follow up with increased number of endpoints. The 
current cohort will be followed up to 5 and 10 years for mortality.  
 
DNA based methylation parameters were inferior to TL in predicting frailty status in 
the current study population. However, there is increased interest in the role targeted 
and individual specific CpG sites instead of using DNA methylome parameters to 
correlate with clinical outcomes. as the status at specific sites may be more accurate. 
Data from 6 CpG sites correlating with cellular senescence is available and there is an 
idea to analyse these methylation beta values against frailty and mortality outcomes in 
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